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SUMMARY
Prostate cancer (CaP) has the highest incidence of any malignancy affecting
South African males. The aetiology of prostate carcinoma indicate that ethnicity
is one of the most important risk factors. The causes of these ethnic differences
are unknown but presumably involve both environmental and genetic factors.
Carcinoma of the prostate is androgen dependent, and it has been suggested
that variations in androgen metabolism and synthesis may affect an individuals'
risk. Therefore, genes involved in these pathways are candidates for
determining CaP susceptibility.
In this study two candidate genes in the androgen biosynthetic and metabolic
pathway were analysed, viz., the androgen receptor gene (AR), involved in
androgen transport and transcriptional activation, and the cytochrome p450c17a
gene (CYP17), important for testosterone biosynthesis. Comprehensive
mutation detection assays were designed (appropriate for analysis of archival
paraffin-embedded material) for almost the entire coding region (excluding
polymorphic repeat sequences), and including all splice site junctions of the AR
gene, as well as the entire coding region of CYP17. The aim of this study was
thus to determine the type and frequencies of genetic variants of these androgen
metabolism genes within the diverse South African population, and to determine
if the observed ethnic variation in the incidence and progression of CaP can be
explained by ethnic-based genetic differences.
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2For high sensitivity mutation detection, the most powerful of the pre-screening
methods was used, namely denaturing gradient gel electrophoresis (DGGE). 20
CaP and 25 control benign prostatic hyperplasia (BPH) tissue samples were
screened in order to identify possible mutations. Blood samples from the same
patients were analysed in order to determine whether mutations are germline and
therefore present in all cells of the body. Additional blood samples from the
Western Province Blood Transfusion Service (WPBTS) (Refer to section 2.1.2,
Table) were also analysed in order to determine the frequency of identified
polymorphisms within the general population. Certain polymorphisms were
further analysed in paraffin-embedded wax material (exclusively from Blacks) to
determine the distribution of these polymorphisms in the Black population. Direct
sequencing of mutant-containing DNA fragments was performed to determine the
exact location and nature of mutation.
Using the AR- DGGE assay 4 novel mutations were identified as well as a
previously reported codon 211 (E211) polymorphism. With the CYP17- DGGE
assay, 3 novel single nucleotide polymorphisms (SNPs) were detected. Three
base variants occured, in codons 36 (L36), 46 (H46) and 65 (S65), as well as
intronic substitutions in intron 4 (IVS+58G4C) and intron 6 (IVS-25C7A).
Frequencies of SNPs were measured in the CaP and BPH samples.
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3In conclusion, the identified polymorphisms could be used as markers in
determining CaP susceptibility and may thus facilitate the identification of
individuals with a high- or low-risk of developing carcinoma of the prostate.
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4OPSOMMING
Prostaatkanker vertoon die hoogste voorkoms van enige kwaardaardigheid wat
Suid-Afrikaanse mans aantas. Die etiologie van prostaatkarsinoom dui aan dat
etnisiteit een van die mees belangrike risikofaktore is. Oorsake van hierdie
etniese verskille is onbekend, maar vermoedelik is omgewing en genetiese
faktore albei betrokke. Karsinoom van die prostaat is androgeenafhanklik en
daar is voorgestel dat variasies in androgeenmetabolisme en androgeensintese
'n persoon se risiko mag affekteer. Gevolglik, is gene betrokke in hierdie paaie
kandidate vir die bepaling van prostaatkanker vatbaarheid.
In hierdie studie het ons twee kandidaat gene in die androgeen biosintetiese en
metaboliese pad geanaliseer, naamlik, die androgeen reseptor geen (AR),
betrokke in androgeen vervoer en aktivering van transkripsie, en die sitokroom
p450c17a geen (CYP17), belangrik vir testosteroon biosintese. Ons het
omvattende mutasie-bespeurings-essai-sisteme ontwikkel (ook uitvoerbaar op
argivale paraffien-bewaarde materiaal), wat amper vir die hele koderende streek
van die AR geen gebruik kan word (uitsluitend herhalende polimorfiese reekse)
en wat alle splytpunt-aansluitings van die AR geen insluit, asook vir die hele
koderende streek van CYP17. Die doel van hierdie studie was dus om die tipe
en frekwensies van genetiese variante van androgeen metabolisme gene in ons
diverse Suid-Afrikaanse bevolking te bepaal, en om vas te stelof die
waarneembare etniese wisseling in die insidensie en vordering van
prostaatkanker verstaan kan word deur etnies gebaseerde genetiese verskille.
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5Die mees sensitiewe tegniek wat tans beskikbaar is vir vooraf-sifting vir
onbekende mutasies is gekies, naamlik denaturerende gradiënt gel elektroforese
(DGGE). Om moontlike mutasies op te spoor, het ons 20 prostaatkanker en 25
benijne prostaathiperplasie (BPH) monsters geanaliseer. Analise was gedoen op
bloedmonsters van dieselfde pasiënte om vas te stelof kiemlyn mutasies (in alle
liggaamselle) teenwoordig is. Bykomstige bloedmonsters (van die Westelike
Provinsie Bloedoortappingsdiens) is ook geanaliseer om die frekwensie van
bespeurde polimorfismes in die algemene bevolking te bepaal. Argivale
paraffien-bewaarde materiaal (eksklusief van Swartes) is ook geanaliseer om die
verspreiding van sekere polimorfismes in die Swart bevolking te bepaal. Direkte
DNA volgorde bepaling van mutante DNA fragmente is uitgevoer om die ligging
en tipe van mutasies te bepaal.
Met die toepassing van ons AR-DGGE mutasiesisteem het ons 4 nuwe mutasies
ontdek asook 'n kodon 211 (E211) polimorfisme wat voorheen gevind is. Vyf
enkel nukleotied polimorfismes is met die CYP17-DGGE mutasiesisteem
opgespoor. Die polimorfismes sluit in: drie basis veranderinge wat voorkom in
kodons 36 (L36), 46 (H46) en 65 (S65), asook introniese substitutisies in intron 4
(IVS+58G4C) en intron 6 (IVS-25C7A). Frekwensies van die polimorfismes was
bereken in die prostaatkanker en BPH monsters.
Die resultate aangebied in hierdie tesis dui aan dat die gevonde polimorfismes as
merkers gebruik kan word om prostaatkanker vatbaarheid te bepaal en daardeur
Stellenbosch University http://scholar.sun.ac.za
6individue te identifiseer met In hoë of lae risiko vir prostaatkarsinoom
ontwikkeling.
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7ABBREVIATIONS
aa : amino acid
AAG : androstanediol glucuronide
AIS : Androgen insensitivity syndrome
AR : Androgen receptor
ARE : Androgen response element
Bp : base pairs
BPH : Benign prostatic hyperplasia
DC : degrees celsius
cAMP : cyclic adenosine monophosphate
CaP : Prostate cancer
CGH : comparative genome hybridisation
CYP17 : Cytochrome p450c17a
CYP3A4 : Cytochrome p450 3A4
d :deviation
df : degrees of freedom
DGGE : denaturing gradient gel electrophoresis
DHEA : dehydroepiandrosterone
DHT : dihydrotestosterone
DNA : deoxyribonucleic acid
DRE : digital rectal examination
ds : double stranded
E : glutamate
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8ER : estrogen
ERa : estrogen receptor a
FISH : fluorescence in situ hybridisation
GR : glucocorticoid receptor
GRE : glucocorticoid receptor element
GTP : green tea polyphenols
H : histidine
hKLK2 : human glandular kallikrein-1
HRE : hormone response element
HSP : heat shock protein
IL : interleukin
L : leucine
LBO : ligand binding domain
LO : linkage disequilibrium
LH : lutein ising hormone
LNCaP : lymph node prostate cancer
LOH : loss of heterozygosity
MAB : maximal androgen blockade
MMTV : mammary tumour virus
MR : mineralocorticoid receptor
mRNA : messenger ribonucleic acid
ORF : open reading frame
p : probability value
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PAA
PCR
PR
PSA
RARE
RARy
RXRa
S
SBMA
scc
SHBG
SNP
9
: polyacrylamide
: polymerase chain reaction
: progesterone receptor
: prostate specific antigen
: retinoic acid response element
: retinoic acid receptor gamma
: 9-cis-retinoic acid receptor alpha
: serine
: spinal and bulbar muscular dystrophy
: side chain cleavage
: sex-hormone binding globulin
: single nucleotide polymorphism
SSCP : single strand conformation polymorphism
SRD5A2 : steroid 5-a-reductase type"
ss : single stranded
TA : thymine / adenine
TAD : transactivating domain
TIF : transcription intermediary factor
Tm : melting temperature
TNF : tumour necrosis factor
TP53 : p53 gene
TR cx : thyroid hormone receptor alpha
TRAMP : transgenomic adenocarcinoma of the mouse prostate
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TSC : The SNP consortium
UCSC : University of California at Santa Cruz
UF : urea and formamide
UTR : untranslated region
WPBTS : Western Province blood transfusion service
Stellenbosch University http://scholar.sun.ac.za
11
FIGURES AND TABLES PG
CHAPTER 1: INTRODUCTION
Figure 1 SECTION 1.2.4 33
Figure 2 SECTION 1.2.5 35
Table 1 SECTION 1.2.5.1 40
Figure 3 SECTION 1.2.6.1 43
Figure 4 SECTION 1.2.6.1 45
Table 2 SECTION 1.3.1 61
Figure 5 SECTION 1.3.1.2 65
Table 3 SECTION 1.3.2.3 83
CHAPTER 2: MATERIALS AND METHODS
Figure 6 SECTION 2.1.1 94
Table 4 SECTION 2.1.2 96
Figure 7 SECTION 2.2.2 99
Table 5 SECTION 2.2.3 103
Table 6 SECTION 2.2.3 104
Table 7 SECTION 2.3 109
Figure 8 SECTION 2.4 111
Table 24 SECTION 2.4 113
Figure 9 SECTION 2.4 114
Figure 10 SECTION 2.4 117
Stellenbosch University http://scholar.sun.ac.za
Figure 10
Figure 11
Table 25
Table 26
APPENDIX II Table 8-23
12
SECTION 2.4
SECTION 2.4
SECTION 2.4
SECTION 2.4
117
118
118
121
202-212
Stellenbosch University http://scholar.sun.ac.za
TABLE OF CONTENTS PG
SUMMARY 1
OPSOMMING 4
ABBREVIATIONS 7
FIGURES AND TABLES 11
CHAPTER 1. INTRODUCTION 13
1.1 PROSTATE CANCER: GENERAL INTRODUCTION 13
1.1.1 Clinical aspects of Prostate cancer 13
1.1.2 Aetiology of Prostate cancer
1.1.2.1 Age and Race-ethnicity
1.1.2.2 Familial Prostate cancer
16
16
18
1.2 ANDROGENS AND PROSTATE CANCER 20
1.2.1 Circulating Testosterone levels and Prostate cancer 21
risk
1.2.2 Androgens and Prostate cancer risk (Environment and 22
Prostate cancer aetiology)
1.2.2.1 Diet and Nutrition 22
1.2.2.2 Obesity 24
1.2.2.3 Physical Activity 24
1.2.2.4 Vasectomy 24
1.2.2.5 Sexual behaviour 25
Stellenbosch University http://scholar.sun.ac.za
ii
1.2.2.6 Requirements of androgens in experimental 2
carcinogenesis
Hormonal patterns among racial-ethnic groups 211.2.2.7
1.2.3 Androgens and the treatment of Prostate cancer
1.2.4 Androgen Biosynthesis
1.2.5 Molecular Mechanisms of Androgens
1.2.5.1 Genes regulated by Androgens
2~
31
1.2.6.3 Steroid Sa-reductase type2
3f
4(
Sj
5~
1.2.6 Genes in the Androgen Metabolism Pathway
1.2.6.1 The Androgen Receptor: Structure and Function
1.2.6.2 Cytochrome P450c17a
1.3 GENETICS OF PROSTATE CANCER
SS
1.3.1 Genetic Progression of Prostate Cancer
SS
1.3.1.1 AR Gene Amplification 62
1.3.1.2 AR Mutations 64
1.3.2 Genetic Susceptibility to Prostate Cancer 70
1.3.2.1 Polymorphic Variants and Disease association 70
1.3.2.2 Association Studies 76
1.3.2.3 AR gene Susceptibility Alleles 79
1.3.2.4 CYP17 Susceptibility Alleles 86
1.3.2.5 Other Susceptibility Alleles and Prostate Cancer 88
1.3.2.5.1 SRD5A2 88
1.3.2.5.1 CYP3A4 89
1.4 AIM OF STUDY 89
Stellenbosch University http://scholar.sun.ac.za
iii
CHAPTER 2. MATERIALS AND METHODS 91
2.1 HUMAN POPULATIONS 91
2.1.1 The South African Population (Historical background) 92
2.1.2 Patient cohort and specimen collection 95
2.2 MUTATION DETECTION 96
2.2.1 DNA Amplification 96
2.2.2 DGGE 98
2.2.3 Primer Design 102
2.2.4 DNA Sequencing 105
2.3 ASSOCIATION STUDIES 106
2.3.1 Data Comparisons and Statistical Analysis 110
2.4 RESULTS 112
2.5 DISCUSSION 123
2.6 FUTURE PROSPECTS 134
REFERENCES 139
APPENDIX I
APPENDIX II
199
202
ACKNOWLEDGEMENTS 213
Stellenbosch University http://scholar.sun.ac.za
13
CHAPTER 1
INTRODUCTION
The focus of molecular genetic analysis has moved away from single gene disorders
which usually have a simple Mendelian pattern of inheritance, to more complex
multifactorial diseases like most cancers (Lander and Schork, 1994; Gray et aI, 2000;
Emahazion et aI, 2001). These complex diseases do not exhibit classic Mendelian
recessive or dominant inheritance due to a single causative factor and occur at a
much higher frequency than monogenic disorders. Multiple susceptibility genes may
be quite common in the population and could each contribute a small effect but
collectively increase the risk of developing cancer indirectly. Variant sequences in
such genes in a common pathway could result in a "polygenic" aetiology of cancer,
facilitating the identification of individuals with a high- or low-risk polygenic profile.
1. PROSTATE CANCER: GENERAL INTRODUCTION
1.1.1 Clinical aspects of prostate cancer
The prostate is a small, male gland which surrounds the urethra'. This gland
produces semen (prostatic fluid) 2. Prostate cancer (CaP) develops in the prostate
gland and early detection greatly improves the chances of effective treatment. This
cancer is generally slow growing and progressive and may not show any symptoms
at all. The early warning signs include difficulty in passing urine, a frequent need to
urinate (especially at night) and difficulty in starting and stopping the urinary stream,
usually caused by the tumour pressing on the urethra and affecting or blocking the
flow of urine (http://www.cansa.org.za.2000). These symptoms could also, however,
1 The tube which carries urine from the bladder to the outside of the body
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result from benign prostatic hyperplasia (BPH), a common progressive enlargement
of the prostate gland, which obstructs the flow of urine and can eventually, at worst,
stop it completely. It occurs in 50-75% of males over the age of 50 in the presence of
testes that are functioning normally (Berry et ai, 1984). The reason for this
spontaneous prostate growth is not exactly known, however research has shown that
abnormally high levels of the hormone dihydrotestosterone (DHT) is present in the
prostates of individuals with BPH (Wilson, 1980 and 1996). Treatment for BPH is
normally surgical with removal of the prostate via open prostatectomy or, more
usually, transurethai resection.
Most cases of early CaP show no symptoms but can be detected by a blood test
which measures the levels of PSA (prostate specific antigen); a protein made by
prostate cells. Measurement of serum PSA has proven to be the most sensitive
overall marker available for CaP (Catalona et ai, 1994). The majority of studies have
accepted 4.0 ng/ml as the upper limit of normal, while some investigators have
suggested a lower cut off level of 3.0 ng/ml (Catalona et al, 1991; Labrie et al, 1992;
Crawford et al, 1996; Rietbergen et al, 1997; Heyns et al, 2001). PSA levels reflect
the likelihood of having CaP and generally men with high levels of > 4.0' ng/ml are
advised to have a biopsy (a sample of tissue from the gland) to check for the
presence of cancerous cells. Early CaP can also be detected by rectal examination.
However, the combination of a rectal examination together with the measurement of
serum PSA concentration, provides a better method of detecting CaP than PSA
alone (Smith and Catalona, 1995).
2 A white substance which is important for the motility, nourishment and fertility of sperm
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If a biopsy indicates the presence of CaP, a pathologist assigns each tissue sample a
grade, based on the architectural patterns of cancer cells observed under a light
microscope. This indicates how far the cells have travelled along the path from
normal to abnormal. The grade offers a good clue to the tumour's behaviour. A
tumour with a low grade is likely to be slow growing, while one with a high grade is
more likely to grow aggressively or to have spread outside the prostate
(metastasised). The most widely used grading method for CaP is known as the
Gleason grading system, which assigns a grade to each of the two largest areas of
cancer in the tissue samples (http://www.phoenix5.org, 2000). Grades range from 1
to 5, with 1 being the least aggressive and 5 the most aggressive. Grade 3 tumours
for example seldom have metastases, but metastases are common with grade 4 or
grade 5. The two grades are then added together to produce a Gleason score. A
score of 2 to 4 is considered low grade; 5 through 7, intermediate grade; and 8
through 10, high grade. A tumour with a low Gleason score typically grows slow
enough that it may not pose a significant threat to the patient in his lifetime.
Advanced symptoms of CaP are blood in the urine, a painful or burning sensation
when passing urine, any of the aforementioned symptoms combined with pains in the
lower back, upper thighs or pelvic area. If left untreated, the cancerous cells in the
prostate could spread to other parts of the body such as bone, the liver, lungs and
adrenal glands (http://www.cansa.org.za.2000). CaP treatment involves either
surgery to remove the prostate gland (radical prostatectomy) or radiation
(radiotherapy).
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Carcinoma of the prostate is the most frequently diagnosed malignancy and one of
the leading causes of cancer deaths in men in Western countries (Parker et ai,
1997). It has histologically been diagnosed as the second most common cancer in
South African men, with an annual estimated incidence of 19.1 / 100 000 men (Sitas,
1994). CaP incidence varies among race groups and a comparison shows that it is
the second most common histologically diagnosed carcinoma in Coloureds and
Blacks (comprising 9.12% and 8.00 %, respectively), the third most common cancer
in Whites (7.11%), and the fourth most common malignancy in Asian (Indian)
(4.56%) men in South Africa (Sitas, 1994). Risk factors are known to influence the
incidence of CaP, which will be discussed further in the next section.
1.1.1 Aetiology of prostate cancer
CaP, like all cancers, is a multifactorial disease where environmental stimuli and
genetic risk factors, in varying proportions, are important promoters in disease
aetiology. Most environmental factors have been linked to hormonal exposures,
which will be covered in Chapter 1.2. The only established risk factors are age, race-
ethnicity and family history of CaP (MettIin, 1997).
1.1.2Age and race-ethnicity
The two most important risk factors for CaP are age and race-ethnicity. CaP is
extremely rare before the age of 40 years but the rate of increase with age is greater
than for any other cancer; rates increase at approximately the 9th -10th power of age
whereas figures for other common epithelial cancers like lung and colon cancer are
between 5 and 6 (Cook et aI, 1969). For CaP the rate of increase is steepest early in
the age-specific curve and then gradually dissipates with age. This contrasts with
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some epithelial cancers such as colon cancer, for which the relationship between age
and incidence is strictly linear in log-log units (Cutler and Young, 1975).
Substantial differences in the prevalence of CaP are observed among populations
and several studies have suggested that Black (African) men have a higher incidence
of disease. African-American men have been reported to have the highest incidence
rates in the world. Even though rates differ slightly among African-American men
across the United States (US), average rates are about 50-70% higher in African-
Americans than in Caucasians (Ross and Schottenfeld, 1996). The higher incidence
of CaP in Black compared to white men has been documented for more than 20
years. Even though incidence rates rose strikingly in both races starting in the early
1990s secondary to PSA-based early detection, the difference between races has
remained. The differences in incidence are most dissimilar in the age group younger
than 65 years, where Caucasians have a rate of 45.5 I 100 000 and Blacks 81.5 I
100 000 (Brawley et aI, 1998a and 1998b). However, there has been no sufficient
relative data on CaP rates among Blacks in South Africa to substantiate these
increased incidence rates. Interestingly, the other end of the racial-ethnic range of
CaP incidence shows that Asian populations (Native Japanese and Chinese men)
have the lowest CaP rates in the world. Although the difference in incidence
between African-Americans and these Asian populations was approximately 50-fold
(Ross and Schottenfeld, 1996), it has been demonstrated that different detection
strategies for CaP are mainly accountable for this difference and that the difference
in incidence is in fact much smaller; in the order of 2- to 3-fold (Shimizu et el, 1991).
Even so, Japanese- and Chinese-Americans have rates higher than those of men in
their respective homelands (about 40-50% higher), however, their rates still remain
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much less than US Caucasians and are even lower than those of African-Americans,
although the Japanese, in particular, represent a highly acculturated immigrant
population in the US (Bernstein and Ross, 1991). Several studies have reported
higher proportions of CaP cases with advanced stage and poorer survival rate
among Blacks than among Caucasians (Brawn et aI, 1993; Optenberg et a/1995 and
Powell et aI, 1995). Therefore Black men do not only have a higher risk of CaP, they
also have a greater risk for the more aggressive forms of the disease (Montie and
Pienta, 1999) but as yet there are no published comparable South African data which
show similar results.
In the past few years, decreased mortality rates from CaP have been observed,
possibly as a result of early detection and treatment. The mortality rate, however,
has been greater in Black than in Caucasian men, with the greatest disparity noted in
younger men. It has been shown that age-specific mortality rates are twice as high in
Blacks between the ages of 40 and 60 years, and slightly less than two times greater
in men older than 70 years (Powell, 1998). For men diagnosed after the age of 70
years, mortality rates are similar (Pienta et aI, 1995).
1.1.2.2. Familial prostate cancer
Many studies have suggested that CaP clusters within male members of a family
(familial CaP) (Krain, 1974; Meikle et al, 1985; Spitz et al, 1991, Eeles et al, 1997;
Schaid et aI, 1998). One case-control study (Steinberg et aI, 1990) was carried out
to determine the frequency of CaP in 691 male relatives with CaP and 640 male
relatives of their spouses as controls. Results showed that men with an affected
father or brother were twice as likely to develop the disease than men with no
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affected relatives. It was also found that men with two or three first-degree relatives
affected had a 5- and 11-fold increased risk of developing CaP. Inherited risk for
CaP, however, represents less than 10% of CaP cases (Carter et aI, 1992).
Some studies support an X-linked (traits which are determined by genes on the X-
chromosome) or recessive model of inheritance (Monroe et aI, 1995; Narod et aI,
1995), whereas other data suggest an autosomal dominant mode of inheritance
(male to male transmission) for early onset disease (Carter et aI, 1992; Gronberg et
aI, 1997; Schaid et aI, 1998). This rare allele (alternative form of a gene) could
account for 9% of all CaP cases at ~ 85 years of age and 43% of CaP cases
diagnosed at ~ 55 years of age. In addition to the normal allele or alleles, most
identified loci also have one or more rare alleles. Many human loci were in fact
identified through a clinically significant disorder caused by a rare mutant allele
(Thompson et aI, 1991). Even though the dominant alleles have a low population
frequency of 0.36-1.67%, they are highly penetrant (the all-ar-none expression of a
mutant genotype) so that by the age of 85 years, 63-89% of men carrying a mutation
would be likely to be diagnosed with CaP (Carter et aI, 1992; Gronberg et aI, 1997;
Schaid et aI, 1998). Inherited susceptibilities 3 seem to play a role in the
development of CaP as highly penetrant genes linked to CaP have been identified on
the X chromosome (Monroe et aI, 1995 and Xu et aI, 1998) and chromosome 1
(Smith et al, 1996; Gronberg et al, 1997; Eeles et al, 1998 and Gibbs et al, 1999).
Mutations in the Hereditary prostate cancer 1 gene (HPC1), located on chromosome
1q24-q25, have been found in patients with hereditary CaP and account for about 1
in 500 cases. Further research into HPC1 is ongoing.
3 Hereditary CaP is a subtype of the disease in which Mendelian inheritance of a susceptibility gene is
evident
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Although there is strong evidence for genetic susceptibility to CaP, most of the genes
underlying susceptibility remain to be identified. Recently, the results of eight
genome-wide searches were reviewed, based on 1.293 families with multiple cases
of CaP (Easton et aI, 2003). Results from this study showed that even larger family
sets would be required to reliably evaluate linkage.
Due to the nature of CaP the search for genetic determinants involved in the disease
has been challenging, partly because such a complex disease is not compliant to be
characterised by methods used as in the case of diseases with simple Mendelian
genetic inheritance. CaP is more likely to result from "inherited susceptibility" - low
penetrant genes will be discussed in Chapter 1.3.
1.2 ANDROGENS AND PROSTATE CANCER
Androgens are male hormones (e.g. testosterone and dihydrotestosterone) and are
essential in several stages of male development. DHT is responsible for sexual
differentiation by sculpturing the human embryo in the uterus to cause development
of internal and external male genitalia. During puberty, a flow of testosterone initiates
and maintains spermatogenesis (male sex drive and performance) and secondary
male characteristics like growth of accessory sex organs, including the prostate
gland. Other secondary male characteristics stimulated by testosterone in adults
include muscle development, voice deepening, rugation and pigmentation of the
scrotum, some phallus growth and penile erections, axillary and pubic hair
development, and male psychosexual orientation. DHT is also important in
maintaining the structure and function of the mature prostate. Without androgens,
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the prostate undergoes apoptosis (programmed cell death) and significant atrophy
(Trapman and Brinkmann, 1996).
Androgens therefore play a crucial role in their primary target organs by controlling
cell proliferation and an increased cell proliferation appears to be a shared event in
disease production or development of many human cancers (Preston-Martin et ai,
1993). Even though hormonal secretion and metabolism can be environmentally
influenced (for example through a change in diet); hormonal-pattern control is
directly or indirectly regulated genetically. Environmental and genetic factors which
change the hormonal environment and therefore cell division rates in target organs
would be expected to alter the rate of malignant transformation in these target tissues
as well (Henderson et aI, 1988a).
1.2.1 Circulating testosterone levels and Prostate cancer risk
Studies of circulating hormone levels and CaP risk are complicated as a result of
inter- and intra-assay variability, cyclical and sporadic variations in the target
hormone, the requirement for large prospective studies and difficulty in determining
tissue-specific exposure. However, one adequate prospective serologic study has
been conducted to date in which a rather strong relationship between circulating
testosterone levels and CaP development was found (Gann et aI, 1996). In this
study, steroid hormone binding globulin (SHBG) levels, which are firmly linked with
testosterone levels, were measured and a strong pattern of increased CaP risk with
increasing levels of circulating free testosterone was observed.
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1.2.2 Androgens and Prostate cancer risk (Environment and Prostate cancer
aetiology)
Results of various epidemiological studies suggest that environmental risk factors like
diet and other risk factors such as level of physical activity, vasectomy, obesity and
sexual behaviour could be related to a hormonal mechanism.
1.2.2.1 Diet and nutrition
There has been considerable consistency among studies showing that a high intake
in fat can increase CaP risk (Berg, 1975; Lew and Garfinkel, 1979; Kolonel ef aI,
1983; Kaul ef aI, 1987; Severson ef aI, 1988 and 1989). Theoretically, high levels of
dietary fat could lead to a higher production of sex hormones and high circulating
levels of androgens can lead to increased CaP (Nobel, 1959; Coffey, 1979;
Hamalainen ef aI, 1984). The exact mechanism is not completely understood but an
increased hormonal bioavailability as a result of a high-fat diet has been implied. The
concentrations of plasma in fatty acids are responsive to dietary fat and these levels
correlate with concentrations of bioavailable sex steroids (Bruning and Bonfrer,
1989). In addition to this, a low intake of dietary fibre and complex carbohydrates
and a high intake of protein and energy have been found to be associated with the
increased risk for CaP in some studies (Bosland, 1988; Nomura and Kolonel, 1991;
Bosland, 1994; Kolonel, 1996).
CaP risk and the associations with individual nutrients or food that have been
reported are not very strong. Even though CaP is rare in China and Japan, the
studies of migrants from these countries to the US have shown that they have a
considerable increased risk (Nomura and Kolonel, 1991; Bosland 1988). These
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changes are thought to be the result of differences in the environment such as
lifestyle and diet (Nomura and Kolonel, 1991 and Bosland 1988). Therefore one can
conceive that the combination of the effects of dietary factors on CaP development
and progression are more important than individual effects of any particular dietary
factor (Bosland et aI, 1999). This is supported by lack of effect of dietary fat after
CaP was induced in animal models, whereas epidemiological studies (Bosland 1988,
Bosland 1994; Bosland et al, 1999) show a consistent positive association between
an intake of dietary fat and an increased CaP risk (West 0 et aI, 1991; Andersson et
aI, 1995). There are a number of promising leads concerning other protective or
causative dietary influences on the development of CaP. Evidence from prospective
epidemiological studies (Giovannucci et aI, 1995) and serologic biomarker data
(Gann et aI, 1999) suggest that Iycopene, a potent caretenoid found primarily in
tomato and tomato products, may decrease CaP risk. Vitamin E, another antioxidant
vitamin, was found to be associated with a reduced risk of CaP during a randomised-
controlled clinical trial specifically designed to lower the risk of lung cancer in male
smokers (Heinonen et aI, 1998). Selenium, a soil-based mineral, which has both
proapoptotic and antioxidant properties significantly reduced CaP incidence as a
secondary effect of a prevention trial designed to reduce skin cancer recurrences
(Clark et aI, 1998). Other dietary factors like dietary fibre and phytoestrogens (a
plant-based estrogen) have not been investigated thoroughly but are of interest (fibre
as a means to enhance faecal excretion and possibly lower the levels of
enterohepatic recirculation of androgens, and phytoestrogens by inhibiting androgens
in the epithelium of the prostate; interfering with prostate growth) (Ross and
Schottenfeld, 1996).
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1.2.2.2 Obesity
Present information contradicts whether an increase in body mass index or obesity is
a CaP risk factor (Bosland 1994; Denmark-Wahnefried ef al, 1997; Bosland ef al,
1999). A significant increase in CaP risk was observed (Severson ef aI, 1988) with
an increase in the upper-arm muscle area (but not fat area) and the circumference of
the upper-arm. However, a positive association between muscle mass and the risk
of CaP could be the result of exposure to exogenous or endogenous hormones or
even other anabolic factors (Severson ef aI, 1988; Landry and Primos, 1990).
1.2.2.3 Physical activity
There is contradictory evidence that the level of physical activity could be a possible
risk factor for CaP (Bosland, 1994; Giovannucci ef al, 1998 and Bosland et al, 1999).
Exercise could increase, decrease or have no effect on circulating androgen
concentrations. This depends on the level of exercise, the time the blood sample
was drawn in relation to the exercise and the training program followed (Adlercreutz
et aI, 1986 and Keizer et aI, 1989). Thus it is a possibility that the nature and extent
of physical activity could influence circulating androgen concentrations and even CaP
risk.
1.2.2.4 Vasectomy
Many sources of literature have identified vasectomy as a possible risk factor for CaP
in cohort studies (Giovannuci et al, 1992 and 1993) as well as case-control studies
(Honda et al, 1988; Mettlin et al, 1990; Rosenberg et al, 1990; Perlman et al, 1991;
Spitz et aI, 1991; Peterson et aI, 1992; Hayes et aI, 1993). Three mechanisms have
been proposed by which vasectomy could possibly enhance CaP risk namely, by
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increasing levels of circulating androgens, reducing of seminal fluid production
(Honda et ai, 1988; Mettlin et ai, 1990; Rosenberg et ai, 1990; Howards and
Peterson 1993; Giovannuci et al, 1993; John et al, 1995; Mo et al, 1995) and
immunologic mechanisms involving antisperm antibodies. Some studies (Kobrinsky
et al, 1976; Purvis et al, 1976; Smith et al, 1979; Whitby et al, 1979; Alexander et al,
1980; John et ai, 1995; Mo et ai, 1995) have found slight, yet significant changes in
the circulating levels of certain hormones. In one study, elevated levels of 5a-
dihydrotestosterone, the metabolite of testosterone, was found in the prostate of men
who had undergone vasectomies (Mo et ai, 1995). This could be an important factor
associated with CaP risk.
1.2.2.5 Sexual behaviour
The possibility that sexual factors could play a role in the aetiology of CaP, was
investigated in several case-control studies (Mandel and Schuman, 1987; Ross et ai,
1987; Bosland, 1988; Honda et al, 1988; Fincham et al, 1990; Yoshida et al, 1990;
Hayes et ai, 1992). A significant positive association was reported between the level
of sexual activity (masturbation and intercourse) and the circulation of total
testosterone levels in men between 69 and 70 years of age (Tsitouras et ai, 1982).
No decrease in testosterone levels with aging in men who are sexually active was
found as well. This suggests that a hormonal mechanism could underlie a possible
association between sexual activity and the risk of CaP.
1.2.2.6 Requirement of androgens in experimental prostate carcinogenesis
Menand dogs are the only mammalian species that spontaneously develop CaP with
significant frequency (Coffey, 1993). If castrated before puberty, they do not develop
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CaP. It has proven to be very difficult to produce CaP experimentally which imitates
the human disease histologically. The lack of naturally occurring and experimental
models of disease has slowed down the progress in understanding the pathogenesis
of CaP. In 1977 the first experimental model of prostate adenocarcinoma
(histologically equivalent to the human disease) was produced (Nobel, 1977) by the
subcutaneous administration of testosterone in rats. Additional experimental rodent
models have since been developed; all of which require androgens for tumour
induction and progression.
1.2.2.7 Hormonal patterns among racial-ethnic groups
Since racial-ethnic variation in incidence is such a powerful characteristic of CaP
epidemiology, investigations over the past decade have explored whether underlying
differences exist in the androgen environment of populations at the extremes and in
the middle of CaP incidence.
A comparison of the hormonal status of small groups (n = 11-20) of Black South
African, White-American and African-American men with ages ranging from 40 to 55
years was made by Hill and his co-workers (Hill et aI, 1979; Hill et aI, 1980). In a
separate study, Black South African, White-American and African-American boys of
age 12 to 15 years; and young Black South African and African-American men in the
18 to 21 year old category were compared (Hill et aI, 1984). In the older men (40-55
years), the plasma levels of dehydro-epiandrostenedione (DHEA), the testosterone
precursor, were significantly lower in the two groups of Black men than in the White
men. The plasma levels of androstenedione, also a testosterone precursor, and
estradiol (another sex steroid) were significantly higher in the African men than in the
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two American groups and no differences were observed in testosterone levels among
these groups. Results for DHEA and testosterone were similar in the other study
with the younger men and 12 to 15 year old boys. Androstenedione levels however,
were much lower in the African than in the American subjects and estradiol was
lower in young Black boys of age 12 to 14 years than in White boys but higher in
older Black boys and young Black men than in White boys and men. These results
suggest an interaction between environmental differences and ethnic background
that changes over the years as an individual becomes more sexually mature. In the
studies of Hi" and colleagues among South African Black men, the men in the 18-21
year old group were different from the 40-50 year aids with respect to DHEA and
androstenedione, suggesting the importance of separately analysing the hormonal
profiles of older and younger men.
Hormonal differences among racial-ethnic groups could be present even in the in
utero period, as a study shows which compares the circulating hormone levels in
African-American and White-American women in the first trimester of their
pregnancies (Henderson et aI, 1988a). A 47% higher serum testosterone level was
found in Black than in White women and estradiol levels were also 37% higher;
suggesting that African-American males are exposed to higher levels of androgen
concentrations than White-American males even before birth.
In another study, testosterone levels of healthy young adult African-American (at a
very high risk for CaP) and White men (at half the risk for CaP than Black men) were
compared (Ross et aI, 1986). Even though CaP is a disease of older men, the focus
of this study was on young adult men in order to avoid confusion as a result of effects
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of other chronic diseases associated with ageing. It was also recognised that the
differences in CaP incidence relating to racial-ethnicity is at its maximum during the
early stages at which CaP appears, implying that the hormonal milieu responsible
occurs quite early in life. In the study, it was found that the total circulating
testosterone was 19% higher in the Black subjects than in the group of White
subjects and was even 15% higher after adjusting for known correlates of
testosterone, which include smoking, alcohol use, body mass index and time of
sampling. The free testosterone was 21% higher in the African-Americans than in
the White-Americans. The authors have estimated that differences of such a
magnitude in circulating testosterone is large enough to explain the substantial
difference in CaP incidence (Ross et aI, 1986). This study suggests an association
between CaP risk and high concentrations of circulating androgens and is based on
the fact that CaP incidence rates increase as a power function of age and as tissue
age is a function of the rate of cell division in target tissue, a direct relationship exists
between hormonal changes and prostate tissue age (Pike et aI, 1983).
The study of hormone patterns in African-American and White men (Ross et aI,
1986) were extended to include young Japanese men that were born and raised in
rural Japan and have a low expected lifetime risk of CaP compared to their
previously contrasted U.S. Black and White counterparts (Ross et aI, 1992). These
Japanese men had testosterone levels that were intermediate between those of
African-Americans and Whites and did not differ significantly from these two groups.
In this study circulating levels of androstanediol glucuronide, a reliable index of in
vivo 5a-reductase activity, was measured in all three groups of men. The levels of
this hormone in Japanese men were 25-35% lower than the African-American and
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White men (Ross et aI, 1992) and these two U.S. groups had significantly higher
levels of this androgen metabolite, with African-Americans having elevated levels
compared to whites (Kelsey and Bernstein, 1996). Chinese men in Hong Kong were
also shown to have similarly low levels of androstanediol glucuronide as the
Japanese men (Lookingbill et aI, 1991). These findings suggest that, in comparison
with the high-risk U.S. groups, the low-risk Japanese population has a lower
testosterone metabolism, probably due to a low activity of Sa-reductase that converts
testosterone to DHT and the testosterone precessar androstenedione to
androsterone. The higher levels of androsterone glucuronide in U.S. men, however,
could indicate a higher production of testosterone when compared with Japanese
men. Therefore the differences in CaP incidence among African-Americans, White
Americans and Asians (Chinese and Japanese men) could be due to differences in
testosterone biosynthesis and metabolism.
1.2.3 Androgens and the treatment of Prostate cancer
Androgen stimulation of the prostate over a prolonged period has been identified as a
risk factor that promotes prostate carcinogenesis. In 1941 Charles Huggins and his
colleague reported one of the most important developments in the treatment of CaP.
They documented the clinical benefits of bilateral orchiectomy in CaP patients with
advanced disease (Huggins and Hodges, 1941). Bilateral orchiectomy is the primary
androgen ablation therapy and deprives tumour cells of the proliferative influence of
testosterone. Even decades later androgen ablation therapy is still the mainstay of
treatment for metastatic CaP and is associated with stabilisation or regression of
disease in up to 80% of hormone therapy naive patients, i.e. before treatment with
androgen ablation (The Leuprolide Study Group, 1984; Peeling, 1989). Conversely,
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cytotoxic chemotherapy has not been shown to offer a survival advantage and has
only been administered in patients after all attempts at hormonal therapy have failed.
The mechanical basis of androgen ablation can be observed in the majority of normal
and malignant prostate cells that undergo apoptosis when deprived of androgens.
The AR mediates the maintenance of androgen growth. Antiandrogens are
competitive inhibitors that prevent the natural ligands of the AR from binding to the
receptor, and are used therapeutically in CaP patients. Prostate tumours that have
not previously been exposed to androgen ablation consist of a combination of cells
that differ in their requirements of antiandrogen for growth. Most of the tumour cells
need androgen for growth while a few can grow in the absence of androgen. When
prostate cells are now exposed to hormone therapy, the group of cells that grow
independently of androgens becomes more prominent and the disease progresses
despite androgen ablation. So even though there is an observation of an initial
response in patients with advanced disease, androgen-independent tumours
eventually grow, leaving hormone therapy ineffective. The AR has been identified as
a component in this hormone-resistant tumour growth (Trapman and Cleutjens,
1997). However, resistance to androgen ablation could also develop as a
consequence of a deregulated androgen signalling axis, resulting from AR gene
mutation or amplification, altered interactions of coregulatory molecules during
transcription, or non-steroidal activation of the AR by growth factors and cytokines
(Buchanan et al, 2001).
1.2.4 Androgen biosynthesis
Since the prostate is an androgen-regulated organ that requires the influence of
androgens for growth and development, one can agree that these hormones are the
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main stimulus for cell proliferation in the prostate (Coffey, 1979). Because cell
division and malignant transformation are inextricably linked (Preston-Martin et aI,
1993), the role of androgens in prostate carcinogenesis generates an intense
interest.
Testosterone and DHT are the main biologically active androgens. Less than 10% of
circulating androgens are secreted by the adrenal gland (Canovatchel and Imperato-
McGinley, 1992). Testosterone is synthesised within the Leydig cells of the testis
and is produced from cholesterol following a series of enzymatic reactions involving
several of the cytochrome P450 enzymes (Berkovitz et aI, 1983; Waterman and
Keeney, 1992; Geller et aI, 1997; Miller et aI, 1997). Its rate of synthesis is controlled
by luteinizing hormone (LH), which is secreted by the pituitary gland. The release of
LH by the pituitary gland is controlled, in turn, by luteinizing hormone-releasing
hormone (Singh et aI, 2000). The major metabolic androgen pathways relating to the
prostate and the sites of activity of the gene products that pertain to the prostate are
shown in Figure 1. The first hormonally regulated and rate-limiting step in the
biosynthesis of all steroid hormones is the conversion of cholesterol to pregnenolone.
Steroid secretion is directly related to steroid synthesis, as steroidogenic cells do not
store significant amounts of steroid hormones. Regulation of steroid synthesis
occurs both acutely and chronically. The acute stimulation of steroidogenesis
happens within minutes and is mediated by a steroidogenic acute regulatory protein,
which facilitates the movement of cholesterol into the mitochondria for its conversion
to pregnenolone (Stocco and Clark, 1996; Miller, 1997). Cholesterol is converted to
pregnenolone by the mitochondrial cholesterol side-chain cleavage system,
catalysed by a mitochondrial cytochrome P450 enzyme; P450scc (sec refers to side
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chain cleavage). The human adrenal cortex may now direct this pregnenolone
toward one of three different pathways. When P450c17 is absent in steroidogenic
cells such as the adrenal zona glomerulosa, pregnenolone is converted to
progesterone and further converted to other C-21,17-deoxysteroids, leading down
the mineralocorticoid pathway toward aldosterone. In the human adrenal and gonad,
when the 17a-hydroxylase activity of P450c17 is present, pregnenolone is converted
to 170H-pregnenolone as indicated by reaction I in Figure 1; and to a lesser extent,
progesterone to 170H-progesterone as shown in Figure 1, reaction II. These
steroids can be converted to other C-21,17-hydroxysteroids and proceed to the
principal glucocorticoid, cortisol. In the gonad and post-adrenarchal adrenal
(adrenarche refers to the prepubertal rise in the secretion of adrenal androgens
which occurs only in human beings and higher primates; Cutler et ai, 1978), the
17,20-lyase activity of P450c17 converts 17-OH pregnenolone to the C19 steroid
DHEA (as depicted by reaction III in Figure 1) which is the precursor of androgen
biosynthesis. The conversion of 170H-progesterone to androstenedione (reaction IV
Figure 1) by the 17,20-lyase activity of human P450c17 does not occur very often
(Lin et ai, 1991; Lin et ai, 1993), even though the catalysis of this reaction by
P450c17 occurs readily in rodents and cattle.
Stellenbosch University http://scholar.sun.ac.za
33
HSD3B2
Aldosterone
Pregnenolone ... Progesterone ............ (Mineralocorticoid)
170H Pregnenolone ...... Progesterone ............
I
And roste ned iol
CYP11A
CYP17
CYP17
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CYP17II
HSD3B2
170H Cortisol
(Glucocorticoid)
III IV CYP17
+HSD3B2 HSD17B3
DHEA ---- ........Androstenedione ........... Testosterone
SRD5A2HSD3B2
DHT
Fig. 1. The pathways of steroid hormone biosynthesis. Initiation of synthesis of all steroid hormones occurs by
the conversion of cholesterol to pregnenolone by the cholesterol side-chain cleavage enzyme, mitochondrial
cytochrome P450scc. Pregnenolone may be converted to 170H-pregnenolone by 17a-hydroxylation. The
adrenal and gonad may cleave the steroid C17,20 bond and convert 170H-pregnenolone to DHEA which is
the precursor of all sex steroids.
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1.2.5 Molecular mechanism of androgens
In the bloodstream, testosterone circulates either free or is bound to specific binding
proteins such as SHBG4, or even more loosely bound to albumin (Randall, 1994).
Testosterone enters prostate cells freely, down an activity gradient by a passive
diffusion mechanism (Wilson JD, 1992) and is rapidly converted to its metabolically
more active form, DHT, via cytoplasmic Sa-reductase. These androgens diffuse into
the nucleus where DHT and to a lesser extent, testosterone, bind to the androgen
receptor (AR) as depicted in Figure 2. AR ligand interactions also occur in the
cytoplasm of target cells, leading to dimerisation and subsequent translocation to the
nucleus. Although testosterone and DHT bind to the same androgen receptor
protein, DHT has a much higher affinity for the receptor (Grino et aI, 1990) based on
the decreased rate of dissociation of the DHT-receptor complex resulting in an
increased efficiency in the stability of the binding. In contrast with DHT, testosterone
has an accelerated off-time and at equimolar concentrations is only 33% as active as
DHT (Grover and Odell, 1975).
Only a small amount of DHT re-enters the plasma while a larger proportion is
converted to androsterone or androstenediol that circulate as glucuronide conjugates
(Lookingbill et aI, 1991). The AR has a relatively low affinity for adrenal androgens
such as DHEA and androstenedione (Culig et aI, 1993) and for non-androgenic
steroids like progesterone and estradiol (Wilson and French, 1976).
4 A serum protein which demonstrates a high affinity for androgenic steroid hormones
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Fig.2. Diagrammatic representation of the model for the mechanism of androgen action. T or its metabolite,
DHT, binds to specific androgen receptors (ARs) in cell nuclei. The activated AR-DHT complex binds to
androgen response elements (AREs) of target genes, triggering the appropriate alteration in mRNA and
proteinsynthesis.
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Binding of androgen-ligands to the AR, activates the receptor and induces an
allosteric conformational change of the protein which results in hormone-dependant,
DNA-independent phosphorylation of the receptor at several sites and dissociation
from receptor-associated heatshock proteins (HSPs) (Carson-Jurica et ai, 1990;
Housley et ai, 1990; Smith and Toft, 1993). The mechanisms of receptor activation
are quite complex and could be influenced by local growth factors, neurotransmitters
or vitamins (O'Malley and Tsai, 1992). Removal of HSPs allows for AR dimerization
with another bound AR, which in turn unmasks the highly conserved region of the
DNA-binding domain that is concealed in the inactive receptor. The binding domain
takes the form of zinc fingers which are able to interdigitate with the DNA helix,
binding to specific palincrornic'' androgen response elements (AREs) on androgen-
regulated target genes and their flanking DNA (Freedman, 1992; Wong et ai, 1993).
Binding of AR homodimers to DNA is associated with hyperphosphorylation as a
result of activation of hormone-dependant, DNA-dependant phosphokinase. The
hyperphosphorylated AR-ARE complex interacts with the preinitiation complex in the
promoter region of a regulated gene. The preinitiation complex consists of several
converging cis and trans-factors and enzymes, including RNA polymerase II, which is
involved in gene transcription. It is thought that the upstream AR-ARE complex
associates with the preinitiation complex via DNA loops thus stabilizing the promoter
and increasing the rate of gene transcription. The appropriate genes in the cell are
switched on or off to alter the mRNA and therefore the proteins produced by the cell,
as shown in Figure 2 (O'Malley et ai, 1991). Accessory factors are recruited into this
complex by steroid receptors and include coactivator and corepressor proteins which
function as signalling intermediates between receptors and the general transcription
5 Palindromes are nucleotide sequences in which the 5' to 3' sequence of one strand of a segment of
DNA is the same as that of its complementary strand
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machinery. Some transcription factors such as SRC-120 and TIF-1 (Le Douarin et ai,
1995) seem to interact with most steroid receptors, while others are thought to be
specific for certain steroid receptors. ARA70 has been the first identified ligand-
dependant-associated protein for the AR and shows preference for the AR by
functioning as a specific coactivator for enhancing receptor-dependent transcriptional
activity (Yeh and Chang, 1996).
1.2.5.1 Genes regulated by androgens
Androgen-regulated genes are thought to have hormone response elements (HREs)
in their first exon or 5' flanking region which interact with AR-dimers (Adler et ai,
1992; Roche et aI, 1992). If functional HREs are not palindromic, they exist as
repeats or inverted repeats which contain variable spacer base pairs between repeat
sequences that are important for determining specificity. There are two groups of
HREs; those that aid thyroid, retinoic acid and estrogen responses and those which
regulate the responses of glucocorticoids, progesterone and androgens. The
aforementioned class of HREs are called glucocorticoid receptor elements (GRE);
TGTTCT, as glucocorticoid receptors transduce the greatest response in tyrosine
aminotransferase (TA T) genes and in the mouse mammary tumour virus (MMTV). A
consensus sequence described as a 15-bp element of 2 imperfect indirect repeats
with a 3-bp spacer (Roche et ai, 1992), has been derived for the AR and is quite
similar to the GRE. Two AREs were identified in the 5' flanking region of the
androgen-regulated probasin gene and it has been shown that they have a high AR
specificity (Rennie et aI, 1993). Even though the first ARE was similar to the GRE,
the second ARE was distinct. Together, these AREs mediate the androgen
response. It was further shown that tissue specific accessory factors or so called
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trans-acting factors, could be important in determining the binding specificity to
HREs/ AREs (Rennie et aI, 1993). Specific upstream cis-acting elements have been
identified on androgen-responsive genes which regulate androgen responsiveness
(Adler et aI, 1992; Supakar et aI, 1993). This includes one which interacts with a
nonreceptor trans-acting protein (Adler et al, 1992).
The human prostate-specific kallikreins, human glandular kallikrein-1 (hKLK2) and
prostate-specific antiqen", members of a subgroup of serine proteases (Watt et aI,
1986; Schedlich et al, 1987; Evans et al, 1988; Lundwall 1989), have been shown to
be regulated by androgens on interaction with the AR-complex. There is about 80%
homology between PSA and hKLK2 in the 5' flanking region from -300 to -1 with
respect to the cap site (site of initiation of transcription). The promoters of both
genes contain AREs in their 5' regions, and it is believed that androgens directly
regulate their transcription rates (Wolf et aI, 1992; Klee et ai, 1999). The PSA protein
is well characterised and is now widely used as a serum marker for human CaP
(Wang et ai, 1981). New studies also demonstrate the utility of human kallikrein as
an independent CaP marker (Parker et al, 1988).
1.2.6 Genes in the Androgen Metabolism Pathway
Due to the androgen dependence of prostate carcinoma (Huggins and Hodges,
1941) and the assumption that variations in androgen metabolism and synthesis
could affect a person's risk, genes that encode enzymes involved in the androgen
pathway are considered ideal candidates for CaP susceptibility. It has also been
6 PSA has been used classically in clinical studies, so the term is used interchangeably with hKLK3
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suggested that a cascade of genetic alterations, modulated by epigenetic events',
cause the initiation and progressive growth of prostate tumours.
The genetic control of androgen biosynthesis, transport and metabolism is a very
complex process, which directly or indirectly involves hundreds of genes. A few such
genes in the androgen metabolic pathway have been explored in this study and have
been selected based on criteria suggested by Ross and colleagues (Ross et aI,
1998): The products of the genes involved should possibly play a critical role in
androgen stimulation of the prostatic epithelium, polymorphic genetic markers must
be known and it must be evident that the various polymorphic alleles have functional
consequences or are linked to loci with functional relevance. Since race-ethnicity is
such a powerful feature in CaP, this group also suggested that interracial allelic
variation of the polymorphic markers among the populations at different underlying
risk of CaP should occur in a way predicted by the functional studies of the
polymorphisms. Multiple functional polymorphisms could also be present in the
same gene, so an individual could carry high-risk and low-risk markers and have an
overall risk level that is the same as the general population.
The genes of interest are listed in Table 1 together with the main function of their
protein products.
7
Refers to any factor that can affect the phenotype without change in the genotype
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Table 1. Target genes possibly involved in prostate carcinogenesis in the androgen
metabolism pathway
Target gene Function
Cytochrome p450c17a (CYP17) Testosterone biosynthesis
Cytochrome p450 3A4 (CYP3A4) Testosterone metabolism
Steroid 5-a-reductase type II (SRD5A2) Testosterone bioactivation
Androgen receptor (AR) Androgen transport and transcriptional
activation
The major metabolic androgen pathway relating to the prostate and the relevant sites
of activity of the gene products of interest is illustrated in Figure 2.
The cytochrome p4S0c17a (CYP17) gene encodes the enzyme that regulates critical
steps in testosterone biosynthesis, the cytochrome p4S0 3A4 (CYP3A4) gene is
involved in the biotransformation of testosterone to 2f3-, 6f3-, or 1Sf3-
hydroxytestosterone. The steroid Sa-reductase type " gene (SRD5A2) encodes the
enzyme responsible for converting testosterone to the metabolically more active
DHT, and the androgen receptor (AR) gene encodes the androgen receptor allowing
for androgen binding and transport, DNA binding and transactivation of androgen-
regulated target genes.
1.2.6.1 The androgen receptor: structure and function
After the discovery was made that uterine cells preferably retain radiolabeled
estrogen over other steroid molecules (Toft and Gorsky, 1966; Jensen et aI, 1968),
the concept of intracellular steroid-specific binding proteins or receptors was
introduced. Shortly afterwards, other binding proteins for steroid ligands were found,
which include those for progesterones, glucocorticoids and androgens (Baxter and
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Tomkins, 1971; Belsham et al, 1995). The AR was first described in 1969 (Fang et
aI, 1969). The gene was subsequently cloned by several independent groups
(Lubahn et al, 1988; Trapman et al, 1988; Tilley et al, 1989) and has since been
studied extensively in attempts to elucidate its role in the development and
progression of CaP.
Southern blot analysis revealed that the human AR gene is a single-copy gene,
localised to the centromeric region on the X-chromosome at band q11-12 (Brown et
aI, 1989). The entire gene spans a total length of 75-90kb and produces a
messenger ribonucleic acid (mRNA) transcript of approximately 11kb. Northern
analysis of human and rodent tissues has demonstrated two AR mRNA species of
8.5 and 11kb, respectively, in several cell lines resulting from differential processing
of precursor mRNA (Lubahn et al, 1988; Faber et al, 1991; Wolf et al, 1993). The
different sizes of the mRNA species and the translational open reading frame" is due
to the presence of variable untranslated 5' and 3' sequences (Refer to Section
1.2.6.1, describing the NH2-terminal domain). In the human prostate and in genital
skin fibroblasts, the 11kb size mRNA is predominantly expressed. The AR gene is
divided into 8 exons, separated by introns of up to 26kb in size (Kuiper et et, 1989).
The coding region is spread over an ORF of almost 2760 nucleotides. Exon 1 is a
relatively large 1,613 bp and contains two polymorphic trinucleotide repeat segments.
The structural organisation of the AR gene is essentially identical to those of genes
encoding for other steroid hormone receptors as the exonlintron boundaries are
highly conserved (Kuiper et al, 1989; Lubahn et al, 1989; Zong et al, 1990; Keaveney
et aI, 1991). The structure of the AR gene is illustrated in Figure 3. Two transcription
8 ORF: the interval between the start and stop codon that encodes amino acids for insertion into
polypeptide chains; codons: nucleotide triplet encoding for a single specific amino acid
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initiation sites are found in a 13-bp region in the promoter area (Tilley et al, 1990;
Faber et al, 1991). Homologous down-regulation of AR gene expression occurs in
the prostate but an ARE has not been identified in the promoter region. The
promoter does not contain the classic TATA or CCAT boxes but rather has a GC box
that could playa role in initiation of transcription (Faber et aI, 1993). The presence
and functional involvement of an SP1 site has, however, been reported.
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Intron size (kb) >26 >15 26 5.6 4.8 0.8 0.7
5'
1~3
~ I - LLJ 2 LLJ 3 LLJ 4 LLJ 5 LLJ 6 LLJ 7
(CAG)n (GGC)n 152 117 288 145 131 158 155
Introns 1 2 3 4 5 6 7
Fig.3. The AR gene spans 75-90kb of genomic DNA. The eight exons (numbered within boxes) with their sizes in base pairs (drawn to a
scale of 10mm = 100bp) shown directly below the boxes, are separated by introns (numbered below the diagram) with sizes ranging from
0.7 kb to more than 26 kb. Exon 1, which is relatively large, contains two polymorphic trinucleotide repeats, viz. CAG and GGC tracts that
vary in length within and across racial/ethnic populations.
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A 50-bp purine-rich region situated 70 bp upstream from the transcription start site
has been described as the most important cis-acting element for AR gene
transcription (Mizokami et aI, 1994). In addition, a cyclic adenosine monophosphate
(cAMP) responsive element, AR/CRE, has been identified upstream, as well as
several potential cis-acting elements, including retinoic acid response element
(RARE) and AP-1; implying that the AR gene expression could be regulated by
various mechanisms.
The AR gene codes for a ligand-activated nuclear transcription factor that mediates
the action of steroid hormones, namely the androgen receptor (AR) (Beato, 1989). It
belongs to a large group of proteins with regions of highly conserved structural
homology and includes specific receptors for oestrogen, progesterone,
glucocorticoid, mineralocorticoids, vitamin 0, thyroid hormone, retinoic acid as well as
orphan receptors" (Trapman and Brinkmann, 1996; Trapman and Cleutjens, 1997;
Prins, 2000). The AR ORF codes for a 910-919 amino acid peptide with a calculated
molecular mass of 110 kO (Trapman et ai, 1988; Faber et aI, 1989) (The variable
length of the protein is explained further in the text when the domains of the AR are
described). This primary structure of the AR is depicted in Figure 4. The protein is
nearly ubiquitous, as only bone marrow and the spleen show complete absence of
AR expression (Lindzey et al, 1994; Taplin et al, 1995).
9 The hormone or ligand required for functional activation has not been identified for some receptors;
thus the term orphan receptors
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Fig.4. Schematical representation of the primary structure of the human AR with its different functional domains. Between the
DBD and the LBO is the hinge region, an area with low sequence homology between the AR and other steroid receptors, which
contains the major part of the AR nuclear targeting signal. Grey blocks with the corresponding residue and number of amino
acids below indicate the polyamino acid repeats in the TAD. Regions representing the transactivating capacity of the AR in the
NH2 -terminal and eOOH-terminal domains are shown by black lines. The rest of the numbers indicate the amino acid positions
of the various functional and structural domains.
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The AR was first characterised based on its physicochemical properties such as the
affinity for binding testosterone or DHT (expressed as Kd), specificity for binding
various androgens, sedimentation coefficient, thermolability and DNA binding.
Activation of receptors by androgens changes the structural characteristics of the
receptor from a heteromeric structure'? that forms complexes with other proteins and
does not bind to DNA, to a hornodimer" with a capacity to bind to specific DNA
sequences (Carson-Jurica et ai, 1990; Brinkmann et ai, 1992; Truss and Beato,
1993). Based on these functional studies of the AR protein in cell extracts,
researchers have found that the AR is structurally divided into four domains (as
shown in Figure 4): the amino (NH2)-terminal transcription activation (transactivation)
domain (TAD) encoded by a single exon (exon 1), the central DNA-binding domain
(DBD) encoded by exons 2 and 3, a hinge region encoded by the 5' portion of exon 4
and the carboxy (COOH)-terminal ligand-binding domain (LBO) encoded by
sequences in exons 4 to 8 (Faber et al, 1989; Kuiper et al, 1989; Lubahn et al, 1989;
O'Malley, 1990; Cude et ai, 1999). The domains are independently folded structural
modules linked by extended polypeptides. Three-dimensional structures for the
DBDs or LBDs for a number of these receptors in the superfamily were determined
by X-ray crystallography (Luisi et ai, 1991) or nuclear magnetic resonance (Hard et
aI, 1990), and reveal a folding pattern that is common across the family as predicted
by the conserved amino acid sequences. The ligands for these steroid hormones are
also closely related in structure, however, individual receptors distinguish ligands with
stereochemically specific recognition and accurately activate specific genes in
response to the binding of selected ligands.
10 Composed of different molecules
11 2 identical molecules joined together
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Unbound AR can be found distributed within the cytoplasm and nucleus of prostate
cells (Thompson and Chung, 1984; Brinkmann and Trapman, 1992; Zhuang et aI,
1992; Paris et al, 1994; Bourguet et al, 1995; Trapman and Brinkmann, 1996).
Androgens bind to the COOH-terminus in the steroid binding pocket of the AR. After
ligand binding, the DBD and a lysine-rich nuclear localisation region, located between
the DBD and LBO, are exposed (Veldscholte et al, 1992; Ikonen et al, 1994; Zhou et
al, 1994; Beato et al, 1996; Trapman and Brinkmann, 1996; Culig et al, 1998).
Activated AR's then dimerise and translocate to the nucleus (Beato et aI, 1996). The
DNA binding domains of AR dimers include two "zinc fingers" that recognise and bind
to specific sequences known as AREs in the promoter region of target genes; the first
zinc finger stabilizes the receptor-DNA interaction (Huggins and Hodges, 1941). At
the promoter site, the NH2-terminal and steroid binding domains of the receptors
interact with other transcription factors and cause either an increase or decrease in
the transcription rate of the gene (Fronsdal et al, 1994; Gao et al, 1996; Yeh and
Chang, 1996). This process of androgen receptor activation leading to the eventual
alteration of transcriptional activity of target genes has previously been described in
more detail in Chapter 1.2 (Molecular mechanism of androgen).
The large TAD comprises more than half of the AR protein and has a length of over
500 amino acids. Of the three major domains shared by nuclear receptors, this
region exhibits the least conserved sequences and as result represents the most
immunogenic part of the protein (Wilson et aI, 1992). The NH2-terminus contains the
sequence information to optimise the receptor's transactivation capability (Jenster et
aI, 1991; Simental et aI, 1991) and to specify gene recognition in the regulation of
transcription (Jenster et aI, 1992). This TAD, has been assumed to interact directly
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or indirectly (mediated by co-activators) with other specific and general transcription
factors. It has also been supposed that an interaction takes place between the NH2-
terminal domain and protein components of the chromatin complex. The
experimental evidence for these hypotheses is however, still lacking. Deletion
mapping of the NH2-terminal domain has been performed to identify the regions
necessary for transactivation function. Almost the whole NH2-terminal region was
found to be essential for maximum transactivating activity (Jenster et aI, 1991;
Jenster et al, 1995; Simental et al, 1991). The boundaries of the NH2-terminal
transactivation domain have not exactly been specified but a core segment (AF-1 in
Figure 4), with over 50% activity, has been defined in the region between amino
acids 141 to 338 in the full length AR. In the absence of ligand, the AR and therefore
this domain, is inactive. This is not due to the cytoplasmic location of the receptor
because a truncated AR without the complete LBO, which is constitutively active,
also has almost no transactivating activity. In this artificial construct, the region from
amino acid 360 to 485 (designated AF-5 in Figure 4) is responsible for most of the
transactivational activity in this constitutively active AR mutant, lacking the LBO
(Jenster et al, 1995). The finding of two separate transactivating domains and the
observation that their functionality depends on the presence or absence of the LBO
suggests an interaction between the two domains. In fact, recent in-vivo protein-
protein interaction studies with separate NH2-terminal and ligand-binding domains
demonstrated that such a ligand-dependent, functional interaction is possible (Wong
et al, 1993; Langley et al, 1995; Doesburg et al, 1997). It is however, unknown
whether these interactions can take place in the full length receptor, whether
interactions are direct or indirect (via one or more bridging factors), and whether
these proposed interactions take place between different parts of one receptor
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protein (intramolecular) or between two receptor proteins (intermolecular) in the full
length AR. The former model is possible if the proteins' structural flexibility allows
such an interaction. It also has to be established which parts of the domain form the
protein-protein interphase. In the latter case, the interaction will assist in the
formation of AR homodimers. It is not clear whether interactions can take place
between two LBDs during AR dimerisation, as has been confirmed in the case of the
estrogen receptor (Fawell et aI, 1990). The NH2-terminusmay also contribute to the
three-dimensional structure of the receptor molecule through interactions with other
regions of the protein (Evans, 1988).
The NH2-terminal domain of the AR receptor is characterised by a relatively high
amount of acidic amino acids between residues 100 and 325 which results in a nett
negative charge at this site that could be important in transcription regulation (Faber
et aI, 1989), as acidic domains in yeast factors have been found to be involved in the
regulation of transcription (Ptashne, 1988). This domain of the receptor is unique
among the nuclear receptor superfamily as it contains several homopolymeric amino
acid stretches. These sequences include a polyglutamine tract, a polyglycine repeat
and a polyproline tract (Lubahn et aI, 1988b). The most NH2-terminalof these is the
polyglutamine stretch (~amino acids 58-79) encoded by a polymorphic CAG triplet
repeat region (Sleddens et aI, 1992), containing an average of 21 ± 2 glutamine
residues (La Spada et aI, 1991). A similar polyglutamine tract is also present in the
glucocorticoid receptor and is found in the rat AR (Choong et aI, 1998). Further
downstream is a shorter stretch of eight proline residues, situated approximately at
amino acids 372-379, that does not vary in size. The polymorphic polyglycine region
of about 23 residues (~amino acids 449-472) is closer to the DBD and is encoded by
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GGG repeats. Due to the polymorphic GAG and GGG repeats, the length of the AR
may vary between 900 and 930 amino acids, leading to confusion concerning the
numbering of the individual amino acid residues. Therefore the AR has been
described as having amino acid positions which correspond to a receptor of 918
amino acid residues as indicated in Figure 4. The biological functions of these
polymorphic motifs of the transactivation domain is not known as yet, but evidence
from studies of other transcription factors show that particularly the polyproline and
polyglutamine tracts could play an important role in regulation of transcription via
protein-protein interactions with other transcription factors. Most proteins in which
similar repeats were identified are involved in regulation of gene expression andlor
developmental control (Haynes et aI, 1987; Burglin, 1988). The GAG repeat is
especially extremely polymorphic and offers the possibility of linkage studies in
families with supposed defects in AR function. Variation in the length of this repeat
can also be used as a marker for the AR gene as well as an X-chromosome marker
(Boehmer et ai, 1997; Li et ai, 1998). Based on in vitro experiments after transient
transfeetien of AR cONA's which contain different lengths of GAG repeats (Jenster et
ai, 1994; Kazemi-Esfarjani et ai, 1995), differences in repeat length (8-35 glutamine
residues) were observed in the normal population and have been implicated to be
associated with a mild modulation of AR activity (Nance, 1997; Buchanan et ai,
2001)).
DNA binding domain
The DBD of the AR reveals approximately 80% homology with the corresponding
domains in the mineralocorticoid receptor (MR) and progesterone receptor (PR). The
66 amino acid DBD is rich in cysteine, lysine and arginine, and was predicted to
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associate with DNA based on its similarity to regions within known DNA binding
proteins e.g. TFllla (Weinberger et aI, 1985). Detailed crystallographic information is
also available of the DBD of the estrogen and glucocorticoid receptors complexed
with DNA (Luisi et aI, 1991). In the glucocorticoid receptor (GR) and estrogen
receptor (ER) the DBD region is arranged as a pair of loop structures folded to form a
single structural unit made up of two zinc-binding motifs (Freedman, 1992; Schwabe
et aI, 1993). Central in the structure of the DBD are four cysteine residues, invariably
present in all steroid receptors, which co-ordinately bind a zinc ion, tetrahedrically, in
each of the two zinc clusters (commonly referred to as zinc fingers) (Evans, 1988).
These structures are highly conserved among all members of this gene superfamily.
By analogy with other steroid receptors, it is likely that an a-helix structure, if formed
by the last part of the NH2-terminal zinc finger, directly contacts the bases in the ARE
in the DNA (Green et aI, 1988; Berg, 1989; Freedman, 1992; Truss and Beato,
1993). Nucleotides at the distal end of the first zinc finger encode three amino acids
(glycine577, serine578, valine581) referred to as the "P box", which is supposed to
be important in specific recognition of the ARE. These groups of amino acids are
conserved between the AR, PR, GR and MR. Therefore the homodimers of the four
receptors recognise the same, imperfect, transcriptional enhancer palindromic
sequence (GGAlTACAnnnTGTICT) in or near target genes, in the 5' flanking region.
This consensus sequence is a high affinity binding site for these receptors (Nordeen
et al, 1990; Roche et al, 1992; Lieberman et al, 1993; Kallio et al, 1994). In the
regulatory regions of natural target genes, however, the sequence of the binding site
might differ considerably from the consensus sequence. Nucleotides at the proximal
end of the second zinc-finger, which is highly basic, encodes a region known as the
"0 box" that facilitates co-operative binding of a receptor homodimer to an ARE by
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protein-protein interactions with the DNA phosphate backbone, determining the
spacing of the two ARE half-sites and also mediating dimerisation (Green et ai, 1988;
Berg, 1989; Luisi et ai, 1991; Wong et aI, 1993). At the carboxy-terminal end of this
region of the AR is an argininellysine pair that forms part of the nuclear targeting
sequence as described (Zhou et aI, 1994) under the heading of "The hinge region".
The hinge region
In the absence of its ligand, the AR is distributed over the cytoplasm and the nucleus
and addition of androgen results in a rapid migration from the cytoplasm to its site of
action in the nucleus (Jenster et al, 1991; Zhou et al, 1994). This nuclear
translocation depends on the presence of an intact bipartite nuclear localisation
signal situated in the region between the DBD and the LBO. A low sequence
homology of this region known as the hinge exists between the AR and other steroid
receptors. The main part of the AR nuclear targeting signal consists of a cluster of
basic residues at positions 628-657.
The ligand binding domain (carboxy terminus)
The eOOH-terminal third of the AR is predominantly hydrophobic and encompasses
approximately 250 amino acid residues, containing the receptor's ligand binding
function. This region displays about 50% identity with the corresponding residues in
PR, MR and GR. There are, however, short stretches that have between 65% and
100% similarity. The integrity of the entire domain is important for the specific, high
integrity binding of androgens as most deletions or point mutations in this region
suppress proper ligand binding (Jenster et al, 1991; Simental et al, 1991; Quigley et
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al, 1995). A part of the LBO is also important for receptor dimerisation (Fawell et al,
1990; Doesberg et al, 1997).
Elucidation of the 3D crystallographic structure of the LBO of different retinoic acid
receptors (9-cis-retinoic acid receptor alpha - RXRa and all-trans retinoic acid
receptor gamma - RARy), thyroid hormone receptor alpha (TRa), estrogen receptor
alpha (ERa) and PR reveals that a common tertiary structure with a variable number
(10-12, depending on the type of receptor) of a-helices and an antiparallel 13 sheet
arranged in a helical sandwich are involved in the formation of an interaction surface
for transcriptional coactivators, the transcriptional intermediary factors (TIFs)
(Bourguet et al, 1995; Renaud et al, 1995; Wagner et al, 1995; Brzozowski et al,
1997; Williams and Sigler, 1998; Feng et ai, 1998). Despite differences in structure
and the number of a-helices, a high degree of homology is observed in the 3D
structure of the LBDs of the TRa, ERa and PR. Predominantly involved in the
formation of the hydrophobic binding pocket are the l3-turnand helices 3, 5, 7, 11 and
12. Amino acid residues in these helices are in contact with the ligand. An
interaction surface is formed with ligand binding, allowing interactions with other
proteins (e.g., TIFs).
Various nuclear receptors contain a ligand-dependent transactivation function (AF2)
in their LBDs (Danielian et al, 1992; Barettino et al, 1994; Gronemeyer and Laudet,
1995). In this AF2 region, an independent activating domain, AF-2 AD, which is
conserved among many nuclear receptors, is found in the eOOH-terminal part of the
LBO (Wurtz et ai, 1996). A core region in the AF-2 AD, situated in helix 12, seemed
to be important for the hormone-independent interaction with TIFs and transcriptional
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activity (Danielian et al, 1992; Barettino et al, 1994; Lanz and Rusconi, 1994,
Montana et al, 1996; Berrevoets et al, 1998; Feng et al, 1998). The transcriptional
activity of a broad range of nuclear receptors can be modulated by these TIFs
(Cavailles et al, 1995; LeOouarin et al, 1995; Onate et al, 1995; Vam Baur et al,
1996; Voegel et al, 1996; Yeh and Chang, 1996; Berrevoets et al, 1998). The in vitro
association of the receptor with these TIFs can be destroyed by mutations in the AF2
AD core region. It has recently been found that TIFs display acetyltransferase
activity and this has provided further understanding about the molecular events which
occur at the chromatin level during the activation of transcription. A general
mechanism for nuclear receptor activation was proposed by Wurtz et al (1996), in
which the AF-2 AD core, present in helix 12, plays a central role in the formation of
an interaction surface, allowing binding of TIFs to the LBO. The amino acid residues
involved in this surface have been investigated and identified in the TR LBO, and it
appears that the interaction surface contains a hydrophobic cleft (Feng et ai, 1998).
Residues located in helices 3, 4/5, 6 and 12 form the surface cleft. Formation of this
surface occurs with ligand binding when the COOH-terminal alpha helix 12 is folded
against the scaffold of the three other helices (Feng et ai, 1998).
No information is available for the AR LBOwith respect to 3D structure but based on
the high homology in the various LBOs of the various nuclear receptors, it can be
predicted to resemble the PR to a large extent (Trapman et ai, 1988; Tanenbaum et
ai, 1998). A common 'mouse trap-like' mechanism of ligand binding has been
proposed for the AR. Helix 12, which contains the AF-2 core sequences, folds back
to the core region of the LBO, then comes into close contact with the ligand and seals
the ligand pocket. The conformational change induced by hormone binding could
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create an interaction surface that allows binding of transcriptional co-activators, like
TIF-2 or its mouse homologue GRIP-1 and the AR-specific co-activator ARA70 (Hong
et al, 1996; Voegel et al, 1996; Yeh and Chang, 1996).
A transcription activation function (AF2) has been identified in the LBO of the human
AR even though it is very weak when compared with that found in other steroid
receptors such as ERs and GRs (Hong et al, 1996; Voegel et al, 1996; Berrevoets et
aI, 1998). The AF2 domain can be activated in a hormone-dependent way and is
strongly enhanced in a promoter dependent way by the co-activators TIF2 and
GRIP1 (Hong et al, 1996; Voegel et al, 1996; Berrevoets et al, 1998). The
boundaries of the AF2 domain in the AR LBO have not yet been determined but
contain the core region as defined in the LBOs of several members of the ligand-
dependent nuclear receptor family (as shown in Figure 4). This AF2 activation
domain core region contains the conserved sequence 884-Glu-Met-Met-Ala-Glu-888.
Mutations in this region can result in a decrease in activation capability without
affecting the ligand-binding function, indicative that the amino acid residues of the
AF2-AO core region are not directly involved in ligand binding, but are part of or
determine the interaction surface. This presumption has been confirmed by studies
on mutations in this region and the interaction of coactivators (Feng et ai, 1998;
Berrevoets et al, 1998).
Evidence has been presented for a possible interaction between the LBO and the AF
functions in the NH2-terminal domain as explained under the subheading, 'The
trasactivational domain'. Investigation of this interaction in more detail revealed that
only certain regions in the NH2-terminal domain are involved in this interaction
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(Langley et al, 1995, 1997; Doesberg et al, 1997; Berrevoets et al, 1998). The AF1
core region is not involved in this interaction, but about 33 amino acid residues
before this transactivating region as well as the AF5 region are necessary for an
effective functional interaction. By the substitution of an essential amino acid residue
(Glu 888) for a glutamine residue, it has been found that amino acid residues:
884Glu-Met-Met-Ala-Glu888 in the AF2-AD core region of the eOOH-terminal is
involved in the interaction. The functional interaction of the AR LBO with TIF2 is
affected by a similar sequence variant, which implies that TIF2 and the NH2-terminal
domain recognise the same interaction surface of the LBO with hormone binding
(Berrevoets et al, 1998).
A large multi-protein complex consisting of heat shock proteins is associated with the
unliganded LBO of the AR and maintains the receptor in a transcriptionally inactive
conformation (Housley et aI, 1990; Smith and Toft, 1993). Binding of hormones
results in the dissociation of chaperone proteins from the receptor and initiates
conformational changes in the LBO that are important for receptor dimerisation, DNA
binding and interaction with transcription mediators. Diffusion of the receptor-ligand
complex of the AR and androgens to the nucleus requires the nuclear localisation
signal located in the hinge region between the DBD and the LBO.
Androgen binding to the AR results in two conformational changes of the receptor
molecule (Kuil and Mulder, 1994; Kuil et al, 1995). Initially, a fragment of 35-kDa,
which spans the complete LBO, and part of the hinge region, is protected by the
ligand, but after prolonged incubation times a second conformational change occurs
resulting in protection of a smaller fragment of 29-kDa. Antagonists inhibit the
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biological effects of androgens and compete with agonists for binding to the receptor.
In the presence of various antiandrogens such as cyproterone acetate,
hydroxyflutamide and bicalutamide, only the 35-kDa fragment is protected and no
smaller fragments are detectable upon longer incubations. The 35-kDa fragment is
associated with an inactive conformation, whereas the second conformational
change, which is only inducible by agonists and considered as the necessary step for
transcription activation, is lacking upon binding of antiandrogens. Further analyses
with specific antibodies against different epitopes in the 35- and 29-kDa fragments
have shown that the most COOH-terminal end of the AR protein is represented by
the 29-kDa fragment (Kuil et aI, 1995). Other studies also reveal that antagonists
induce a different conformational change upon binding to the LBO (Zeng et aI, 1994;
Kuil et al, 1995). This aberrant conformation leads to a receptor with a reduced or no
transcriptional activity. Different antagonists could affect various aspects of receptor
functioning like dissociation of heat shock proteins, dimerisation, DNA binding and
interaction with general or specific transcription factors, with coactivators, and with
the NH2-terminal domain.
1.2.6.2 Cytochrome P450c17a
The human 17a-hydroxylase gene has been localised to a specific band, q24.3,
(Matteson et aI, 1986; Fan et aI, 1992) on chromosome 10, spans 6569 bases and is
divided into eight exons by seven introns (Picado-Leonard and Miller, 1987). This
gene is the sole member of a unique gene family (P450XVII) within the P-450
supergene family (Picardo-Leonard and Miller, 1987; Kagimoto et ai, 1988; Nelson et
al, 1993).
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Promoter function is driven by the SF1 protein and the 5' flanking region of the gene
contains 3 functional SF1 elements that collectively mediate 25-fold or greater
induction of promoter activity by SF1 (Hanley et al, 2001). Lin et al. (2001) studied
the transcriptional regulation of CYP17 and found that the most regulatory activity
was confined to the first 227bp. In addition to this a TATA box", a steroidogenic
factor-t site, and 3 previously uncharacterised sites at -107/-85, at -178/-152 and at-
220/-185 were identified. Further experimentation suggested that the -107/-85 site
and the -178/-152 site bind members of the nuclear factor-1 (NF1) family of
transcription factors. Mutations of both these sites reduced basal transcription by
half. Assays also showed that the ubiquitous proteins Sp1 and Sp3 both bind to the -
227/-184 region, and that mutation of their binding sites reduced transcription by
75%. Mutation of the Sp1/Sp3 site and the 2 NF1 sites eliminated almost all
detectable transcription. The authors concluded that Sp1, Sp3 and NF1C proteins
binding to their previously mentioned sites are crucial for adrenal transcription of the
human gene for P450c17 (Lin et al, 2001).
CYP17 encodes a single protein of 508 amino acids, expressed in the adrenal cortex
and gonads (Chung et al, 1987). This microsomal polypeptide, cytochrome P450
steroid 17a-hydroxylase (P450c17), catalyses both 17a-hydroxylase and 17,20 lyase
activities. The dual function of the enzyme in the steroidogenic pathway has been
described in more detail under the section -1.2.4 Androgen biosynthesis.
12 An 8-base-pair sequence conserved in most or all genes studied. It is located about 25 to 30 bases
upstream from the site of transcription initiation and is composed only of thymine = adenine pairs.
RNA polymerase ultimately binds here as part of the initiation complex of transcription
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1.2.6.3 Steroid 5a-reductase type 2
SRD5A2 is located on chromosome 2 at 2p23 (Thigpen et aI, 1993) and spans over
40kb of genomic DNA, with 5 exons and 4 introns (Labrie et aI, 1992b; Russell et aI,
1994). The gene translates into a protein of 254 amino acids (Labrie et aI, 1992b).
The steroid 5a-reductase type II enzyme product is transiently expressed in new-
born skin and scalp, as well as in the liver. It is also found in foetal genital skin, the
male accessory glands, and the prostate, including both BPH and adenocarcinoma of
the prostate (Thigpen et aI, 1993; Luu-The et aI, 1994). The best-known role of this
enzyme is the transformation of testosterone to the metabolically more active DHT,
which in turn transactivates a number of genes involved in prostate development and
growth (Coffey, 1988; Coffey, 1993). Increased DHT synthesis may be involved in
the development of both benign and neoplastic growth of the prostate in elderly men
(Labrie et aI, 1992a) (See section under 1.2.4 Androgen metabolism for further
explanation). It has been suggested that modulation of steroid 5a-reductase activity
could be responsible for some variations in CaP risk among US ethnic groups (Ross
et al, 1992).
1.3 GENETICS OF PROSTATE CANCER
1.3.1 Genetic progression of Prostate cancer
The molecular mechanisms fundamental to the development and progression of CaP
are poorly understood. Transformation of a cell from a normal to a malignant
phenotype and cancer progression depends on a series of genetic changes that
results in activation of proto-oncogenes13 and inactivation of tumour-suppressor
13 Normal genes involved in cell division or proliferation; if activated by some mutational event they
become involved in unregulated cell growth and proliferation responsible for tumour development
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qenes'" normal genes involved in the regulation of cell growth. It has been estimated
that 5-10 such genetic alterations which affect the expression and function of these
critical genes, are required before a normal cell transforms to a fully malignant one.
The majority of these events result from mechanisms like somatic mutations15 and
can also occur due to translocations16 the transfer of a segment from one
chromosome to another or amptfication'",
Development of comparative genomic hybridisation (CGH); allowing the screening of
tumours for DNA sequence copy number changes, and loss of heterozygosity (LOH)
studies, have identified several recurrent chromosomal alterations in CaP. CGH
studies have shown that the loss of genetic material is an event which occurs early in
CaP and is five times more common than DNA copy number gains or amplifications
(Visakorpi et aI, 1995b). This suggests that the inactivation of tumour suppressor
genes is very important in the early stages of CaP. Hormone-independent CaPs
often contain gains and amplifications, which implies that the late progression of CaP
is also characterised by activation of oncogenes (Visakorpi et aI, 1995a). Commonly
occurring chromosomal aberrations include losses at chromosome regions 6q, 8p,
9p, 10q, 13q, 16q, 17p, 18p and 18q and gains at 7p, 7q, 8q and Xq (Cher et al,
1994; Joos et al, 1995; Visakorpi et al, 1995; Cher et al, 1996 and 1998; Nupponen
et al, 1998; Sattler et al, 1999; Alers et al, 2000). Only a few target genes have,
however, been associated with these alterations. Besides the AR, a number of other
mutated genes have been found in CaP and includes p53, Rb, CDKN2 and ras to
mention a few. These genes and their genetic mechanisms are shown in Table 2.
14 Normal genes involved in the regulation of cell growth
15 Mutation occurring in a somatic cell
16
The transfer of a segment from one chromosome to another
17 The production of multiple copies of a sequence of DNA
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1.3.1.1 AR gene amplification
With the aid of fluorescence in situ hybridisation (FISH), about 30% of hormone
refractory prostate carcinomas were shown to contain AR gene amplification. About
20% of hormone refractory tumours contain additional copies of the X chromosome
and the AR gene (Visakorpi et al, 1995; Koivisto et al, 1997). None of the tumours
analysed prior to endocrine therapy for AR gene-copy number shows high-level
amplification of the gene (Visakorpi et al, 1999; Koivisto et al, 1997; Bubendorf et al,
1999). So it seems that AR amplification is exclusively associated with regrowth of
the tumour during endocrine therapy, when the supply of androgens is rate limiting
and the selection of this genetic event is likely to provide an advantage for cell
growth. It has been reported that similar examples of gene amplification lead to
chemotherapy resistance. AR gene amplification is, however, the first example of
such a mechanism that is related to hormone therapy, implying that castration could
act as an equally strong selection force as chemotherapy.
It is believed that gene amplification can lead to an overexpression of the target gene
of amplification (Alitalo and Schwab, 1986). Therefore, it has been suggested that
amplification of the AR gene could result in overexpression, allowing the continued
growth of androgen-dependent cancer cells even in the presence of low androgen
concentrations left in serum after castration (Visakorpi et aI, 1995; Kallionemi and
Visakorpi, 1996). By using mRNA in situ hybridisation, it was in fact shown that AR
amplification is associated with increased expression of the gene in hormone
refractory prostate tumours (Koivisto et aI, 1997). Even the refractory tumours, which
do not contain amplification of the AR gene, seem to express AR quite strongly,
suggesting that the AR signalling pathway could also be active in the nonamplified
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cases. Uniform expression of the AR displays a clear difference between breast and
prostate cancer, as hormone refractory breast cancer typically loses the expression
of the estrogen and progesterone receptors (Kuukasjarvi et al, 1996). Little direct
evidence is available in favour of a functional AR which is amplified and
overexpressed in hormone refractory prostate tumours. Data exist which show that
tumours with an amplified AR gene initially respond better to castration than tumours
that do not acquire amplification, suggesting that these tumours are androgen
sensitive (Koivisto et al, 1997). Also, preliminary studies show that there is a
statistically significant improvement in progression-free and overall survival in
patients with AR gene amplification who received the so-called maximal androgen
blockade (MAB); which abolishes the effects of adrenal androgens, than patients
without the amplification. This is suggestive of a functional AR signalling pathway
(palmberg et a/1997 and 2000).
Finding of this gene amplification illustrates how the genome-wide surveys by CGH
provide a powerful tool to identify specific genetic alterations with an important role in
cancer progression. Together with studies in classical cytogenetics, loss of
heterozygosity (LOH) measurements and other techniques, these results are
beginning to shape a model of the somatic genetic evolution of CaP (Figure 5). The
precise sequence of genetic events in this process still remains to be determined and
only a few of the genes in the affected chromosomal regions have been cloned.
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1.3.1.2 AR mutations
In addition to AR gene amplification, the gene can also be altered by mutation. More
than 300 different mutations of the AR gene have been reported so far, therefore
making it the most often mutated transcription factor known (McPhaul et ai, 1991,
Quigley et ai, 1995, Choong and Wilson, 1998; Gottlieb et ai, 1998). The majority of
these mutations are spread throughout the LBO, with some clustering in exons 5 and
7. This variability could represent as much as two-thirds of AR coding region
mutations (Quigley et ai, 1995). Most of these mutations have been identified in
patients with varying degrees of Androgen Insensitivity Syndrome (AIS) (McPhaul et
ai, 1991; Quigley et ai, 1995) but presently more than 60 different mutations have
been reported in CaP (Gottlieb et ai, 1998). Twenty-eight percent of these CaP
mutations occur in a "hotspot" between codons 726 and 763, however, only 11% (2
of 17) of the mutations in this hotspot are at a CpG site and only 4 of the 17
mutations have been shown to be pathogenie (Culig et al, 1993; Elo et al, 1995;
Taplin et al, 1995; James et al, 1997). The AR mutations present in patients with AIS
are germline mutations (Quigley et ai, 1995), (present in every cell in the body) and
they are loss-of-function mutations as they inactivate receptor function. Mutations in
the AR of CaPs are more often somatic mutations (present only in the tumour)
(Gottlieb et al, 1998).
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Histologic prostate cancer
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18q
RAS
Metastatic cancer 17p (p53) 7
11 8q (MYC)
Xq (AR) +
others
AR
Hormone refractory
cancer
5q and
others
Fig.5. A schematic representation of somatic changes which are likely to underlie the step-wise
progression of CaP. (Adapted from Visakorpi et aI, 1995). The sketch is based on information from
classical cytogenetics (Sandberg, 1992), CGH analyses (Cher et aI, 1994 and Visakorpi et aI, 1995b),
allelic loss (Isaacs et aI, 1994), chromosome transfection (Rinker-Schaeffer et aI, 1994) and other
molecular genetic studies (Macoska et aI, 1993 and Isaacs et aI, 1994). Affected chromosomal
regions are shown followed by known candidate genes; in parenthesis. Each chromosomal region
could also contain other genes that play an important role in tumour progression. The exact sequence
of genetic events in this process still remains to be determined and only a small fraction of the genes
in the affected chromosomal regions have been cloned. The thickness of the arrow in the middle of
the diagram illustrates the accumulative number of vital genetic changes at each step of tumour
progression, e.g. hormone refractory tumours on average contain twice as many genetic changes than
untreated primary tumours (Visakoroi et al. 1995).
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The first AR gene mutation found in CaP was in a well-characterised human prostate
carcinoma cell line, lymph node prostate cancer (LNCaP). This single base mutation
in the HBO (exon 8) converts a threonine to alanine and its position was reported by
Harris et al (1990) to be codon 877 (ACT~GCT) of a 919 codon AR cDNA (Lubahn
et ai, 1988b and 1989; Harris et ai, 1990), while Veldscholte and colleagues (1990)
found the same mutation in codon 868 of a 910 codon AR cDNA (Jenster et al, 1991;
Veldscholte et ai, 1990); these are equivalent positions. Unlike AR gene mutations in
AIS, the LNCaP mutation does not abolish receptor function. The LNCaP mutant
binds androgen with an affinity which is similar to that of wild-type AR, and, like wild-
type AR, is transcriptionally activated by androgen (Veldscholte et ai, 1990).
However, this mutant AR has altered steroid specificity compared to wild-type AR
and can also be transcriptionally activated by estrogen, progesterone, or the
antiandrogens cyproterone acetate or hydroxyflutamide (the active metabolite of
flutamide) (Veldscholte et ai, 1990). The same codon 877 mutation was found in
6/24 (25%) patients with advanced hormone-resistant prostate cancer (Gaddipati et
ai, 1994) and another study described the mutation in metastatic specimens of one
patient (Suzuki et ai, 1993), providing a strong support for the in vivo significance of
this AR mutation.
The first somatic mutation in the AR gene in clinical CaP, occurring in the tumour
before hormonal therapy, was reported in 1/26 specimens as a single base change
found in codon 730, replacing valine with methionine (Newmark et ai, 1992). This
Val (GTG) ~ Met (ATG) mutation results in an altered binding specificity of the AR,
similar to that seen in LNCaP cells (Culig et aI, 1993).
Stellenbosch University http://scholar.sun.ac.za
67
Numerous mutations have been found in the HBO of advanced CaP (Culig et aI,
1993; Gaddipati et aI, 1994; Taplin et aI, 1995; Bentley and Tilley, 1996). Culig and
associates (1993) found a mutation in one hormone refractory tumour at codon 715
(Val ~ Met) that increased the efficacy with which progesterone and adrenal steroids
like DHEA and androstenedione could activate transcriptional activity of the AR,
allowing tumour cell proliferation at low levels of these circulating androgens. These
findings suggest that the mutant receptor leads to a gain of function, rather than a
loss.
Some studies report a relatively high frequency of AR mutations, while other
investigations show a much lower frequency of mutation in clinical specimens; with
the frequency of AR mutations varying between 0% and 50% in different reports
(Newmark et al, 1992; Culig et al, 1993; Suzuki et al, 1993; Gaddipati et al, 1994;
Ruizeveld et al, 1994; Schoenberg et al, 1994; Elo et al, 1995; Takahashi et al, 1995;
Taplin et al, 1995; Evans et al, 1996; Suzuki et al, 1996; Paz et al, 1997).
Discrepancies in methodology and patient sampling could account for this variation.
Marcelli and colleagues examined 137 samples of CaP from different stages in
disease development, for the presence of AR mutations (Marcelli et aI, 2000).
Ninety-nine of these were specimens from localised cancer and 34 from local nodal
metastases. Eighty-four of the 99 localised disease samples were microdissected to
enrich for tumour cells. Analyses revealed no mutations in any of the samples of
primary CaP, irrespective if microdissection was performed or not. In samples of
locally metastatic cancer, however, 8/38 samples contained AR mutations. These
analyses were performed on samples of genomic DNA from local nodal metastases,
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before any therapy. The mutations were only found in samples that were enriched
for tumour DNA by microdissection. Although functional analyses of these mutations
have not been reported yet, many of the mutations are predicted to be inactive in
assays of AR function, based on analyses of similar mutations that were identified
and analysed from patients with various forms of androgen insensitivity.
In a study by Tilley and associates, all 8 exons of the AR gene were analysed from
25 CaP patients prior to hormonal therapy (Tilley et aI, 1996). A high frequency of
point mutations (44%), half of which were located in exon 1, were detected in the
cancer samples. This could partly explain the differences in reported AR mutation
frequencies, as most studies have not analysed exon 1, which comprises 58% of the
coding sequence and encodes the entire transactivating domain of the receptor.
A smaller study was performed in Dallas to investigate the frequency of AR mutations
in samples from patients with stage D cancer, in which tumour growth was androgen-
independent. Results of these experiments, however, showed a very low frequency
of AR mutations of less than 10%, even in these samples (Avila and McPhaul,
unpublished observations). The outcomes of the majority of these studies suggest
that the frequency of AR mutations is low in primary CaPs.
AR mutations have also been found in latent CaP, i.e., histological evidence of CaP.
One such study found 18 of 74 (25%) inactivating mutations in the AR gene in the
latent cancers of Japanese men, whereas no mutations were seen in 43 latent
tumours from American men (Takahashi et aI, 1995). The presence of these
mutations causes the ablation of AR activity which precludes latent tumours from
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progressing to clinically evident disease. Because the inactivating mutations occur
so frequently, they could help to account for the lower rates of clinically evident CaP
in Asian men than in other races.
In contrast to the relatively low frequency of AR mutations found in localised CaP,
various other studies have suggested that a much higher incidence occurs in
metastatic tumours. These studies have focused on the analyses of bone marrow
samples from patients with stage 0 CaP.
A preliminary investigation by Taplin and co-workers found a high frequency of AR
mutations in the metastatic deposits of patients (5/10) that have been treated with
different forms of androgen ablation (Taplin et aI, 1995). The cDNAs in this group of
patients were analysed and shown to encode a number of different mutant ARs,
ranging in frequency from 20-100%. In a later study, many of these mutations were
shown to induce novel activation patterns on the mutant receptors (Fenton et aI,
1997). Taplin and colleagues further investigated the frequency and nature of
mutations in metastatic CaP samples from patients treated with AR antagonists and
from patients not treated with AR antagonists (Taplin et aI, 1999). An increased
proportion of these samples were found to express mutated ARs after treatment with
AR antagonists (1/17 untreated as opposed to 5/16 treated). Interestingly, the
mutations identified in the AR antagonist-treated groups were predominantly
composed of substitution mutations at amino acid 877. This mutation together with a
position 874 sequence variant, corresponds to mutations found in cell lines from
patients with CaP (Veldscholte et aI, 1990; Tan et aI, 1997; Zhao et ai, 2000).
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From these studies it seems that the frequency of AR mutations is low in localised
forms of CaP, even in androgen-independent tumours. Also, the frequency of AR
mutations increases as the tumours become metastatic to local lymph nodes and
even rises further when distant metastatic deposits are analysed. These
observations suggest that AR mutations confer some sort of selective advantage that
is most effective as the tumours metastasise.
1.3.2 Genetic susceptibility to Prostate Cancer
The familial nature of complex diseases such as diabetes, heart disease,
hypertension, osteoporosis, psychiatric conditions, infection and cancer, clearly
indicates a significant genetic component. Unlike monogenic disorders, the genetic
contribution consists of multiple disease genes of modest effect. The genetic
complexity could be partly due to heterogeneity where different combinations of gene
mutations may result in similar phenotypes, such as when genes are needed for a
common biochemical pathway or cellular structure. Also, some individuals who
inherit a susceptibility allele may not display the disease (incomplete penetrance),
whereas others who do not inherit susceptibility alleles may still get the disease as a
result of environmental or random causes (phenocopy). Therefore the genotype at a
given locus could affect the probability of disease, but not fully determine the
outcome.
1.3.2.1 Polymorphic variants and disease association
Linkage analysis and association studies are methods with different approaches to
analyse the genetic aetiology of complex disease. Linkage refers to the physical
Stellenbosch University http://scholar.sun.ac.za
71
relationship between two or more genetic markers18 used to identify the position of a
disease gene. Linkage analysis uses family materials and involves constructing a
transmission model" to compare the inheritance pattern of genetic markers to a
disease outcome. Sequences that are closely linked are less likely to be separated
by the reshuffling of deoxyribonucleic acid (DNA) that occurs during meiotic
recombination than more distantly spaced sequences. Therefore markers that are
co-inherited with the disease pinpoint the approximate chromosomal region of an
underlying disease gene. The advantage of pedigree analysis is that disease
inheritance can be compared to patterns of linkage over large genomic areas in order
to map gene mutations. Pedigree studies have been very successful in mapping
hundreds of highly penetrant disease loci for Mendelian diseases due to mutations in
a single gene. It is, however, very difficult to recruit affected families of sufficient
sizes or numbers in order to effectively apply this method. For complex diseases, the
number of families required is not practical and the results obtained for the families
are not additive. Therefore, linkage studies could have limited power for identifying
the moderate gene effects hypothesised to contribute to these diseases that depend
on the interaction of several or many genes and the environment (Risch and
Merikangas, 1996).
Alternatively, association studies based on single nucleotide polymorphisms (SNPs)
have become the prevalent way to approach the genetics of complex diseases (Kwak
et aI, 1996; Brookes, 1999). A SNP is a stable, single base substitution that occurs
at a frequency of more than 1% within the general population and about 90% of
genetic variations in humans are attributable to these allelic variants (Collins et aI,
18 Predefined polymorphic sequences with known sublocations on chromosomes predefined
polymorphic sequences with known sublocations on chromosomes
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1998; Brookes, 1999). The rest of the sequence variation results from
rearrangements, deletions or insertions of one or more bases and repeat length
polymorph isms.
Techniques for SNP identification on a large scale within the human population are
resulting in an exponential increase in the number of SNPs (Wang et aI, 1998).
Within the last two years the search and discovery of SNPs have been so successful
that 1.69 million have been reported since June, 2001, as part of the publication of
the draft human genome sequence (The International SNP Map Working Group,
2001). The NIH SNP database (http://www.ncbi.nlm.nih.gov/SNP) already contains
over 2.8 million cases. There are several other databases including ENSEMBL
(http://www.ensembl.org), UCSC (University of California at Santa Cruz;
http://genome.ucsc.edu) and TSC (The SNP Consortium; http://snp.cshl.org). After
coverage of SNPs on 24,953 exons, it was also reported by The International SNP
Map Working Group, that approximately 85% of all exons were within 5kb of the
nearest SNP.
About 5% of SNPs in the public database have been discovered by gene-based
studies (The International SNP Map Working Group, 2001). Efforts to re-sequence a
gene or set of genes that belong to a common biological pathway have proceeded
slowly. Progress is underway to identify and validate SNPs present in genes from
critical pathways, like the Th1 and Th2 cytokines, complement cascade factors and
mediators of apoptosis. These in turn can be applied to specific studies based on a
reasonable hypothesis. Using this approach enables one to examine a biological
19 Multi-generation family pedigrees
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process as a whole and the choice of candidate SNPs can be extended to include
known genes that take part in the active process.
Even though SNP databases are an important resource, it is not the end result
needed to map complex diseases. It is therefore useful to refer to these SNPs as
candidate SNPs because nothing is known about the frequency in populations for
most of them. Various groups have started characterising the candidate SNPs and
one pilot study in particular was undertaken to see how effective these SNPs in the
public database would be if they were to be developed into genetic markers (Marth et
aI, 2001). Results from this study show that 17% of the SNPs were monomorphic,
i.e., only one of the two predicted alleles was found in all 3 population samples of
African-Americans, Asians and Caucasians in the US and no detectable difference
was observed in any of these 3 major US population groups. Thus these candidate
SNPs would not be useful for genetic studies. The majority of the candidates
represent real variants but with no significant population frequency. Approximately
6% were uncommon SNPs and had rare allele frequencies below 20% in any
population, 52% of candidates were common with minor allele frequencies in 2 or 3
populations and 27% of SNP candidates were common in all 3 populations. The
outcome of this research estimates that if one uses these publicly available candidate
SNPs, there is only a 66-70% chance that they have an appreciable minor allele
frequency and a 50-50 chance that the SNPs are common in a specific population.
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According to a study by Miller and Kwok, 2001, the "life-cycle" of a SNP can be
divided into 4 stages (lettered a - c):
(a) occurrence of a new variant allele by nucleotide mutation
In spite of effective DNA repair mechanisms (Wood et aI, 2001), mutations cause
disease alleles and normal variants in humans. A common SNP is found more or
less every 1000 bp. All combinations of substitution polymorphisms are observed in
humans, with AlG substitution and the reverse complement TIC SNPs as the most
prevalent (Taillon-Miller et al, 1999; Miller et al, 2001).
Methyl CpG to TpG transitions are the most frequently found mutations in humans
and represent 25% of all mutations (Wang et aI, 1998a; Taillon-Miller et aI, 1998).
This is probably a main cause of deficiency of CG dinucleotides observed in the
genomic sequence, as many will eventually become TG. New CpG sites, however,
will be created by other less common mutations. It is a challenge in understanding
how and when mutations cause disease. SNPs in coding (cSNPs) and regulatory
regions are the most likely to affect gene function (Collins et aI, 1997; Chakravarti,
1998; Syvanen et aI, 1999). SNPs, which occur in the promoter regions of genes
that co-ordinate the immune response, for example tumour necrosis factor (TNF),
interleukin 4 (lL4), IL6 and IL 10, have been associated with various infectious and
autoimmune disorders (Taylor et aI, 2001). This suggests that small differences in
the regulation of key genes can strengthen or lessen the effect of a biological
pathway. Since only a small proportion of the genome contains coding regions
(Lander et aI, 2001), the majority of SNPs are likely to have little functional
consequence. Approximately 50% of cSNPs cause missense mutations in the
corresponding proteins, while the other half are silent (Cargill et ai, 1999; Halushka et
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aI, 1999). Missense SNPs could be neutral and not detectably alter the phenotype,
or they could cause differences in individual characteristics, different responses to
drugs or varied susceptibility to disease. It has been proposed that a combination of
SNPs confer susceptibility in many complex diseases but it is not certain whether
rare or common variants will be the responsible determinants (Collins et aI, 1997;
Pritchard, 2001).
(b) survival against odds of the allele through early generations
The second stage of the SNP life cycle is referred to as "survival against odds" as the
majority of new mutations are expected to be lost in early generations due to
sampling. As an example, if a person is heterozygous for a new, selectively neutral,
autosomal mutation and has two children, there is a probability of 0.75 that the
mutation will be found in at least one of the children. Providing the mutant allele
copies are carried by heterozygote individuals in the population who each have two
children, the probability that the new mutation will be lost is 1- (0.75)g, where g =
generations, with the mutation occurring in g = O.
(c) an increase to significant frequency as well as survival through population
changes:
If a mutation survives early generations and increases in frequency to a point where
it becomes homozygous in some people, the third stage is entered and the risk of
loss is reduced. Due to random variables and genetic hitchhiking20, the frequency of
a new allele is expected to show variation, but hindrances in population size will
result in survival of the alleles with the highest frequencies and the loss of rare
alleles.
20 Occurs when linked neutral variants are dragged along with advantageous mutations
Stellenbosch University http://scholar.sun.ac.za
76
(d) fixation
During the fourth stage of the lifecycle, a few SNPs will cease to exist because the
"new" allele will reach 100% in the population and become a difference between
humans and a closely related species. Based on the divergence and variability
within humans, Miller and Kwak, 2001, predicted that the lifetime in which a SNP
becomes fixed for a new allele is 284 000 years.
1.3.2.2 Association studies
One of the main motivations for the discovery of SNPs has been the potential search
for complex disease loci using association studies. In these studies SNPs can be
used as markers for linkage disequilibrium (LO). LO can be described as a measure
of the degree of association (co-segregation) of two closely linked genetic markers
and is therefore used to identify chromosomal regions that are associated with
disease in a population (Morton et aI, 2001). Surrogate markers are used to identify
the gene regions, which show association with the disease and usually indicate the
location of the adjacent causative gene. LO can be generated by selection, mutation
or admixture of populations with different allele frequencies and generally depends
on the population size, generations and distance between genetic markers. Usually
with greater distance between markers, the quicker disequilibrium will decay. For
highly polymorphic markers such as rnicrosatellites, the high mutation rate
significantly contributes to random association of alleles.
Theoretical approaches using computer simulations have predicted that LO would be
limited to ~3kb in the human population, implying that 500 000 SNPs would be
required for a whole-genome association study (Kruglyak, 1999). However,
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predictions from the literature based on empirical data, suggest that 30 000 SNPs
would be sufficient (Collins et ai, 1999).
One study, representing the largest genotyping effort, was performed to evaluate
variation and the extent of LO between the AR trinucleotide repeat loci (CAG and
GGC tracts) in human populations; specifically those of African descent such as
African Americans (Kittles et ai, 2001b). This would be an important requirement to
determine if there are subpopulations of disease chromosomes segregating in high-
risk groups like African Americans. Results showed that the populations of African
descent possess significantly shorter alleles than the non-African groups at a P-value
less than 0.0001. The allelic diversity was higher for both markers among African
Americans" than other populations. Analysis of molecular variance revealed that
almost 20% of CAG and GGC repeat variance could be ascribed to differences
between populations. All non-African populations had the same common haplotype
while the three populations of African descent possessed three varied common
haplotypes, where haplotypes are the particular combination of alleles at different
sites on a single chromosome. Significant LO was observed in the sample of healthy
African Americans and could be as a result of recent migration of African Americans
from various rural communities following urbanisation, admixture with European
Americans and recurrent gene flow from diverse West African populations. The
assessment of LO in the African American population is quite significant because the
high level of stratification could be confusing in disease association studies if the
substructure is not controlled for. Also, the identification of high-risk haplotypes may
be more powerful in disease studies than single locus analyses. The research team
21 Including indigenous Africans from Sierra Leone and Nigeria ncluding indigenous Africans from
Sierra Leone and Nigeria
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of Kittles and co-workers intend to increase the resolution in identification of these
possible high-risk haplotypes for CaP by typing SNPs within the gene and performing
haplotype analysis. Finally these studies will provide a clearer understanding of the
role AR variation plays in CaP aetiology.
One can also search for disease association by genotyping one or a few SNPs from
specific candidate disease genes with hypothesised functional importance.
Association studies of this nature do not concern familial inheritance patterns at all.
They are case-control studies based on a comparison of unrelated affected and
unaffected individuals (controls). An association could be inferred if susceptibility
factor at a gene of interest occurs at a significantly higher frequency among affected
compared with control individuals. A variant might not directly result in a disease
phenotype, but could be a genetic marker in linkage with a nearby locus. Association
studies could be quite useful in identifying genetic markers that modify the risk for the
outcome of disease. Even though association can be performed for any randomly
occurring polymorphism, it is most meaningful when it uses genetic markers
assumed to have a biological relation to the trait.
There are also limitations when using case-control studies, as a positive association
can occur as a result of population admixture. In a mixed population, any
characteristic that is present at a higher frequency in an ethnic group will show a
positive association with any allele that happens to be more common in that group.
Limitations in genotyping technology make it impractical to test large numbers of
SNPs in large numbers of individuals. As a result, published studies have
considered a small number of mutations in candidate disease genes, based on
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previous research. However, only a few of the disease associations appear to be
reproducible when they are retested with independent clinical materials. This may
lead to increased doubt concerning the usefulness of genetic association analysis
(Lernmark and Ott, 1998; Editorial, 1999), or scepticism about whether results can be
generalised to other groups with various genetic and environmental profiles
(Terwilliger and Goring, 2000).
Studies using SNPs to investigate the genetic basis of human disease may provide
insight into the susceptibility to a disease. The study of SNP distribution, especially
in different populations can also be useful for investigating molecular events that
underlie evolution such as genetic drift, selection and recombination (Nachman,
2001). SNPs are a product of the past and could provide clues about human history
like tracing the origin of populations and their migrations.
1.3.2.3 AR gene susceptibility alleles
The highly variable trinucleotide microsatellite of GAG-repeats in exon 1 of the AR
gene has been the target of unprecedented interest in recent years and is implicated
in various disease processes. Previous studies show that this GAG repeat varies in
length between 11 and 31 repeats in healthy men (Edwards et ai, 1992) and
variations of the GAG repeat length have been linked to alterations in AR function.
Individuals with a marked expansion of GAG repeats (between 40 and 52 repeats)
suffer from Kennedy syndromel spinal and bulbar muscular atrophy (SBMA), a rare
neuromuscular disorder of adult onset resulting in severe depletion of lower
motornuclei in the spinal cord and brainstem (Kennedy et ai, 1968; La Spada et ai,
1992; Nance, 1997). SBMA is characterised by progressive muscle weakness and
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atrophy (Kennedy et aI, 1968) and partial androgen insensitivity22. Patients with
SBMA often exhibit endocrinological abnormalities which include testicular atrophy,
infertility, gynaecomastia, oligo- or azoosperrnia=', impotence and elevated serum
gonadotropin levels (Arbizu et aI, 1983; Amato et aI, 1993). An earlier onset,
severeness of muscle weakness (Igarashi et aI, 1992; La Spada et aI, 1992), slight
androgen resistance (Shimada et aI, 1995) and a diminished transcriptional activity of
the AR (Choong and Wilson, 1998) are associated with extended CAG repeats. A
study by Tut and colleagues found that patients with 28 or more CAG repeats in their
AR have a four-fold increased risk for impaired spermatogenesis which is an
exquisitely androgen-dependant process (Tut et aI, 1997). This defective sperm
production could be related to the partial androgen insensitivity, which is seen in
individuals with SBMA. In another study, breast cancer diagnosis was made earlier
among women with mutations in their BReA 1 genes who also have very long CAG
repeats (Rebbeck et aI, 1999). On the other hand, one study showed that men with
shorter CAG tracts of :::;19 repeats have a substantially greater risk for developing
BPH than those with CAG repeats of;::: 25 in length (Giovannucci et aI, 1999). Short
CAG repeats have also been associated with androgen-mediated skin disorders in
men and women (Sawaya and Shalita, 1998) where men with androgenic alopecia 24
had 19 ± 3 repeats, whereas women with this condition had 17 ± 3 repeats as
opposed to the controls where a range of 12-29 repeats was found. In rheumatoid
arthritis in males, shorter CAG repeats of the AR are related to a younger age of
onset (Kawasaki et aI, 1999). These rheumatoid arthritis patients had significantly
22 Androgen insensitivity is an X-linked disorder associated with abnormalities in male sexual
morphogenesis; genetic males with severe or mild defects in the development of the male phenotype
are partially androgen insensitive
23 Reduced or no sperm production
24 Partial or complete loss of hair
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shorter CAG repeat lengths than the younger male controls (21.8 vs. 23.2) or the
older-onset male patients (21.8 vs. 23.2).
Differences in AR CAG repeat length have also been linked to CaP risk in some but
not all studies (Hardy et al, 1996; Giovannucci et al, 1997; Ingles et al, 1997;
Stanford et aI, 1997). Several population-based studies have shown that African-
American men have a higher incidence of CaP, they are younger at diagnosis and
often present with a more advanced form of disease, when compared with other
ethnic groups (Mebane et aI, 1990; Boring et aI, 1992; Morton, 1994). The average
number of CAG repeats in African-Americans, Caucasians and Asians is 18, 21 and
22, respectively (Coetzee and Ross, 1994). Shorter CAG repeat lengths result in an
increased transcriptional activity of the AR (Chamberlain et aI, 1994). Based on the
differences of CAG repeats in the aforementioned ethnic groups in combination with
the inverse relationship between the length of CAG tracts and AR transactivation
function, it has been hypothesised (Coetzee and Ross, 1994) that the variation in
race in CaP risk could partly be due to differences in AR CAG repeat length. There
has since been several groups that have investigated the relationship of CAG repeat
length to different epidemiological and clinical variables in CaP. The results from
some of these studies are found in Table 3. Depending on the study, shorter CAG
repeats fall in the range between < 17 to < 23 and have been correlated with a
younger age at diagnosis of CaP (Hardy et aI, 1996; Bratt et aI, 1999), an increased
overall CaP risk (Giovannucci et al, 1997; Hakimi et al, 1997; Ingles et al, 1997),
lymph node-positive disease (Hakimi et aI, 1997) and extraprostatic extension
(Giovannucci et aI, 1997; Ingles et aI, 1997). Various other studies, however, have
shown that the CAG tract is not associated with CaP risk (Irvine et aI, 1995; Bratt et
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ai, 1999; Correa-Cerro et ai, 1999; Edwards et ai, 1999), earlier age of cancer onset
(Hakimi et ai, 1997; Correa Cerro et ai, 1999), stage of disease at diagnosis (Hardy
et ai, 1996; Stanford et ai, 1997), histological grade of disease at diagnosis (Stanford
et ai, 1997; Correa-Carro et ai, 1999) or different clinical variables, including
response to treatment and time to progression after hormonal therapy (Hardy et ai,
1996), disease-free and overall survival (Edwards et ai, 1999). It is difficult to
compare the results of many of these studies as they have different designs, variable
study populations and reference CAG lengths.
When looking at the case-control studies (Irvine et ai, 1995; Giovannucci et ai, 1997;
Hakimi et al, 1997; Ingles et al, 1997; Stanford et al, 1997; Correa-Cerro et al, 1999),
one cannot be certain that individuals of the control groups did not have undiagnosed
CaP or would even develop the disease, therefore affecting the results.
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Table 3. Summary of results from 10 groups which analysed the link between CAG/GGN repeats or both and CaP association. Compilation of
patient populations (Cases/controls) and CAG/GGN results are shown. CAG analysis and GGN analysis entailed comparison of various repeat
lengths used in statistical analysis in the different studies
Author Irvine et al (1995) Giovannucci et al Hakimi et al (1997) Hardy et al (1997) Ingles et al (1997)
(1997)
Cases/control 68/123; 57 cases 587/588; study cohort 34 stage B, 25 stage 0/ 101 cases,95% 57/169; Caucasian
s Caucasian; predominantly 370; Caucasian, 82% patients and control
controls: 45 African- Caucasian ( >95%) entire study group with stage C or 0 subjects
American, Caucasian disease
39 Caucasian, 39 Asian
CAG analysis < 22 vs. ~ 22 ~ 18 vs. ~ 26 < 17 vs. ~ 17 ~ 22 vs. >22 < 20 vs. ~ 20
CAG results No statistical significance 1.5 times higher CaP Cases have 4-times Significant Short CAGs
between CAG length and risk for men with CAG < greater likelihood of association associated with a
CaP risk 22 than men with long having short CAG between short CAG two-fold increase in
CAGs; shorter CAG repeats; men with lymph- and younger age at CaP risk and also
repeats associated with node positive disease diagnosis; no linked to
extraprostatic extension, have 8-times higher correlation with extraprostatic
distant metastases, high probability of having CAG CAG length and disease
grade and disease repeats of < 17 stage of disease at
mortality diagnosis, baseline
PSA, response to
hormonal therapy,
or disease
progression
GGN analysis 16 vs. '* 16 NA ~ 14 vs. >14 NA NA
GGN results A two-fold, non-significant NA 4-fold higher risk of short NA NA
elevated risk among GGN repeats in men with
patients with CAG < 22 CaP; GGN not linked to
combined with GGN '* 16 age of diagnosis or
where CAG and GGN tracts aggressive disease; CAG
are in linkage disequilibrium and GGN alleles not in
in CaP patients linkage disequilibrium
83
Stellenbosch University http://scholar.sun.ac.za
Author Stanford et al (1997) Platz et al (1998) Bratt et al (1999) Correa-Cerro et al Edwards et al
(1999) (1999)
Cases/control 301/277; study cohort 592/588 - CAG analysis, 190/186; control alleles 132/105; French 178/390; X-
s consists of Caucasians of for GGN analysis 794 from women. Entire group German subjects chromosome female
ages 40-64 controls; 95% of Swedish" for all cases and controls; British
population Caucasian controls Caucasian
population+
CAG analysis < 22 vs. ~ 22 < 21,21-23, >23 15-20,21-23,24-31 <22vs. ~22 s 21 vs. > 21
CAG results Small, non-significant CaP risk highest in men No significant correlation No association CAGs not
increased CaP risk in men with CAG < 21 and GGN between CAG repeat between CAG significantly linked to
with CAG repeats of < 22; length = 23 when length and CaP risk; length and CaP risk for CaP, disease
3% decrease in risk of CaP compared with CAG >23 shorter CAG repeats susceptibility, age free and overall
with each additional CAG and GGN :1;23 linked to younger age at at diagnosis, or survival; inclination
repeat; no association diagnosis; patients with histological grade towards correlation
between CAG and disease longer CAGs (mean 22.7) of disease between CAG
stage/grade at diagnosis have good responses to repeats of> 21 and
endocrine therapy metastatic disease
GGN analysis s 16 vs. >16 23 vS.:I; 23 NA NA :s; 16 vs. >16
GGN results Men with GGN repeats of s CaP risk decreases for NA No correlation GGN repeats not
16 had a 1.6-fold elevated each repeat change in between GGN associated with CaP
CaP risk and increased risk GGN length of < or > 23; repeat length and risk; long GGN
for aggressive disease; no significant CaP risk repeat lengths
those with CAG < 22 and association between linked to elevated
GGN :s; 16 had a 2-fold GGN and age at risk for disease
increased risk of CaP diagnosis; CAG and relapse and
development; CAG and GGN in linkage mortality; CAG and
GGN are not in linkage disequilibrium in GGN alleles not in
disequilibrium population linkage
disequilibrium
* CAG alleles of female controls and male patient CAGs were used to determine the correlation between CAG length and CaP risk.
+ Female GAG alleles in the control group in addition to male case CAGs were used to assess the ethnic distribution of GAG repeats.
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The trinucleotide GGN polymorphism (where N=C, G or T) in the NH2-terminal
domain of the AR has also been associated with CaP. The length of this polyglycine
tract varies from 10-30 repeats in normal individuals (Platz et ai, 1998) and is less
polymorphic than the CAG repeat (Edwards et ai, 1999). As for the CAG repeat,
results are conflicting when comparing the GGN repeat data and CaP variables. The
results from a few of these studies are shown in Table 3. Certain studies have found
short GGN repeats (Stanford et ai, 1997; Hakimi et ai, 1997) of :s; 16 and s 14,
respectively, to be associated with an elevated CaP risk, whereas other groups
(Correa-Cerro et ai, 1999; Edwards et ai, 1999) reported no link between the GGN
tracts and risk for CaP. Some studies have shown that the GGN repeat is not
associated with disease aggressiveness (Hakimi et ai, 1997) or age at diagnosis
(Hakimi et el, 1997; Platz et el, 1998), though longer GGN alleles of > 16 are
associated with an increased risk for disease relapse and mortality (Edwards et aI,
1999). It has even been reported that there is linkage disequilbrium between the
CAG and GGN alleles and therefore certain combinations of alleles are co-inherited
and together could be associated with an increased CaP susceptibility (Irvine et el,
1995; Platz et aI, 1998). Other studies, however, have found that the CAG and GGN
alleles are not in linkage disequilibrium (Hakimi et ai, 1997; Stanford et aI, 1997;
Edwards et al, 1999).
Due to the great variation in the above findings, it is difficult to see exactly how the
CAG and GGN repeats affect the development and progression of CaP. The genetic
influences of these polymorphisms, together with environmental factors, could
possibly contribute to a person's overall risk for CaP development as well as
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assisting to determine disease characteristics like histological grade, tumour
aggressiveness and the response to therapy.
1.3.2.4 CYP17 susceptibility alleles
The 5' untranslated region of CYP17 contains a common single nucleotide
substitution (T~C) located 34 base pairs upstream from the translation initiation site.
This polymorphism creates a potential Sp1-like (CCACC box) binding site, that may
lead to an increased transcription and enhanced androgen biosynthesis (Carey et ai,
1994).
To date, only a few studies have shown an association of the CYP17 gene and CaP
risk, however there have been contradictions in terms of which allele is associated.
In a North Carolinian Caucasian population, Lunn and co-workers (1999) observed a
borderline significant association between the TIC genotype and CaP risk. A smaller
study by Gsur et al. (2000) also reported increased risk for Caucasian men
homozygous for the C allele. In contrast, among Japanese men (n = 252 cases and
n = 131 controls), Habuchi and colleagues (2000) observed men with the TIT
genotype to have increased risk of CaP and BPH. Similarly in a Swedish study,
(cases, n = 178; controls, n = 160), Wadelius et al. (1999) also reported a significant
elevation in risk for the TIT genotype. The opposing findings of previous studies
could be attributable to inaccurate genotype frequency estimates resulting from small
sample sizes (all studies have less than", 250 cases and", 160 controls). Linkage
disequilibrium between the Tand C alleles of CYP17 with different functionally
relevant polymorphisms in specific ethnic groups may explain the contradictory
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findings observed in studies conducted in different white or nonwhite ethnic
populations.
There seems to be little difference between CYP17 allele and genotype frequencies
in African Americans and European Americans (Feigelson et al, 1997; Weston et al,
1998; Lunn et aI, 1999). This is unlike several other candidate genes for CaP which
display striking allele frequency differences that parallel differences in CaP incidence
(Rebbeck et al, 1998; Ross et al, 1998; Paris et al, 1999). To date, no allele and
genotype frequency data exist on clinically evaluated indigenous Africans and
African-American CaP patients. To further investigate the involvement of the CYP17
variant with CaP, Kittles et al. (2001a) typed the polymorphism in three different
populations and evaluated its association with CaP and clinical presentation in
African Americans. This group genotyped the CYP17 polymorphism in Nigerian (n =
56), European-American (n = 74), and African American (n = 111) healthy male
volunteers, along with African American men with CaP (n = 71). They found that the
common CYP17 variant was associated with increased risk of CaP in African
American men. Comparison of genotypes revealed a significantly higher risk among
individuals homozygous for the C allele for developing high grade/stage CaP.
African American patients with the CC genotype were seven times more likely to
present with more aggressive disease. As sample sizes were moderate for the
African American samples, results should be interpreted with caution until larger
studies further evaluate the polymorphism.
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1.3.2.5 Other susceptibility alleles and Prostate cancer: SRDSA2, CYP3A4
SRDSA2
Two polymorphisms in the coding region have been identified in the SRDSA2 gene.
The one, a germline missense substitution, results in an alanine residue at codon 49
being replaced with threonine (A49T) (Reichardt et ai, 1997). This variant has been
linked to pathological characteristics of CaP and increases the levels of steroid 5-a,-
reductase activity. It has been reported to be more common in African-American and
Latino men with CaP, as compared with healthy African-American and Latino
controls, and was found to be most common in African-American and Latino men
with advanced disease (Reichardt et al, 1997). More recently, Makridakis et al.
(1999) provided additional support for the hypothesis that the A49T variant was
associated with CaP risk in African-American and Hispanic men and also reported
that the variant enzyme had a higher activity in vitro than the normal enzyme. The
effects of this mutation in other races have not been previously reported.
The other polymorphism, V89L, reported in SRDSA2 is caused by a G to C
transversion that results in the substitution of a leucine for a valine amino acid in
position 89 (denoted the L allele) and was associated with lower levels of
androstanediol glucouronide (AAG). It was found that the distribution of this mutation
appears to parallel the frequency of CaP within different ethnic groups, with
Caucasian and African-American men having a low prevalence of the L allele (24%
and 22%, respectively), compared with a prevalence of 46% among Asian men. The
LIL genotype was associated with a significantly lower mean serum AAG
concentration within the Asian men, suggesting that the L allele may reduce 5-a,-
reductase activity (Makridakis et ai, 1997). This polymorphism, however, has not
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been found to be significantly associated with Caucasian men (Febbo et ai, 1999;
Lunn et ai, 1999). If small differences in serum AAG levels reflect larger differences
in intraprostatic androgen activity then these genetic differences may be of biological
relevance to CaP risk.
CYP3A4
Genetic variations of CYP3A4 have recently been reported. A mutation in the 5' -
upstream region termed CYP3A4*1 B (A290G) results in an alteration in a
transcriptional regulatory element that may be required for CYP3A4 gene expression.
This variant was observed in 52% of African-Americans and 9.6% of Caucasians, but
has not been identified in Asians (Bali et al, 1999; Rebbeck, 2000; Sata et al, 2000).
It was suggested to be associated with advanced stage CaP in men and the
association between CYP3A4 genotype and tumour stage was most pronounced in
men diagnosed at a relatively old age who reported no family history. of CaP
(Rebbeck et ai, 1998). The identification of the CYP3A4 genotype as a biomarker
associated with CaP has potential implications for the treatment and prevention of
CaP and warrants further investigation.
1.4 AIM OF THE STUDY
CaP has the highest incidence of any malignancy affecting South African males
(National Cancer Registry of South Africa, 1992). The incidence of this cancer type
shows strong age, race and geographical dependence. It is a disease of older men,
with its highest incidence and mortality rates having been reported in African-
Americans. The differences in incidence and mortality rates of CaP observed among
different ethnic groups suggest that environmental and genetic factors may be
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important risk factors for the development of this cancer. A model for the malignant
progression of CaP remains incomplete. Various genes, however, have been
identified as possible candidates involved in this malignant progression, either as a
result of "gain of function" or "loss of function".
The aim of this study is therefore the identification of genes involved in the
predisposition to and I or progression of CaP within the diverse South African
population, specifically:
1) to determine the type and frequencies of genetic variants of genes involved in
androgen metabolism (AR, CYP17), and
2) to determine if the observed ethnic variation in the incidence and progression of
CaP can be understood by these ethnic-based genetic differences (i.e.
differences in the frequencies of genetic variation).
Our understanding of the genetic changes involved in the progression from normal
epithelium to malignancy and thus, ultimately the knowledge gained from such a
study, should yield information important for the early diagnosis and prognosis of
patients, as well as providing mechanisms for the development of therapies.
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CHAPTER2
MATERIALS AND METHODS
2.1 HUMAN POPULATIONS
The human species is divided into many distinct subpopulations, the largest of which
are commonly called races. Races are defined as major population groups whose
gene pools differ from each other (Thompson et ai, 1991). There are three major
racial divisions in South Africa, Whites, Blacks, and Coloureds, each of which has
numerous genetically different subgroups. Although the human chromosomes and
the loci they contain are identical in all members of the species, allele frequencies at
many loci vary widely among population groups. Some variants are virtually
restricted to members of a single group, although they are not necessarily present in
all members of the group. More often, variant alleles have different frequencies in
different populations. Within each population there is extensive variation, greater on
the average than the mean differences between groups.
The basis of the genetic differences among races and among their subpopulations is
mutation. The selection of favourable mutations in response to environmental
conditions or the chance survival of specific neutral or even harmful mutations,
together with a degree of reproductive isolation between the groups, allowed genetic
differences between population groups to be established. Subsequently, each group
is subdivided further into numerous distinct subpopulations, often called ethnic
groups, with their own characteristic set of gene frequencies. There are often
dramatic differences in allele frequencies between population groups, both for alleles
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that cause genetic disease and for presumably selectively neutral genetic markers,
such as certain blood group and protein polymorphisms and some DNA
polymorphisms. Although the former are highly significant for determining recurrence
risks for genetic diseases in specific population groups, the latter are important as
markers of recent human evolution.
2.1.1 The South African Population (Historical background)
Portuguese sailor, Bartholomeu Dias, was the first recorded European to traverse the
South African coast (in 1488) in his search for a sea route from Europe to the riches
of the East. It was only, however, until the middle of the 17th century that Western
European settlers established colonies on the southern tip of the continent. Today
this White population in South Africa are mainly Dutch, French, German and British
immigrants of European descent (Mead, 1997).
In 1652, the Dutch East India Company established a small white settlement in Table
Bay (now known as Cape Town) under the command of Jan Van Riebeeck (Grutter
and Van Zyl, 1981). The Black population, the nomadic Hottentots, came into
contact with the European settlers by trading their cattle. Soon after the Europeans
arrived at the Cape, they made contact with the earliest indigenous inhabitants, the
San. As the colonists intruded further upon the land and water sources, and stepped
up their demands for livestock and labour, the San were forced further inland and
today the only living members of these people are found in the Kalahari Desert of
Namibia. The San were not enslaved and therefore foreign slaves were brought in
from Angola and Benin and thereafter they were mostly imported from Madagascar
and Mozambique. Most of these slaves were men and some of them took San
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women as their wives, so there was a natural increase in the slave population. For
much of the eighteenth century slaves were imported at the rate of two or three
hundred a year. By the 1790s the slave population had risen to 25,000 compared
with 21,000 white colonists.
From the 1770s, colonists also came into contact and conflict with Bantu-speaking
chiefdoms some 700km east of Cape Town. Five main groups of Bantu are
distinguished today (Government Communication and Information System, 2001).
The first, the Nguni, spread through Mpumalanga25 down the east coast. Several
Nguni nations can be distinguished. Of these, the Xhosa live in the old Transkei and
Ciskei regions, the Zulu in Zululand and KwaZulu Natal, the Swazi in Swaziland and
the Transvaar" and the Ndebele in Zimbabwe. A second group of Bantu, the Sotho,
spread westward about 500 years ago, the North Sotho (Pedi) settling in the
Northern Province and Mpumalanga, the West Sotho (Tswana) furthest west in
Botswana and adjacent areas of South Africa and the South Sotho (Basotho) in
Lesotho and the Free State (formerly Orange Free State). A third group, the
Ovambo-Herero, went even further west, settling in what is today known as Namibia.
About 300 years ago, a fourth group, the Venda made their appearance in the
Northern Province. Even later, in the course of the 19th century, a fifth group, the
Tsonga, migrated from the east coast to the Transvaal. Maps of South Africa with its
former divisions and the provinces as they are today are depicted in Figures 6A and
6B, respectively. (South African maps and boundaries data with the kind
complements of Antonio Martins; http://www.fotw.ca. 2000).
25 Formerly eastern Transvaal formerly eastern Transvaal
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FIG.6A. Shows a map of South
Africa with it's former divisions; viz,
the Cape Province, Natal, Orange
Free State and Transvaal.
FIG.6B. Since 27 April 1994, South
Africa has 9 provinces: The Eastern
Cape, Free State, Gauteng, Kwazulu-
Natal, Mpumalanga, Northern
Province, Northern Cape, North-West
Province and the Western Cape.
The origins of the 'Coloureds', or people of mixed race go back to the Cape region
around the 17th century when many of the Hottentots mixed with and married the
early Dutch sailors. At the same time, Malay women were brought to the Cape as
wives for Dutch sailors and settlers. Nine tenths of the Cape Coloured population are
Christian and 90,000 are represented by a subgroup, the Cape Malays, who practice
Islam as their faith and are geographically limited to the Cape Peninsula (Shillington,
1987).
The so-called 'coloured' population of the Cape was the result of interbreeding
between Europeans and Khoikhoi (local Hottentot inhabitants), and Khoikhoi and
slaves (Grutter and Van Zyl, 1981). Many of the early white settlers at the Cape
were single men and a number took Khoikhoi women as their unofficial wives. On
the farms there was also interbreeding between male slaves and female Khoikhoi
servants. Gradually there developed a 'coloured' servile population, part slave and
26 Now divided into Mpumalanga, Limpopo (formerly Northern Transvaal) and the North-West Province
(formerly Western Transvaal)
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part 'free'. They adopted the Dutch language of the colonists and began to lose their
African or Asian cultural identities. During the nineteenth century whites began to
use the term Cape Coloured to refer to the whole of this Dutch (Afrikaans)-speaking
servile population of slaves, mixed race and Khoisan. These groups have all
interbred and blended so that there are no recognisable separate descendants from
any of them, except for the Cape Malays (Shillington, 1987).
2.1.2 Patient cohort and specimen collection
In this study, CaP tissue and peripheral blood samples from the diverse South
African population was used. The study population included patients of a Black,
Coloured and Caucasian descent who have undergone a prostatectomy I prostate
needle biopsy at the Tygerberg Hospital. Peripheral blood was drawn from the same
patients after fresh tissue was obtained. Personal and clinical data (including tumour
Grade 1 to 3 classification, metastasis, hormone dependence and PSA levels where
possible) were obtained from the medical records at Tygerberg Hospital and all
sampleswere obtained with informed consent (extra samples were obtained from the
Western Province Blood Transfusion Service (WPBTS) in order to calculate
population frequencies. Our samples included 20 blood and tissue CaP's, 25 control
(BPH) blood and tissue samples (either with or without prostatitis) and 6 blood and
tissue samples of which the clinical data are outstanding. The remaining samples
include 30 archival paraffin embedded CaP biopsies (5x10~m slices) from Blacks.
The number of samples of CaP and BPH for each race group in addition to the
numbers of controls from the WPBTS27 is summarised in Table 4. DNA was isolated
from the nuclei of peripheral blood, fresh frozen prostate tissue and paraffin samples
27 D'ffI ers across markers as the same patients were not tested for all markers
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using standard procedures (Qiagen Kit) as described in the QIAamp DNA Mini Kit
and QIAamp DNA Blood Mini Kit Handbook (blood and body fluid spin protocol: pg
22-24; tissue protocol: pg 28-31; genomic DNA isolation from paraffin-embedded
tissue: pg 40-41). This study forms part of a project that was ethically approved by
the Research Committee of the University of Stellenbosch (Ethical approval number:
2001/C1 01).
Table 4.The study cohort consisting of Black, Coloured and White population groups
Blood/tissue CaP
Blood/tissue BPH
Blood/tissue unknown *
Paraffin-embedded material
WPBTS controls': AR E211
CYP17H46
CYP17 S65
CYP17IVS4+58G>C
CYP17IVS6-25C>A
Blacks Coloureds TOTALWhites
2
1
2
30
50
23
24
50
33
20
25
6
30
159
43
44
104
64
15
16
4
3
8
o
57
20
20
52
30
52
2
1
* Clinical diagnosis inconclusive
o Controls consisting of samples from males and females were tested for identified markers (no
controls were looked at for the CYP17 L36 marker at the time of writing up)
2.2 MUTATION DETECTION
2.2.1 DNA Amplification
One of the prerequisites for many recombinant DNA techniques is the availability of
large amounts of a specific DNA segment. Polymerase chain reaction (PCR) allows
a direct, dramatic amplification of specific DNA segments and it can be used on
fragments of DNA that are initially present in infinitesimally small quantities.
PCR reactions were performed for the AR and CYP17 amplicons using the DGGE
primer sets shown in Table 5. Each reaction mixture consisted of 100ng / 200ng
denatured genomic DNA28, 0.1mmoIII dNTPs, 20pmol of each primer, 2.5mmolll 10X
Mg2+ reaction buffer, and 0.5 units Taq polymerase (Roche Diagnostics, Mannheim,
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Germany) in a total volume of 50~1. The automated amplification cycle was carried
out on a thermocycler as follows: an initial denaturation step at 960e for 3min,
followed by 32 cycles of denaturation at 960e for 45s, annealing for 1min (various
temperatures shown in Table 5), and elongation at 720e for 1min20s. An additional
extension step of 720e for 7min followed the last cycle. Before DGGE analysis of
samples, an additional heteroduplexing step was performed. This involved
denaturation at 960e for 10min, followed by renaturation at the various annealing
temperatures of peR amplification. peR products were checked by electrophoresis
of a mixture of 5~1 (10%) of each amplified sample with 5~1 loading buffer on a 2%
agarose gel. The gels were run in an agarose electrophoresis system containing 0,5
X TBE buffer with ethidium bromide (10mg/ml) (10~1of the stain per litre of buffer), at
150V for about 30 minutes and viewed under UV light to verify amplification.
Nested peRs were carried out for the analysis of DNA extracted from paraffin-
embedded material for exon 1D of the AR gene and exon 1A, 4 and 7 of the CYP17
gene. The peRs with the external primer sets (Table 6) were performed using 1~I of
DNA isolated from paraffin material in a 30~1 reaction mixture as described before,
with a variation in primer concentrations as listed in Table 6. peR reactions
consisted of 25 cycles as specified previously with annealing temperatures as shown
in Table 6. Re-amplification of 1~I of the external amplified peR products was carried
out using the internal DGGE primer sets in Table 5 (AR1D, eYP17.1A, 4 and 7) and
the same peR conditions as initially described. Direct peR amplification, however,
is possible, but fixation of tumour-rich material in paraffin degrades the DNA and
greatly reduces its amplification rate due to the low concentrations of DNA.
28 200ng of template was required for amplifications of DNA isolated from tissue samples
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2.2.2 Denaturing gradient gel electrophoresis
In this study denaturing gradient gel electrophoresis (DGGE), a polymerase chain
reaction (PCR)-based mutation detection method, was used to analyse almost the
entire coding region of the AR gene and the polymorphic coding regions (exons 4
and 7) of the CYP17 gene.
Application of the DGGE technique, developed by Fischer and Lerman in 1983,
facilitates the separation of double-stranded (ds) DNA molecules based on their high
sequence dependant melting behaviour. The order of bases in a sequence
determines the melting behaviour of that fragment. The principle of DGGE is shown
in Figure 7 as a time-travel gel (Myers et aI, 1985). As ds DNA is electrophoresed
through a gradient of increasing concentration of denaturants (urea and formamide
[UF]), it will melt at specific UF concentrations. A high melting temperature (Tm) of a
fragment requires a high [UF] to melt the fragment. Partial denaturation of a DNA
molecule causes a conformational change which results in reduced electrophoretic
mobility of the fragment. Using DGGE, sequence variants have been identified that
differ by only a single base. When a fragment becomes completely single-stranded
(ss), its mobility continues so that it will run off the gel and variants could be missed.
To prevent this, a GC-rich sequence (GC-damp) is introduced during fragment
amplification to the 5' end of one of the primers (Myers et ai, 1985).
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Fig.7 A) Diagrammatic representation of the principles of DGGE (Figure obtained complement of V.M.Hayes). During fragment amplification, a GC-
rich clamp is attached to one end of an amplicon, creating a high stability domain. The DGGE gel is a PAA gel with an increasing denaturing
gradient of urea and formam ide. The gel is run at a constant gel temperature of 60°C. As the ds DNA passes through the gel, its mobility decreases.
The fragment melts out and becomes ss, yet held together by its GC-clamp. This is known as its optimal melting temperature as depicted on the
gel. B) Time-travel gel (V.M.Hayes).
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The GC-c1amp alters the melting characteristics of the clamped fragment and
increases the percentage of single nucleotide changes detectable by DGGE
(Sheffield et aI, 1989; Abrams et aI, 1990). The sensitivity of DGGE is also enhanced
by heteroduplex analysis which results in the formation of heteroduplexes during the
denaturation and re-annealing of target DNA with two different alleles. These
heteroduplexes have a lower Tm than the more stable homoduplexes and will
therefore melt earlier. Thus small deletions or insertions, where homoduplexes have
a similar melting profile would otherwise be undetected without a heteroduplexing
step.
Addition of a GC-c1ampduring PCR-amplification, together with heteroduplexing, has
been estimated to increase the number of detectable sequence variants from 40% to
virtually 100% (Myers et aI, 1985; Sheffield et ai, 1989; Abrams et aI, 1990). Due to
this high sensitivity, DGGE is believed to be the most powerful of the pre-screening
methods currently available (Sheffield et aI, 1989;Guldberg et aI, 1993).
The success of DGGE requires optimal experimental conditions. Appropriate
selection of PCR fragments and primers is very important. A DNA fragment needs
an optimal melting profile, i.e. one with a single melting domain for the fragment to be
analysed and a higher melting domain that represents the GC-c1amp (Wu et aI,
1998). Theoretical melting profiles can be predicted by using special computer
programs designed to analyse the melting behaviour of a DNA fragment. This
facilitates the selection of PCR primers that will give rise to fragments that are
suitable for DGGE (Lerman and Silverstein, 1987). From the Tm , the range of
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denaturant concentration needed for optimal melting of the fragment can be
predicted.
Ways have been found to adapt the melting profiles of DNA fragments by
modification of primers and their positions, thereby increasing the effectiveness of
DGGE. Analysing the natural melting curve (without the GC-clamp), one could
understand why fragments that seem suitable for DGGE did not pick up mutations.
Modified primers include addition of G/C or TlA tails and result in the detection of
mutations previously missed (Wu et ai, 1998).
Other experimental conditions such as the gel composition and electrophoretic
parameters also contribute to the success of DGGE. It has been discovered that the
use of 9% polyacrylamide (PAA) gels, a denaturing gradient with a difference of 30%
to 50% between the lowest and the highest concentration of denaturant, and
electrophoresis in 0.5 X TAE-buffer at a voltage greater than 100 and lower than 200
volts (optimal at 110V), ensures optimal mutation detection for broad-range DGGE
analysis (Hayes et ai, 1999). DGGE is highly sensitive for detection of somatic
mutations in tumour material even when surrounded by large amounts of normal
tissue. Even for archival paraffin-embedded material, where DNA fragments of a
maximal length of 300bp are amplifiable, DGGE is well-suited (Hayes et ai, 1999). If
DGGE assays are designed correctly one can achieve a mutation detection rate of
100% (Wu et aI., 1998; Hayes et ai., 1999).
See Appendix I for solutions used for DGGE gels.
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2.2.3 Primer design
DGGE primers (oligonucleotides that hybridise to opposite strands of the sequence
to be amplified) were designed for almost the entire coding region (excluding
polymorphic repeat sequences), and including all splice site junctions of the AR
gene, as well as the promoter region (amplicon 1A) and polymorphic coding regions
(amplicans 4 and 7) of the CYP17 gene. The DGGE primers are listed in Table 5.
To ensure appropriate selection of DGGE fragments and primers the MELT 87
computer program was used (Lerman and Silverstein, 1987), keeping in mind the
conditions as set out in Wu et al. (1998).
The coding sequence of the AR gene was divided into 14 amplicons for analysis.
Due to its large size, exon 1 was separated into 6 overlapping fragments and exon 7
was divided into 2 overlapping fragments according to the various melting domains
within this exon. To prevent fragments from becoming completely single-stranded, a
GC-rich sequence (GC-clamp) was attached to the 5' end of an amplicon in each
primer set during amplification. In this way the mobility of fragments is decreased
and they will not run off the gel, thereby enhancing mutation detection. To ensure
optimal mutation detection, primers for exons 1B, 1F and 6 were modified by the
insertion of TA (thymine, adenine) nucleotides between the GC-clamp and primer.
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TABLE 5. DGGE-PCR primers and experimental conditions for the AR gene as well as the promoter
region (exon1A) and exons 4 and 7 of the CYP17 gene
Size Temgerature ( Cl
Amplicon Amplimers,5'-3' (bp) Melting Annealing
1B AR.1 BF: [40GC][6A T]GCAGCAGCAGCAAGAGACTAGC 224 79 65
AR.1 BR: AGGCTCTGGGACGCAACCT
1C AR.1 CF: CAACCTICACAGCCGCAGTC 282 81 60
AR.1 CR: [40GC]TGAAGGAGTIGCATGGTGCT
10 AR.IDF: [7GC]ACCTI AAAGACATCCTGAGCGA 248 77 60
AR.1 DR: [40GC]TGGACACCGACACTGCCTI A
1E AR.1 EF: [40GC]TICTGACAACGCCAAGGAGT 259 78 58
AR.1 ER: TCTICAGTGCTCTIGCCTGC
iF AR.1 FF: [40GC][6A T]AGGTICTCTGCTAGACGACA 232 76 55
AR.1 FR: AGTGCTCCGGACTIGTAGA
1G AR.1 GF: [40GC]AGCTCCGGGACACTIGAACTGC 234 80 65
AR.1 GR: CAGGCGCTGCCGTAGTCCA
2 AR.2F: [40GC]CCTGAGACTICACTIGCCTA 289 73 58
AR.2R:GAGAAGTGCATGTGCAAGAC
3 AR.3F: TCAGGTCTATCAACTCTIGTA 224 70 52
AR.3R: [40GC]GAAGGAGGAGGAAGAGAA
4 AR.4F: [40GC]A TICAAGTCTCTCTICCTICC 386 74 55
AR.4R: TATCTCATGCTCCCACTIC
5 AR.5F: CACTGCCTCTGCCTCTICT 262 75 58
AR.5R: [40GC]TCTGGCCAAGCTGCTGT AT
6 AR.6F: CCTCTGTGTATCTCCTICC 255 74 50
AR.6R: [40GC][7 AT]CCTCTCTGAA TCTCTGTGC
7A AR. 7AF: GTCT AATGCTCCTICGTGG 219 71 58
AR. 7AR: [40GC]AGCGTCTIGAGCAGGATGT
7B AR.7BF: [40GC]TCAAGGAACTCGATCGTAT 190 75 52
AR. 7BR: CTCT ATCAGGCTGTICTCC
8 AR.8F: [40GC]GGCCACCTCCTIGTCAAC 341 73 58
AR.8R: CAAGGCACTGCAGAGGAGT
1A CYP17.1 AF: [6GC]CCACAGCTCTICT ACTCCA 266 77 52
CYP17.1 AR: [40GC]GCTIGAAGAAGTIGTIATGC
4 CYP17.4F: [40GC]TGGAAGAAGGGTGGATI 245 67 58
CYP 17.4R: CAGTGTGT AGAA TGGACTCC
7 CYPi7.7F: [40GC]CATGAGGCTGAGCAAGGAAG 261 77 58
CYP 17.7R: AGAGTCCAGGCTCGCTGTGT
bp, base pair.
GC-stretch (Wu et al, 1998) and GC-clamp used:
[7GC]CGCCCGC;[6GC]CGCCCG;[40GC]CGCCCGCCGCGCCCCGCGCCCGGCCCGCCGCCCCCG
CCCG.
AT-stretches used: [6AT]TATAAT; [7AT]TATAATA.
A comprehensive DGGE assay was designed for the entire coding region of CYP17.
Amplicon 1A covers the region from the CTG nucleotide in the 5' untranslated region
(UTR) to base pair 364. Amplicon 4 includes base pair 186 in intron 3 to base pair
353 in intron 4, and base pair 177 in intron 6 to base pair 357 in intron 7 is the region
which covers amplicon 7. For the partial analysis of exon 1 of the CYP17 gene, the
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forward primer was modified by the addition of a short GC-clamp of 6 nucleotides to
its 5' end, to ensure optimal mutation detection.
For the amplification of small amounts of mutant DNA extracted from paraffin-
embedded material, external nested primers were designed for the polymorphic
regions of the AR and CYP17 genes. Amplicons of less than 300bp in length were
chosen for the purpose of a nested PCR. Direct PCR was possible but the success
rate would have been reduced due to the low concentrations of DNA. Nested PCR
was therefore the preferred means of amplification to obtain sufficient product for
DGGE analysis. The primers used in the nested PCR are listed in Table 6. All
nested amplifications were confirmed by repeated PCR to reduce the error rate
created by Taq polymerase.
TABLE 6: External primer sets for Nested AR and CYP17- PCRs with their annealing temperatures
and primer concentrations
Size Annealing Primer
Exon Amplimers,5'-3' (bp) Temperature (0C) concentration
(pmol)
10 AR.1 DextF: TCGTCCCTGTIGCACCTACC 289 60 10
AR.1 DextR: GATGCTCCAACGCCTCCACA
CVP 17.1AextF: GCCTCCTIGTGCCCT AGAGT 288 53 15
CYP17.1 AextR: TIGGTGCCCAT ACGAACAGA
4 CYP17.4extF: GAGAGACTCTGGCAGCTGGA 270 58 15
CYP17.4extR: ATGTGCCAGGTICTCTGCTI
7 CVP 17.7extF: GTGAGTGGGAA TGAGGGAGT AA 248 60 10
CYP17.7nR: CGCAGGACAGGACAGACTCA
bp, base pair.
Optimised DGGE conditions were used for broad-range analysis as laid out in Hayes
et ai, 1999. All amplicons of the AR gene were resolved by electrophoresis after
multi-layering of the samples, in a 9% polyacrylamide gel containing a 35-75% urea
and formamide (UF) denaturing gradient for amplicons 2-8 and a 50-90% UF
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gradient for amplicons 1B-1G. The CYP17 gene was also analysed using two
different gel conditions, i.e. in a 9% PAA gel containing 50-90% (amplicon 1A and 7)
and 10-50% (amplicon 4) UF denaturing gradients parallel to the direction of
electrophoresis. 100% UF = 7molll urea per 40% deionised formamide.
Electrophoresis was performed overnight at 110V at a constant gel temperature of
59°C. The gels were stained with ethidium bromide and photographed under an
ultraviolet transilluminator.
2.2.4 DNA Sequencing
The ultimate characterisation of a DNA segment is the determination of its nucleotide
sequence. The ability to sequence DNA has added immensely to our understanding
of gene structure and the mechanisms of gene regulation. One of the f1uorescence-
based methods for DNA sequencing uses fluorescently labelled dideoxynucleotides
to terminate the extension of the sequencing primer and is known as the dye
terminator method (David and Menotli-Raymond, 1998). On an Applied Biosystems
sequencer, each different dideoxynucleotide is labelled with a different f1uorophore
(fluorescent dye), so that the sequencing reaction can be performed in a single tube
containing an unlabelled primer and all of the four different dideoxynucleotides.
Generally, DNA fragments of the same size generated in the sequencing reaction are
labelled at the 3' end with the same dye. After performing the sequencing reactions,
additional sample processing is generally required before loading the samples on the
gel. The dye-labelled dideoxynucleotides must be removed (accomplished by
ethanol precipitation or using a spin column). The samples are resuspended in a
loading buffer and denatured prior to sample loading. The electrophoresis produces
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a coloured pattern of peaks, representing the four bases that can be read to provide
the sequence.
PCR products which showed mobility shifts on DGGE gels were purified using the
High Pure PCR Product Purification Kit (Roche Molecular Biochemicals). Direct
sequencing of these samples was performed on an ABI sequencer using a non-GC-
clamped primer and the Big Dye Terminator V 3.0 Ready Reaction Cycle Sequencing
Kit (Applied Biosystems). Variable banding patterns were confirmed by sequencing
bidirectionally.
2.3 ASSOCIATION STUDIES
From a genetic point of view, a population is a local group of individuals who belong
to a single species and in which mating is actually or potentially occurring. The set of
genetic information carried by reproductive members of a population is referred to as
the gene pool. Genes are the fundamental physical units of heredity and occupy
specific positions on a chromosome known as a locus. Alleles are the alternative
forms of the same gene that contain modified genetic information and often specifies
an altered gene product. For a given locus, the gene pool includes all the alleles of
that specific gene present in the population. One approach used to study a
population's genetic structure is to measure the frequency of a given allele. This
allele frequency equals the frequency of homozygote alleles plus half the proportion
of heterozygotes within a population (Klug and Cummings, 1997a).
In an ideal population, a dominant allele does not automatically increase in frequency
until it replaces its recessive counterpart. Such an infinitely large population, in which
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random mating occurs in the absence of factors like mutation and selection, and,
where genotype distribution is proportional to the individual allele frequencies and
remains constant from one generation to the next, is the basic tenet of the
cornerstone of the Hardy-Weinberg law (HWL). The HWL can be demonstrated as
follows: when one thinks of a locus as having two alleles, A and a, and the frequency
of allele A is represented by p, and the frequency of a is q, then p+q =1 because the
sum of pand q represents 100 percent of the alleles for a particular gene in the
population. A population that demonstrates the basic features of the HWL is said to
be in Hardy-Weinberg equilibrium, which describes the expected relationship
between allele frequencies and genotype frequencies of individuals in the same
population group. In the state of genetic equilibrium the genotype frequencies
remain constant from one generation to the next, at frequencies of p2, 2pq and q2.
Unlike these hypothetical alleles, not all alleles in a population are in equilibrium.
Populations in nature are dynamic, so changes in structure or size are part of their
life cycles. The ideal situation, however, allows one to perform statistical goodness-
of-fit tests where results obtained from a given sample are compared to a
prespecified distribution (Thompson et al, 1991).
Statistical hypothesis tests are most commonly used in analysing and reporting the
results of scientific studies. The Fisher exact test is a nonparametric test that is used
when the independent or predictor variable is dichotomous, i.e. this variable is made
up of two mutually exclusive groups or independent samples and there are no
repeated measures. This test is used when both the independent and dependent
variables are at the nominal level of measurement and is especially useful when
sample sizes are small (McNemar, 1969). The main purpose of such a test is to
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examine whether two populations differ from each other in the proportion of subjects
who fall into one of two classifications. To undertake the Fisher exact test, the
dichotomous data to be analysed are first cast into 2 x 2 contingency tables in which
entries represent scores. The probability associated with all possible 2 x 2 tables
that have the same row and column totals as the observed data are now evaluated,
making the assumption that the null hypothesis is true. The null hypothesis here is
that the row and column variables are unrelated. These probabilities are then used
to calculate the overall probability of getting the observed data, or a less likely result,
when the null hypothesis is true. The mathematical formula used to calculate each
probability is rather complicated, so the calculation is much better done with the use
of computer programs. A more common procedure has been described by Cox and
Hinkley in 1974, where t=t(x) is a function of the observations and T=t(X) the
corresponding random variable. T is called a test statistic for testing Ho if certain
conditions are satisfied. These criteria are that the distribution of t when Hois true is
known at least approximately and the larger the value of t the stronger the evidence
of departure from Hoof the type it is required to test. For given observations x, lobs =
t(x) and the level of significance Pobs can be calculated by Pobs = pr (T ;?: lobS; Ho). The
result is a number, Pobs, called the level of significance, or p-value and the procedure
is called a significance test. An essential component of significance tests is the
concept of strength of evidence. A p-value is supposed to indicate "the strength of
evidence against the hypothesis" (Fisher, 1958), with conventional interpretations as
described by Burdette and Gehan in 1970, as shown in Table 7.
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Table 7. Reasonable interpretations of the results of significance tests are as follows:
Significance Level of Data Interpretation
Less than 0,01
0,01 to 0,05
More than 0,05 and less than 0,1
0,1 or more
Very strong evidence against null hypothesis
Moderate evidence against null hypothesis
Suggestive evidence against null hypothesis
Little or no real evidence against null
hypothesis
In genetics it is important to be able to evaluate observed deviation. When we
assume that data will fit a given ratio such as 1:1, 3:1, or 9:3:3:1, we establish the
null hypothesis. The hypothesis assumes that there is no real difference between the
measured ratios and the predicted ratios. The apparent difference can be attributed
purely to chance. Evaluation of the null hypothesis is accomplished by statistical
analysis. Based on this, the null hypothesis may either be rejected or fail to be
rejected. If it is rejected, the observed deviation from the expected is not attributed to
chance alone. If the null hypothesis fails to be rejected, any observed deviations can
be attributed to chance. Therefore statistical analysis provides a mathematical basis
for examining how well observed data fit or differ from predicted or expected events,
testing the goodness of fit.
One of the simplest statistical tests devised to assess the goodness of fit of the null
hypothesis is Chi-square analysis (x2) (Klug and Cummings, 1997a). This test takes
into account the observed value of each component of an expected ratio as well as
the sample size and reduces them to a single numerical value. This value (X2) is
then used to estimate how frequently the observed deviation can be expected to
occur strictly as a result of chance. The formula used in chi-square analysis is
2 (0 - e)2
X == Le, where 0 is the observed value for a given category and e is the
expected value for that category. L (sigma) represents the "sum" of the calculated
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values for each category of the ratio. As (0 - e) is the deviation (d) in each case, the
d2
equation can be reduced to x2 = L e
The final step in the chi-square analysis is to interpret the x2 value. To do this one
must determine the value of the degrees of freedom (df), which is equal to n -1 where
n is the number of different categories into which each datum point may fall.
Degrees of freedom must be taken into account because the greater the number of
categories, the more deviation is expected as a result of chance. The x2 value can
now be interpreted in terms of a corresponding probability value (p). This calculation
is complex and p values are usually located on a table or graph. Statistical programs
are available, making chi-square analysis much easier.
A probability value of 0.05 is the relative standard set to serve as the basis for either
rejecting or failing to reject the hypothesis. When applied to chi-square analysis, a p
value < 0.05 means the probability is only 5% or less that the deviation in the set of
results could be obtained by chance alone. Such a p value indicates that the
difference between the observed and predicted results is substantial and thus serves
as a basis for rejecting the null hypothesis. P values of 0.05 or > (1 - 0.05) indicate
that the probability of the observed deviation being due to chance is 5% or more.
The conclusion would therefore be not to reject the null hypothesis.
2.3.1 Data Comparisons and Statistical Analysis
(a) The occurrence and frequency of somatic mutations (if any) occurring in the CaP
samples will be compared according to grade classitication" so as to determine
29 including any relevant information on metastasis or hormone resistance
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possible involvement in tumourigenesis and if that involvement is either an early
or late event in the progression of the cancer.
(b) The blood samples of patients who had mutations in their CaP samples, will be
analysed genetically, for possible occurrence of germ-line mutations to clarify
whether the genetic variation in the tumour sample was somatic.
(c) Genetic comparisons of tumour and blood material of the CaP patients and that
obtained from the BPH (normal tissue), as well as blood samples from the general
population will be performed, to determine the allele frequencies (by manual allele
counting) of polymorphic sites. Chi-square and Fisher exact tests will be
performed to compare genotype distribution and allele frequencies among
patient" and control groups31. The statistical heterogeneity as assessed by
Fisher exact and Chi-square tests were determined with the aid of computer
programs, viz., Instat version 3.1 and JXK Chi-squared 2002 programs,
respectively.
Data comparisons and Statistical analysis for the identified AR and CYP17 SNPs
are summarised in Appendix II. Raw data for the CYP17 L36 SNP was not
included since no extra controls were analysed at the time of writing-up and the
polymorphism was found in only one individual from the patient cohort.
30 Tumour and blood from grade 1,2 or 3 prostate carcinoma, with or without metastasis and with or
without hormone resistance
31 Patients with BPH, with or without prostatitis
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2.4 RESULTS
AR-DGGE assay
A comprehensive mutation detection assay was developed for almost the entire
coding region (excluding polymorphic repeat sequences) and including all splice
site junctions of the AR gene. This coding region was divided into 14 amplicons
for analysis and due to its large size, exon 1 was divided into six overlapping
fragments (1B-1G) and exon 7 was divided into two overlapping fragments (7A
and 7B). Examples of the normal banding patterns are shown below in Figure 8.
1 2 1 2 3 4 5
A B
FIG.S. The denaturing gradient gel electrophoresis patterns of 14 pooled PCR amplicons of the AR
gene. The amplicons 1B-1G (A; lanes 1 and 2) and 2-8 (B; lanes 1-5), were analysed on single 9%
PAA gels with 50-90% and 35-75% UF gradients, respectively. A. Amplicons 1F, 1E, 1B (lane 1)
and amplicons 10, 1G and 1C (lane 2) can be layered. B. The layering of pooled amplicons 2 and 6
(lane 1); 3, 8 and 7B (lanes 2 and 3); 4, 7A and 5 (lanes 4 and 5).
The assay allowed for the complete analysis of 13 patients on a single gel for
amplicons 1B-1G and 9 patients per gel for amplicons 2-8. Since the AR gene is
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single-copy, mutant PCR products were mixed with standard controls before
heteroduplexing for easier visualisation of aberrant bands.
AR mutations
Using the AR-DGGE assay and the primer sets in Table 5 for the analysis of 20
CaP, 25 BPH and 6 tissue samples of unknown clinical diagnosis, five germline
mutations were identified, including a previously reported polymorphism. Direct
sequencing of the aberrant DGGE banding patterns confirmed these variant
sequences which are listed in Table 24 according to the intron or amplicon in
which they occur.
TABLE 24. List of identified AR mutations ordered according to the intron or amplicon in which
they occurred
IntiAmplicon bp / codon Mutation Amino acid change Previously reported
Int 1 -38 bp g-a Novel
10 211 GArJ-GA8 (E211) Silent Yes
1E 242 TCG- TCl (5242) Silent Novel
1F Nd
1G 341 TCl -TCQ (5341) Silent Novel
Int, intron; -bp, number of base pairs downstream from acceptor splice site.
E211: silent codon 211 change coding for glutamate (E), 8242: silent codon 242 change
coding for serine (8), 8341: silent codon 341 change coding for serine (8).
Novel indicates new mutations reported in this study; Yes indicates previously reported
mutation.
Nd, not determined.
One mutation was located in intron1 (IVS1-38G>A) and the E211, S242
(amplicon 1E), amplicon 1F and S341 (amplicon 1G) variants were all found in
exon 1. No mutations were found in the remaining exons 2 through to 8. The
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single base E211 substitution occured at a frequency of more than 1% within the
various populations (Table 26) and was therefore classified as a single
nucleotide polymorphism (SNP). Examples of these DGGE banding patterns are
shown in Figure 9. The E211 SNP in lanes 2 and 3 (Figure 9B) and the
mutations in lane 1 (Figure 9A, C, D and E), appear heterozygous on the gels,
due to mixing of normal control DNA to the patient DNA prior to heteroduplexing.
1 2 1 2 3 1 2 1 2 1 2
A B c o E
FIG.9. Aberrant denaturing gradient gel electrophoresis banding patterns found in the AR gene. All variants
are heterozygous on the gels and three of these variant banding patterns are represented as four bands; two
upper heteroduplexes and two lower homoduplexes (A, B and C). (A) The IVS1-38G>A variant is shown in
lane 1 with the normal control in lane 2. (B) The E211 mutation (lanes 2 and 3) as compared to a normal
control in lane1. (C) S242 variant (lane 1), normal control DNA (lane 2). (D) Amplicon 1F mutation (lane 1)
and (E) the S341 mutation (lane 1) are seen as three bands due to the presence of more mutant than normal
cells resulting in loss or weaker intensity of the homozygous normal band. Normal controls for amplicon 1F
mutation in lane 2 (D) and the normal control for the S341 variant in lane 2 (E).
The variation that was observed in amplicon 1F could not be detected in the
sequencing data. For sequencing of this variant the reverse primer without the
GC-clamp was used. Since the forward primer was designed with a GC-clamp, it
could not be used for sequencing. One could redesign the forward primer
without a clamp and use it for sequencing.
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All these mutations occur in the NH2-terminal region of the AR, except for the
IVS1-38G>A variant. A splice site usually occurs at the position 38bp
downstream from this intron 1 variant and therefore one cannot exclude the
possibility that it could affect the splicing mechanism. The IVS1-38G>A change
and the S242 mutation co-existed in a cancer sample (Gleason grade 2) of a 75-
year-old patient of Coloured descent. The S341 mutation occurred in 2 BPH
samples, one from a 64 year old Black patient and the other from a patient of
Coloured origin of age 74. These same BPH patients also have the amplicon 1F
mutation, indicating that the S341 variant and the ampjoon IF change could
be linked polymorph isms that may be in linkage disequilibrium i.e. associated
with the disease locus. Both the S242 and S341 mutations resulted in no amino
acid change and are therefore silent. The average age of these patients with
sequence variants is 71 years.
The previously reported AR-E211 SNP was found at a relatively high allelic
frequency in the Black and Coloured populations, at 44/121 (36%) and 42/120
(35%), respectively, and at a lower frequency of 16/88 (18%) within the White
population group (combining frequencies of males and females for all three
population groups). The allelic frequencies in the different population groups
were obtained by analysing the E211 polymorphism in the patient cohort in
addition to samples from the Western Province Blood Transfusion Service. For
the AR E211 SNP, there were 41 Black females and therefore 41x2 alleles = 82.
There were 39 Black males and therefore 39 alleles since males only have one
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copy of the AR gene, which is located on the X chromosome. The combined
allele number for males and female Blacks was therefore 39+82 =121 (Table 26).
The total number of alleles was calculated the same way for Coloureds and
Whites. Although the frequency of this allele in CaP versus BPH was higher, at
values of 17/52 (32%) to 7/26 (26%), we found a P-value of 0.1876, considered
not statistically significant. Further statistical analysis yielded a Chi-square value
of 1.529 and a resulting probability of 0.465. This single nucleotide
polymorphism has previously been reported in individuals with varying degrees of
androgen insensitivity syndrome (Batch et ai, 1992; Gottlieb et ai, 1999) and
male infertility (Wang et aI, 1998b). The research team of Ross and his
colleagues (1998) have already tested the SNP as a potential marker for CaP
susceptibility. Results from their study show the SNP to be statistically significant
with a near 3-fold increased risk of CaP among men under the age of 65. This,
however, does not correlate with findings from the patient cohort in this study
where no statistical significance with disease association was found.
Mutations in paraffin-embedded prostatic carcinomas
In order to analyse the distribution of the AR-E211 SNP within the Black
population specifically, our AR-DGGE assay was further tested on 30 paraffin-
embedded CaP samples in a nested PCR-amplification, using the external
nested primers as shown in Table 6. Two sequence variations were found in
amplicon 10 of the AR gene and these variant banding patterns are shown in
Figure 10.
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1 2 3
FIG. 10. The denaturing gradient gel
electrophoresis (DGGE) gel shows mutations
that occur in amplicon 1D of AR after nested
amplification of DNA extracted from paraffin-
embedded prostate tumours. Lanes 1 and 2
represent DGGE variations, showing three
bands. The lower homoduplex bands appear as
a single, more prominent band. The control
DNA was run in lane 3.
From lanes 1 and 2 on the gel, it is clear that one cannot distinguish between the
normal and mutant homozygous alleles. This could be because mutant alleles
are exhausted by competition during formation of the heteroduplex hybrid bands.
The resulting three bands on the gel could more likely be from the homoduplex
bands that are lying on top of each other, due to the band intensities. This
sequencing data was incomplete at the stage of writing-up.
CYP17 DGGE assay
A comprehensive DGGE assay was designed for the entire coding region of
CYP17. Using this assay, three novel CYP17 SNPs were identified (Hayes and
de Beer, Communication). The three amplicons 1A, 4 and 7, where these SNPs
were located in the CaP, BPH and control population, were screened to
determine the allele frequencies, as well as search for possible associations with
CaP risk. The novel L36 SNP, and the H46 and S65 variants were found in
exon 1. Examples of these aberrant CYP17 DGGE banding patterns are shown
in Figure 11.
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FIG.11. The DGGE banding patterns of CYP17 SNPs. (A) Amplicon 1A was analysed on a 9% PAA gel containing
a 50-90% UF gradient. The heterozygous S65 variant can be seen in lane 2 with the homozygous form in lane 3.
The homozygous H46 SNP can be visualised in lane 4 with the heterozygous form of the mutation in lanes 5, 6 and
7. Combinations of SNPs include the heterozygous H46 and -34T>C variants in lane 1 and the homozygous S65
and heterozygous H46 variants in lane 8. The heterozygous L36 variant can be seen in lane 9. CYP17 amplicon 4
(B) and 7 (C) DGGE analysis was performed on 9% PAA gels with 10-50% and 50-90% UF gradients, respectively.
(B) Lane1 shows the IVS4+58G>C variant and is represented by three bands viz., 2 heteroduplex bands and 2
homoduplex bands which almost have the same melting behaviour and mobilities and therefore appear as a single
slightly more diffuse band. Lane 2 consists of normal control DNA. (C) Lane 1 contains the IVS6-25C>A
substitution and is represented by 2 upper heteroduplex bands and 2 lower homoduplex bands. Control DNA is
seen in lane 2.
Direct sequencing of the CYP17 exon 1 variants showed that they all represent
silent mutations as listed below in Table 25.
TABLE 25. CYP17 mutations ordered according to the region or exon in which they occurred
Intron/Exon bp / codon Base change
4 +58 bp T-C
6 -25 bp T-A
1 36 CTG - CT.Q (L36)
1 46 CAI - CA.Q (H46)
1 65 TCl - TC~ (S65)
Amino acid change Previously reported
Silent
Silent
Silent
Novel
Novel
Novel
Yes
Yes
+bp: number of base pairs downstream from exon 4, -bp: number of base pairs
upstream from exon 7.
L36: silent codon 36 change coding for Leucine (L), H46: silent codon 46 change coding
for Histidine (H), S65: silent codon 65 change coding for Serine (S). Novel indicates new
mutations reported in this study.
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From the sequencing data, a previously reported SNP was detected in the 5'
untranslated region of the CYP17 gene. This SNP, a TlA -C/G transition, is
found 34bp upstream from the initiation of translation and 27 bp downstream
from the transcription start site and creates an additional Sp-1 type (CCACC box)
promoter site. Results from a study by Kittles, et al (2001a), suggest that the C
allele of the CYP17 SNP is significantly associated with an increased CaP risk
and a clinically advanced form of the disease in African Americans.
Allele frequencies of single base substitutions
The allele frequencies of the identified polymorph isms within the patient cohort
and additional samples from the WPBTS (Refer to Table 1; Section 2.1.2), was
analysed. This was used to obtain the allele frequencies within the different
population groups. These results are shown in Table 26.
The allelic variants found in the CYP17 gene are all substitutions of a single
base and from the data in Table 26 it can be seen that they occur at frequencies
of 1% or more within the various populations. For allelic frequency data and
comparative analysis of CaP versus BPH for identified SNPs (Fisher exact and
Chi-square analysis), refer to the raw data in Appendix II.
Three silent mutations are located within exon 1 of the CYP17 gene. A
heterozygous CYP17 L36 substitution was found in a patient of mixed ancestry
diagnosed with carcinoma of the prostate assigned a Gleason Grade of 2. This
rare SNP occurs at an allelic frequency of 1% (1nO). The H46 SNP in CYP17,
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was identified in individuals from all three ethnic backgrounds, at allelic
frequencies of 40% in the Africans (24/56) and Coloureds (42/110) and at a
slightly elevated frequency in Whites at 50% (11/22). The H46 8NP occurred
more frequently in the cancer samples, at 50% (21/40), compared to 38% (21/56)
in BPH samples. Further statistical analysis showed no significance (Fisher
exact P = 0.1408) and yielded a X2= 0.0057 and p (probability) of 0.997.
The third silent polymorphism was located in the CYP17 gene in codon 65 (865)
and was found exclusively in the Coloured population at an allelic frequency of
10% (15/110). This 8NP was only present in BPH patients of Coloured ethnicity
at 13% (7/56) and absent in all individuals of Coloured origin with CaP. The
comparison of the frequency of 865 among CaP and BPH patients was
performed to see if there was a possible association of this 8NP with CaP risk.
The result of the comparison was a P-value for statistical significance of 0.0174
(considered to be significant) when the numbers for individuals of all race groups
were included (x2 = 2.53, P = 0.282). By excluding the Blacks and the Whites
from the equation, we applied the Fisher exact test again and found a P-value of
0.0053 (considered to be very significant), indicating a possible association with
a reduced CaP risk in Coloureds.
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TABLE 26. Allelic frequencies of Single Base Substitutions identified in the AR and CYP17 genes within our patient cohort
and including additional samples from the WPBTS (controls), with their possible association to Prostate cancer susceptibility.
*Number of Individuals Allelic frequencies Possible association with CaP risk
Sequence Variants Blacks Coloureds Whites Blacks Coloureds Whites CaP BPH P-value
AR E211 Females 41 28 25 33/82 19/56 11/50 - - -
0.40 0.34 0.22
AR E211 Males 39 64 38 11/39 23/64 5/38 17/52 7/26
0.28 0.36 0.13 0.32 0.26 0.1876
CYP17 L36 5 35 11 0/10 1/70 0/22 1/40 0/56 -
0 0.01 0 0.02 0
f-----------
CYP17 H46 28 55 11 24/56 42/110 11/22 21/40 21/56
0.4 0.4 0.5 0.5 0.38 0.1408
CYP17S65 29 55 11 0/58 15/110 0/22 0/40 7/56 0.0174
0 0.1 0 0 0.13 Significant
CYP17IVS4+58G>C 85 87 13 8/170 7/174 0/26 3/98 3/52 0.3530
0.047 0.04 0 0.037 0.058
CYP17IVS6-25C>A 68 65 12 4/136 11/130 2/24 5/98 4/52 0.2545
0.027 0.084 0.083 0.05 0.07
Sample numbers vary between the different population groups and sample types. Analysis was performed as samples were
collected. The patient samples consisted of prostatic carcinoma and benign prostatic hyperplasia tissues, as well as blood from the
same patients. Controls from the WPBTS was DNA isolated from blood samples. * Number of individuals = patients + controls
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Two intronic polymorph isms were also found in CYP17. The intron 4 SNP
(IVS4+58G>C) was identified exclusively in an African based population at
similar allele frequencies of 4.7% (8/170) in Blacks and 4% (7/174) in Coloureds.
An elevated frequency of 5.8% in BPH versus 3.7% in CaP samples was
observed even though statistical analysis showed no significance (Fisher exact P
= 0.353). A x2 value of 2.45 was obtained with p = 0.293. An intron 6
transversion (IVS6 -25C>A), where a pyrimidine (C) was substituted for a purine
(A), was found in all three population groups at high allele frequencies of 8.2%
(11/130) in Coloureds and 8.3% (2/24) in Whites and at a lower frequency of
2.9% (4/136) in Blacks. The frequency of the A allele of this SNP was higher in
BPH (7%) than in cancer (5%), even though sample numbers were so low.
Further statistical analysis showed a "l value of 2.65 with a corresponding
probability of 0.265.
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2.5 DISCUSSION
CaP is the second most common histologically-diagnosed cancer in South
African males (Sitas, 1994). Since the prostate is an androgen-regulated organ,
there has been a tremendous interest in the role that androgens play in prostate
carcinogenesis. The two most important apparent risk factors for CaP are age
and race or ethnicity. CaP is very rare before the age of forty but the subsequent
rate of increase with age is greater than for any other cancer. African-American
men have been reported to have the highest rates of CaP worldwide. There has
been no appropriate comparative data on CaP rates among African Blacks,
however, there are findings which suggest high rates of CaP in some African
populations (Kehinde, 1995). Various ethnic and cultural groups also exhibit
different environmental factors (diet, lifestyle, effects of migration, etc), levels of
genetic variation and patterns of gene-environment interactions. A combination of
all these factors could playa key role in determining CaP predisposition.
Two types of germline variants predispose to cancer (Ross and Coetzee, 1996).
Some germline mutations directly predispose to the disease. These single
inherited genetic traits are uncommon in the population and therefore carry low
population attributable risks. Genes containing these variants are, however,
highly penetrant and individuals with these genetic traits could have a high
overall risk for disease development.
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Susceptibility genes are much more common and have a low overall risk but a
possible strong population influence, since the higher risk genotype could be
relatively common and maintained in the population. Androgen metabolism
genes like these, in combination with one another are highly penetrant and could
indirectly affect the risk of cancer.
Part of this study was to design a comprehensive mutation detection assay for
almost the entire coding region (excluding polymorphic repeat sequences), and
including all splice site junctions of the AR gene in order to identify possible
SNPs in our population. Secondly, the identified CYP17 SNPs were analysed
within our South African cohort (the assay was already up and running), to
investigate possible associations with CaP risk. (DGGE was our method of
choice for SNP detection because it is virtually 100% sensitive and also suitable
for the analysis of archival-embedded paraffin material).
AR gene: type and frequency of variants
Five mutations were identified in the AR gene, including a previously reported
E211 SNP. No additional SNPs were found. All the sequence variants
represented germline events. Except for the intronic base substitution (g-a) 38bp
downstream from the acceptor splice site in intron 2, the remaining four amino
acid substitutions all occur within the coding region of exon 1. Three of these
four variations represent silent changes.
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A previous study by Coetzee and Ross (1994) have involved the analysis of the
polymorphic CAG tract in exon 1, since AR activity seems to be negatively
associated with CAG length. Shorter CAG alleles may be associated with CaP
(Hardy et aI, 1996; Ingles et aI, 1997; Stanford et aI, 1997). Additional studies
even identified phenotypic subgroups among CaP cases based on CAG repeats
(Giovannucci et al, 1997; Hakimi et al, 1997). Another study analysed the CAG
and GGC repeats in addition to the previously identified E211 SNP, located
roughly between the two polymorphic markers (Ross et aI, 1998 and 1999).
The SNP was found to be associated with a statistically significant almost 3-fold
increase in CaP risk among African-American men under the age of 65 (n = 208,
healthy men without CaP were used as controls). In this study the AR-E211 SNP
was found to be more common in the Coloured (n=92) and African (n=80) than in
the White population group (n=63). Although sample numbers were small, when
comparing the allele frequency in CaP (n=52) and BPH (n=26) for this SNP, our
observation conflicts with the study of Ross and Coetzee (1998) in that no
statistically significant association was found. The low frequency of this allele in
our prostate carcinoma patients is a discrepancy that may be explained by our
small sample size, which creates a major analytical limitation.
The silent S242 variant and the intronic base substitution, IVS2-38G>A, were
found in the same 75 year old patient of mixed ancestry. After two biopsies were
taken from this patient a Gleason grade 2 prostate carcinoma was diagnosed.
Tumours of this grade are well-differentiated, rarely have metastases, are
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typically slow growing and is not life threatening to the patient. The CaP
samples in our cohort (excluding paraffin material) have been assigned with low
Gleason grades of 1 to 3 which are indicative of generally slow growing cancers.
Our findings of such few mutations within our cancer samples therefore
correlates with various other studies which found that AR mutations are very rare
in localised disease and occur more frequently in metastatic tissue.
Age and functioning testis are the only known etiological risk factors for BPH
(Lee et ai, 1997a). This condition develops when mean testosterone levels are
falling. The role of androgens in BPH is therefore likely to be facilitatory rather
than causative. In BPH epithelium the AR is mostly expressed in luminal cells
rather than basal cells, while AR expression in the stroma has been detected in
smooth muscle and fibroblasts (Cooke et ai, 1991). There are almost no studies
reporting AR mutations in BPH. In one study, the genetic and immunodetection
of p53 gene32 mutations were compared in malignant and benign prostate
tissues. Two reference CaP cell lines, 26 patient specimens (including 8 BPHs,
16 CaPs and 2 lymph node metastases), 1 prostate and 9 kidney cell lines were
used for p53 analysis. The TP53 status of the samples were characterised using
single-strand conformational polymorphism (SSCP) analysis. This approach
identified 14 of 15 (93%) cell lines and patient samples having TP53 missense
mutations in the exons 5 to 8 region (Wertz IE et ai, 1996). More recently,
another group evaluated the correlation between specific genotypes in androgen
and oestrogen-regulating genes (AR, SRD5A2, CYP17 and CYP19), and age-
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related prostatic changes. The genetic susceptibility to morphological and
pathological criteria in 195 French Caucasians were tested, using allelic variants
for candidate genes involved in androgen/oestrogen prostatic activity: androgen
receptor (CAG repeats), 5alpha-reductase type 2 (TA repeats, V89L and A49T
mutations), A2 variant of the 17alpha-hydroxylase (CYP17) and the simple
tandem repeat polymorphism (STRP) and the aromatase (CYP19)
polymorphisms. Results from this study suggested that common variants of the
CYP17 gene are associated with prostate enlargement and therefore may
increase the risk of BPH development in this population, while infrequent variants
of the CYP19 gene could be of a protective nature (Azzouzi AR et al, 2002). Our
results support the findings of other studies which have used BPH as a factor of
comparison and have found either no mutations or detected silent mutations (Elo
et aI, 1995; Evans et aI, 1996). Currently, the focus of comparison between CaP
and BPH has been in protein expression studies. One study compared serum
biological androgen activity between men with newly diagnosed CaP and age-
matched men with BPH (Raivio T et aI, 2003), while another group determined
the luteinizing hormone-releasing receptor gene mRNA expression in CaP and
BPH tissue (Straub B et aI, 2003). In general, caution should be taken when
comparing CaP to BPH to determine risk of developing prostate cancer, since the
relationship between BPH and CaP is not well established. There are a number
of similarities that make it difficult to disprove a relationship as both are common
in ageing men, both diseases show androgen dependence and may be under
comparable genetic control. BPH has been linked to CaP diagnosis in some
32 TP53, the most commonly mutated gene in human cancers
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studies while other association studies have failed to find an association between
BPH and CaP (Brawley et aI, 1998b). It is very possible that BPH does not
increase the risk of developing clinically significant CaP but increases the risk of
being diagnosed with CaP. Here we report an unsequenced variant in exon 1
and a silent S341 mutation, both occurring in clinical BPH specimens from a
Black patient (aged 64) as well as another 74 year old patient of Coloured
ethnicity. BPH values33 of 35 and 20 were assigned to these patients,
respectively, after digital rectal examinations (ORE). Histopathological
examination of the samples verified the diagnosis of BPH and both individuals
still displayed symptoms following transurethral prostatic resection. The
occurrence of the two sequence variants in both patients suggests that they
could be linked polymorphisms but confirmation is limited by the small sample
size. One would have to increase the number of patients in the study cohort to
determine the frequency of this variant. Of a total number of eleven White
patients, eight were diagnosed with BPH and none had the unsequenced variant
or the S341 mutation. Both these mutations were identified in one of two Blacks
with BPH and in one of fifteen Coloureds with the condition and therefore appear
to be restricted to an African-based population.
The frequency of AR somatic mutations in CaP varies between studies and has
ranged from very rare to as high as 44% in clinical specimens of advanced
tumours (Tilley et aI, 1996). A general finding has been that the frequency of AR
somatic mutations increases with stage, being low in organ confined disease
33 This is the estimated mass of the prostate in grams, estimated by the doctor on DRE
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(Tilley et aI, 1994; Takahashi et el, 1995; Taplin et aI, 1995) and higher in
metastatic disease (Culig et aI, 1993; Taplin et aI, 1995; Tilley et aI, 1996). Many
investigators analysed only exons 2 through 8. Tilley and colleagues (1996),
however, have shown that 50% of their amino acid substitutions identified in the
AR were within exon 1. This partly explains the discrepancies in the reported
mutation frequencies since exon 1 accounts for more than half of the AR gene
and encodes the entire transactivation domain of the receptor. Similarly, we
identified four germline sequence variants that were all located within exon 1.
Due to the few AR mutations we identified, different sections of the same CaP
samples were sent to pathologists for further analysis to confirm tumour-
containing status of the material. The sensitivity of mutation detection was
considered by using DGGE, which allows for optimal detection of mutations by
increasing the percentage of single base changes detectable to virtually 100%.
Also, by DGGE, as little as 5% of mutant DNA (Hovig et aI, 1992) can be
detected in "tumour material", while some studies have even detected as little as
0.1% of mutant DNA (Keohavong et aI, 1997). AR SNPs, however, are very rare
and the previously reported E211 SNP is currently the only SNP that has been
detected in the coding region of the gene.
Failure to use tumour-enriched DNA could account for our findings and those that
some authors have published in the past. Reports from the clinicians did not
specify whether or not specimens were enriched for tumour before analysis. The
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presence of a substantial proportion of nontumour tissue may very likely hamper
attempts to detect a mutation. It is probable that more sensitive techniques, such
as laser microdissection, could have improved the tissue integrity for mutation
detection. There were, however, additional paraffin-embedded CaP tissue
samples from Blacks to screen. The fixation process of these samples damages
the DNA and a nested-PCR is required in order to amplify sufficient amounts of
DNA. This experiment is quite time-consuming and nested-PCR is prone to
contamination. One would only be able to detect contamination after two rounds
of PCR and testing of the PCR products on an agarose gel. Taking this into
consideration, we decided to screen only those samples with polymorphism
positive status. It is therefore possible that a number of base changes within the
other regions, could have been missed.
The important roles of androgen in the differentiation of prostate tissue and the
development and progression of CaP make the AR a link in the multistep
pathway to oncogenesis. As with other multifactorial cancers, CaP risk may not
be as a result of a single (or small number) of yet unknown predisposing genes,
but rather due to a large number of common but weaker genes that collectively
lead to a patients' "risk profile".
CYP17 gene: type and frequency of variants
Using the CYP17 DGGE-assay four SNPs viz. H46, S65, intronic substitutions
IVS4+58G>C and IVS6-25C>A, as well as the L36 mutation were identified. The
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heterozygous L36 mutation, identified in one Coloured patient with CaP, is very
rare and its frequency will probably decrease when screening larger numbers.
The H46 SNP is very common and occurs at a relatively high allelic frequency of
40% in Coloureds (42/110) and Blacks (24/56), and at a slightly higher
frequency of 50% in Whites (11/22), though sample numbers for whites were
very low. H46 is present in both the heterozygous and homozygous forms and
from sequencing data, it was found that the heterozygous H46 SNP occurs in
combination with the previously reported 5'UTR-34T>A variant as well as the
homozygous S65 SNP. When testing for an association with CaP risk, the H46
SNP was present at a slightly higher proportion in the CaP group compared to
BPH samples, though not at statistical significance level. The intronic
IVS4+58G>C SNP was found at allelic frequencies of 4.7% in Blacks (8/170), 4%
in Coloureds (7/174), and absent in Whites and therefore appears restricted to
African-based populations. The other intronic SNP, IVS6-25C>A, is present in all
three population groups at similar higher allelic frequencies of 8.2% in Coloureds
(11/130) and 8.3% in Whites (2/24) when compared to 2.9% in Blacks (4/136).
Numbers, however, for Whites were quite low. Both the IVS4+58G>C and IVS6-
25C>A SNPs were present at higher frequencies in BPH when compared to CaP
and no association with CaP was found. Small sample size is definitely a limiting
factor when analysing these SNPs. Therefore possible associations should be
further evaluated in a larger sample group.
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Our results reflect that there is a low risk of CaP development within our South
African cohort. This, however, may be due to sampling bias, i.e. the small
number of cases in the study. Difficulties in involving the various ethnicities or
heterogeneous reproducibility of phenotype assignment related to anatomical
and clinical definition in cases and controls could explain the results. The extent
of this problem could be so great that the frequency of any SNP contributing to a
disease phenotype will only be slightly elevated in the disease group compared
with unaffected controls. Association studies with a large sample size, where
cases of disease are compared to controls from the same population, are likely to
give a greater chance of detecting small effects. Prostate cancer is selected in
the first step on PSA, an androgen dependant parameter that could cause a bias
in the relation observed between prostate carcinoma risk and genes involved in
androgen pathways. On the other hand, it is possible that for a single gene there
could be situations in which an individual carries both a high- and a low-risk
marker at different loci resulting in no overall difference in risk. We did,
however, detect a silent S65 SNP that was significantly different in controls and
cases, as revealed by statistical analysis. The S65 allele was only found in the
mixed ancestry group and also exclusive to the BPH controls. Chi-square
analysis yielded a value of 2.53 (p = 0.28), indicating that there is a 28%
probability that the observed deviation is due to chance, giving us no reason for
rejecting the null hypothesis. As individuals with BPH have never been shown to
develop CaP, this CYP17 genotype (S65) may be associated with a reduced risk
of prostate carcinogenesis in Coloureds.
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Complex multifactorial diseases such as CaP may not be amenable to
characterisation by linkage analysis and positional cloning, as is the case for
monogenic diseases such as cystic fibrosis, sickle cell disease, etc. The results
presented in this dissertation therefore form a basis for further investigation as
there is a new emphasis on using genome-wide scans to look for single
nucleotide polymorphisms, including short deletions, insertions and
multinucleotide changes. In light of the difficulties surrounding the genetics of
CaP, technologies such as microarrays (DeRisi et ai, 1996) provide possibilities
for the identification of new target genes involved in CaP. With improvements in
technology and the collection of family data, novel methods for the statistical
modelling of CaP will be key to the understanding of the multifactorial nature of
the condition. CaP still remains one of the major health problems in the world and
therefore the understanding of the genetics of this disease will ultimately lead to
better diagnostic and therapeutic strategies.
The greatest limitation of this study was the lack of patients and tissue and blood
samples that were studied. To perform association studies of any statistical
relevance would require much larger numbers of cases (CaP versus BPH) and
controls within each of the population groups to be studied. Statistical programs
like Epi Inf034 and Statistica Power Analysis'" can be used to find the ideal
sample size to enrich research with a variety of tools for estimating confidence
intervals and conducting comprehensive power analysis to avoid Type" errors.
34 Version 6, Nov 1993. © 1999, Henry Ford Health System
35 © Statsoft, Inc 1984-2004
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In conclusion, comprehensive DGGE assays were designed for the analysis of
the entire coding region of the AR and CYP17 genes. Using these assays, novel
sequence variants were identified, including 5 AR and CYP17 SNPs. One
CYP17 SNP appears to be exclusive in an African-based population and another
possibly reduces CaP risk in Coloureds. Using a patient cohort of adequate size,
these SNPs can be used as markers in determining CaP risk.
2.6 FUTURE PROSPECTS
Polymorphic trinucleotide repeat analysis
Since the length of the AR trinucleotide CAG and GGC repeats in the South
African population remains unknown, future analysis of these polymorphic tracts
should be performed since case-control studies have reported associations
between CaP risk and one or both the trinucleotide repeat lengths.
Possible candidate genes and multi gene interactions
Other genes involved in androgen metabolism have also been implicated in the
aetiology of CaP. Polymorphisms in CYP3A4, involved in the oxidative
deactivation of testosterone and possibly the 3a-, 313-, and 17J3-hydroxysteroid
dehydrogenases, involved in DHT inactivation and testosterone biosynthesis,
may influence prostate carcinogenesis (Reichardt et aI, 1995; Devgan et aI,
1997; Ingles et aI, 1997) and require further investigation.
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Possible associations may therefore be explained by the fact that relevant
interactions among multiple genes and exposures have not been studied. Thus
complex interactions among these genes in the androgen metabolism pathway
may be required to understand their effects in CaP aetiology. As a result,
associations found may not only be due to linkage disequilibrium alone, but could
also be attributed to some combination of linkage disequilibrium and multigene
interactions. This should include a formal statistical evaluation of genotypes.
Larger sample sizes may therefore be required to evaluate the potential
interaction effects.
Developing a polygenetic model for CaP by incorporating multiple loci from
individual genes could maximise the ability to identify individuals who are at high
risk of developing carcinoma of the prostate. Little is known about molecular
markers that may help early diagnosis of this carcinoma and the identification
through genetic variation, of population subgroups that are at elevated risk of
developing malignant prostate tumours could be of importance.
Alternative mutation detection technique for SNP identification
Denaturing high-performance liquid chromatography (DHPLC) is an efficient
method for detection of mutations involving a single or few number of
nucleotides, and it has been successfully used for mutation detection in disease-
related genes (Mogensen et ai, 2003). DHPLC analysis is cost-effective and
allows a rapid throughput of large numbers of samples in minimal time.
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Therefore it should be considered when possible large-scale population
screening is likely in the event of a variant posing a high-risk.
Haplotype analysis and functional studies
Unfortunately, due to the limited sample size and lack of material from families,
haplotype analysis could not be performed to "track" the transmission of variant
alleles. Functional studies on the variants identified in this thesis could also not
be performed by collaborators (The Norris Comprehensive Cancer Centre,
University of Southern California), due to the restricted sample size. However,
this study is being performed on a larger cohort by Dr Vanessa Hayes (Project
Leader: Genitourinary Cancers, Garvan Institute of Medical Research, Australia),
for publication purposes.
Animal models
Transgenic mouse models are proving to be invaluable in the effort to understand
the molecular basis of metastatic CaP. In general, transgenic models feature
higher penetrance, faster progression, and greater overall reproducibility of
metastatic properties compared to spontaneous or induced models. The
autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP)
model, which spontaneously develops metastatic CaP, is one such model that
mimics progressive forms of human disease. A study performed by Gupta and
colleagues (2001), employing male TRAMP mice, showed that oral infusion of a
polyphenolic fraction isolated from green tea (GTP) at a human achievable dose
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(equivalent to 6 cups of green tea per day), significantly inhibited CaP
development and increased survival in these mice. In order to elucidate the
molecular mechanisms of CaP metastasis, it will be necessary to compare gene
and protein expression patterns and biochemical analyses of clinical metastatic
disease with data obtained from current models.
A consideration in the design of new models would be the ability to track the
progression and spread of metastases to distant sites in live animals using new
reporter genes and improved imaging technology. Assaying classic reporter
genes such as galactosidase and alkaline phosphatase commonly requires the
sacrifice of the animal. However, because metastatic spread occurs at variable
time points and targets a variety of secondary sites, new live imaging
technologies will be advantageous in eliminating some of the guesswork in
animal sacrifice and tissue collection, hereby allowing investigators to use each
animal to its full potential (Winter et aI, 2003).
Genomic approaches to the development of CaP diagnostics
Combining proteomic technology with artificial intelligence based bioinformatics
may be a powerful tool in the detection and diagnosis of CaP. A technique still
under evaluation, based on the analysis of protein patterns, will be useful in the
future for deciding whether men with marginally elevated PSA levels should
undergo biopsy (http://www.cancer.gov.2004).This diagnostic test relies on
computer software that detects key patterns of small proteins in the blood. Mass
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spectroscopy is used to sort proteins and other molecules based on their weight
and electrical charge. Artificial intelligence is then used to train a computer to
identify patterns of proteins that differed between patients with CaP and those in
which a biopsy had found no evidence of disease. This new approach will prove
useful in detecting and diagnosing many other cancers and diseases in the
future.
Using bioinformatic and genomic approaches, several candidate genes have
been identified that are differentially expressed in CaP (Ali S et ai, 2003).
Candidate genes were chosen that showed a strong specificity for expression in
prostate tissue and also a significant upregulation in cancerous tissue compared
with normal tissue. Expression analysis of these candidate genes further
determined the tissue-specific expression and whether higher levels of
expression are indicative of CaP. Expression analysis data using RNA from
different tissues and disease states helped rank these candidates, the majority of
which have been cloned and expressed in bacteria. These candidates, either
individually or grouped in panels have the potential to become new CaP
biomarkers for early detection, differential diagnosis, disease monitoring and
surveillance.
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Notes to Appendix II:
Allele frequencies
Genetic comparisons of tumour and blood material of the CaP patients", and
that obtained from the BPH (normal tissue), as well as blood samples from the
general populatiorr" were performed, to determine the allele frequencies (by
manual allele counting) of polymorphic sites. Control samples from the WPBTS
consisted of males and females. The number of individuals referred to in allelic
frequency tables are either homozygous (MM), heterozygous (MN) for a specific
SNP, or without the SNP (NN).
When calculating allelic frequencies it must be remembered that the AR gene is
located on the X chromosome and males therefore only have a single copy of the
gene, as opposed to females" who have two X-chromosomes and therefore two
copies of the gene.
Testing for Hardy-Weinberg equilibrium
Allele frequencies determine genotype frequencies. p2 is the measure of the
frequency of MM homozygotes for a specific SNP in the ensuing generation. In a
similar way, 2pq describes the frequency of the MN heterozygotes, and q2 is a
measure of the frequency of the NN " normals", i.e. individuals without SNPs.
The distribution of homozygous and heterozygous genotypes in the next
36 Including paraffin material for the AR E211 and CYP17IVS4+58G>C and IVS6-25C>A SNPs
37 Obtained from the Western Province Blood Transfusion service (WPBTS)
38 Controls from the WPBTS
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generation can be expressed as p2+ 2pq+ q2= 1. The observed trequencies"
varied significantly from the expected frequencies'? and therefore Chi-square
analyses were performed, to confirm that the population was in a state of
nonequilibrium.
Chi-square test
Chi-square analyses were performed for the identified SNPs within the CaP and
BPH samples, in all 3 population groups. P values of > 0.05 were obtained for
all SNPs, giving no reason to reject the null hypothesis.
Fisher exact tests
Fisher exact tests were performed for each SNP to compare genotype
distribution and allele frequencies among patient" and control groups42, in order
to determine any association with CaP risk. This test excluded any samples from
the WPBTS and therefore included only samples from males. Since males have
a single copy of the AR gene, total number of alleles for example, would be 47 if
there were 47 individuals with CaP.
39 From allelic frequency calculations for all SNPs
40 From Hardy-Weinberg calculations for all SNPs
41 Tumour and blood from grade 1, 2 or 3 prostate carcinoma, either with or without metastasis
and either with or without hormone resistance. Forthe AR E211 and the CYP17IVS+58G>C and
IVS6-25C>A SNPs, paraffin-embedded cancer material was also used.
42 Either with or without prostatitis
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APPENDIX I: SOLUTIONS
Solutions used for DGGE gels
20x TAE-buffer (10 litres) :
969 9 Tris-HCL
544 9 NaAc
74.5 9 EDTA
Adjust the pH to 8.0 with 300-350 ml NaOH and fill up to 10 litres with distilled
H20.
9% PM (1 litre):
25 ml 20xTAE
225 ml 40% PM (acryl: bisacryl = 37.5: 1)
Fill up to 1 litre with distilled H20.
80% UF /9% PM (1 litre) :
25 ml 20xTAE
225 ml
336 9
40% PM (acryl: bisacryl = 37.5: 1)
urea
320 ml formamide (deionised)
Fill up to 1 litre with distilled H20.
OR
For a 90% UF / 9% PM stock solution, 378 9 of urea and 360 ml of deionised
formamide can be used instead.
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20% ammoniumpersulphate (APS) (1 litre) :
20 gAPS filled up to 100 ml with distilled H20. Dispense into 1 ml aliquots and
store at -20°C.
10x Gel loading buffer (GLB) (100 ml) :
250 mg broomphenolblue
25 g ficoll
10 mM Na2EDTA
Fill up to 100 ml with distilled H20.
Deionisation of formamide :
Mix 50 ml of formamide with 5 g of mixed-bed ion-exchange resin (Bio-Rad AG
501-X8, 20-50 mesh). Stir for 1 hr at room temperature. Filter once with
Whatman No. 1 filter paper and store at -20°C.
Stellenbosch University http://scholar.sun.ac.za
201
Solutions used for agarase gel electrophoresis
5 X TBE stock (1L) :
54,5 g
27,8 g
2,9 g
Tris
Boric acid
EDTA
Make up to 11itrewith dH20.
0,5 X TBE made from 5X stock solution (1L) :
0,5/5 X 1000ml :. ~ 100ml of stock made up to 1L
2% agarase gel:
2/100 X x/150 (gel tray holds maximum volume of 150ml)
use 3g of agarose (GIBCO BRL, Ultra Pure Agarase Electrophoresis Grade) +
150ml 0,5 X TBE and heat in microwave till dissolved, cool to room temperature,
pour in gel tray and place gel combs in gel to form slots. Allow about 30 minutes
to set.
Electrophoresis gel loading buffer:
22,7 ml formamide
0,168 g EDTA
0,0125 g xylene cyanol
0,0125 g bromophenol blue
Make up to 25m I with dH20.
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APPENDIX II: Chi-square and Fisher exact tests comparing the genotype
distribution and allele frequencies among patient and control groups for identified
AR and CYP17 SNPs
TABLE 8. Allele frequencies for the AR E211 polymorphism by allele counting
Genotype MM MN NN Total
Number of individuals 53 35 123 211
Number of Malleles 70 35 0 105
Number of N alleles 0 35 157 192
Total number of 70 70 157 297
alleles
MM=homozygotes; MN=heterozygotes; NN=normal
Frequency of M in population: 105/297 = 0.35 = 35%
Frequency of N in population: 192/297 = 0.647 = 65%
Total genotypes for next generation: testing for Hardy-Weinberg equilibrium
Expected frequency of type M = p2
= (0.35) 2 = 0.1225
= 12.25%
Expected frequency of type MN = 2pq
=2(0.35)(0.65) = 0.455
= 45.5%
Expected frequency of type N = q2
=(0.65) 2 = 0.4225
= 42.25%
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TABLE 9. The comparison of two variables (CaP and BPH) for the AR E211 SNP in all
races
*Total
CaP BPH Total
35 19 54
(41%) (28%) (69%)
17 7 24
(24%) (7%) (31%)
52 26 78
(65%) (35%) (100%)
P = 0.1876
.Wild-type
#E211
*Total =number of alleles, for example; there are 50 individuals with CaP (Refer to Table
1: Materials and Methods; Section 2.1.2 where there are 30 parafifin-embedded CaP's
from Blacks, 17 blood/tissue CaP's combined from Blacks and Coloureds and 3 CaP
samples from Whites), therefore 50 alleles (males have a single copy of the gene), etc.
#E211 = number of mutant alleles
+Wild-type =normal number of alleles (Total alleles - the mutant alleles)
TABLE 10. The Chi-square analysis of two variables
(CaP and BPH) for the AR E211 SNP
Class Observed (0) Expected (E)
Blacks
Caucasians
Coloureds
21 9
11 2
26 13
x2 = L (0 - E)2
E
= 1.53 with (3 - 1) = 2 df
P = 0.465
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TABLE 11. Allele frequencies for the CYP17 H46 polymorphism by allele counting
Genotype MN NN TotalMM
Number of individuals 41 36 9720
Number of Malleles
Number of N alleles
41
41
40
o
o
72
Total number of
alleles
82 72 19440
MM=homozygotes; MN=heterozygotes; NN=normal
Frequency of M in population: 81/194 = 0.42 = 42%
Frequency of N in population: 113/194 = 0.58 = 58%
Total genotypes for next generation: testing for Hardy-Weinberg equilibrium
Expected frequency of type M = p2
= (0.42) 2 = 0.176
= 17.6%
Expected frequency of type MN = 2pq
=2(0.42)(0.58) = 0.487
= 48.72%
Expected frequency of type N = q2
=(0.58) 2 = 0.336
= 33.64%
81
113
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TABLE 12. The comparison of two variables (CaP and BPH) for the CYP17 H46 SNP in
all races
#H46
CaP BPH Total
19 35 54
(18%) (34%) (52%)
21 21 42
(25%) (23%) (48%)
40 56 96
(43%) (57%) (100%)
p= 0.1408
+Wild-type
*Total
*Total =number of alleles, for example; there are 20 individuals with CaP, therefore 20X2
alleles, etc.
#H46 = number of mutant alleles
+Wild-type =normal number of alleles (Total alleles - the mutant alleles)
TABLE 13. The Chi-square analysis of two variables
(CaP and BPH) for theCYP17 H46 SNP
Class Observed (0) Expected (E)
Blacks
Caucasians
Coloureds
2 3
5 8
13 21
x2 = L (0 - E)2
E
= 0.0057 with (3 -1) = 2 df
I P=0.997
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TABLE 14. Allele frequencies for the CYP17 IVS4+58G>C polymorphism by allele
counting
Genotype MM MN NN Total
Number of individuals o 12 144 156
Number of Malleles
Number of N alleles
o
o
12
12
o
288
12
300
Total number of
alleles
o 24 288 312
MM=homozygotes; MN=heterozygotes; NN=normal
Frequency of M in population: 12/312 = 0.038 = 4%
Frequency of N in population: 300/312 = 0.96= 96%
Total genotypes for next generation: testing for Hardy-Weinberg equilibrium
Expected frequency of type M = p2
= (0.04) 2 = 0.0016
= 0.16%
Expected frequency of type MN = 2pq
=2(0.04)(0.96) = 0.768
= 7.68%
Expected frequency of type N = q2
=(0.96)2 = 0.9216
= 92.16%
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TABLE 15. The comparison of two variables (CaP and BPH) for the CYP17
IVS4+58G>C SNP in all races
*Total
CaP BPH Total
95 49 144
(69%) (26%) (95%)
3 3 6
(3%) (3%) (5%)
98 52 150
(71%) (29%) (100%)
p= 0.3530
+Wild-type
#IVS4+58G>C
*Total =number of alleles, for example; there are 42 individuals with CaP, therefore 42X2
alleles, etc.
#IVS4+58G>C = number of mutant alleles
• Wild-type =normal number of alleles (Total alleles - the mutant alleles)
TABLE 16. The Chi-square analysis of two variables
(CaP and BPH) in CYP17 for the IVS4+58G>C SNP
Class Observed (0) Expected (E)
Blacks
Caucasians
Coloureds
32 2
11 0
25 4
x2 = L (0 - E)2
E
= 2.45 with (3 - 1) = 2 df
I P=0.293
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TABLE 17. Allele frequencies for the CYP17 IVS6-25C>A polymorphism by allele
counting
Genotype MM MN NN Total
Number of individuals o 17 105 122
Number of Malleles
Number of N alleles
o
o
17
17
o
210
17
227
Total number of
alleles
o 34 210 244
MM=homozygotes; MN=heterozygotes; NN=normal
Frequency of M in population: 17/244 = 0.067 = 7%
Frequency of N in population: 227/244 = 0.937= 93%
Total genotypes for next generation: testing for Hardy-Weinberg equilibrium
Expected frequency of type M = p2
= (0.067) 2 = 0.004489
= 0.449%
Expected frequency of type MN = 2pq
=2(0.067)(0.937) = 0.125558
= 12.556%
Expected frequency of type N = q2
=(0.937) 2 = 0.878
= 87.8%
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TABLE 18. The comparison of two variables (CaP and BPH) for the CYP17 IVS6-25C>A
SNP in all races
*Total
CaP BPH Total
93 48 141
(62%) (33%) (95%)
5 4 9
(2%) (3%) (5%)
98 52 150
(64%) (36%) (100%)
p= 0.2545
+Wild-type
#IVS6-25c/a
*Total =number of alleles, for example; there are 44 individuals with CaP, therefore 44X2
alleles, etc.
#IVS6-25c/a = number of mutant alleles
• Wild-type =normal number of alleles (Total alleles - the mutant alleles)
TABLE 19. The Chi-square analysis of two variables
(CaP and BPH) in CYP17 for the IVS6-25C>A SNP
Class Observed (0) Expected (E)
Blacks
Caucasians
Coloureds
30 2
9 2
29 7
x2 = L (0 - E)2
E
= 2.65 with (3 - 1) = 2 df
I P = 0.265
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TABLE 20. Allele frequencies for the CYP17 S65 polymorphism by allele counting
Genotype MM MN NN Total
Number of individuals 5 6 88 99
Number of Malleles
Number of N alleles
10
o
6
6
o
176
16
182
Total number of
alleles
10 12 176 198
MM=homozygotes; MN=heterozygotes; NN=normal
Frequency of M in population: 16/198 = 0.071 = 8%
Frequency of N in population: 182/198 = 0.92= 92%
Total genotypes for next generation: testing for Hardy-Weinberg equilibrium
Expected frequency of type M = p2
= (0.071) 2 = 0.05
= 0.50%
Expected frequency of type MN = 2pq
=2(0.071 )(0.92) = 0.13064
= 13.064%
Expected frequency of type N = q2
=(0.92) 2 = 0.8464
= 84.64%
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TABLE 21. The comparison of two variables (CaP and BPH) for the CYP17 S65 SNP in
all races
#565
CaP BPH Total
40 49 89
(43%) (49%) (92%)
0 7 7
(0%) (8%) (8%)
40 56 96
(43%) (57%) (100%)
p= 0.0174
.Wild-type
*Total
*Total =number of alleles, for example; there are 20 individuals with CaP, therefore 20X2
alleles, etc.
#S65 = number of mutant alleles
+Wild-type =normal number of alleles (Total alleles - the mutant alleles)
TABLE 22. The Chi-square analysis of two variables
(CaP and BPH) in CYP17 for the S65 SNP
Class Observed (0) Expected (E)
Blacks
Caucasians
Coloureds
5 0
11 0
30 5
x2 = L (0 - E)2
E
= 2.53 with (3 - 1) = 2 df
I p= 0.282
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TABLE 23. The comparison of two variables (CaP and BPH) for the CYP17 565 5NP in
Coloured patients.
#565
CaP BPH Total
28 24 52
(47%) (40%) (87%)
0 8 8
(0%) (13%) (13%)
28 32 60
(47%) (53%) (100%)
p= 0.0053
+Wild-type
*Total
*Total =number of alleles, for example; ther~ are 14 individuals with CaP, therefore 14X2
alleles, etc.
#565 = number of mutant alleles
.Wild-type =normal number of alleles (Total alleles - the mutant alleles)
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